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Thesis Abstract 
There are currently no disease-modifying therapies to halt or prevent the onset of Alzheimer’s 
disease (AD). Immunotherapy and antibodies targeting the neurotoxic amyloid-β (Aβ) peptide for its 
removal from the brain have provided a promising opportunity to provide disease-modifying therapies. 
However, despite promising pre-clinical data, any benefits have failed to translate to the clinic. This thesis 
evaluated an antibody approach that, rather than targeting amyloid per se, binds to the amyloid precursor 
protein (APP) at the β-secretase cleavage site to reduce amyloid production by steric hindrance (Thomas 
et al. 2011, 2013). The main hypothesis of this thesis was that 2B3 administration to aged PDAPP mice 
(Games et al. 1995), which overexpress a mutated form of APP (Indiana mutation; V717F), would (1) 
reduce APP metabolism and (2) Aβ production and (3) alleviate age-associated cognitive deficits in 
PDAPP mice. 
In order to test this hypothesis, PDAPP mice underwent behavioural and pathological 
characterisation at a range of ages to identify the nature and onset of cognitive deficits. Behavioural 
characterisation included an in-house spatial working memory (SWM) foraging paradigm and a battery of 
object and spatial recognition tests. PDAPP mice showed age-dependent deficits in SWM starting at 10-
12 months. Novel object memory remained intact across all ages tested, however an age-dependent deficit 
was observed at 14-16 months of age in a visuo-spatial object-in-place  (OiP) recognition task. ELISA 
analyses confirmed an age-related significant increase in amyloid production in the hippocampus of 
PDAPP mice at 15 months of age. 
In the second phase of the programme of work, 17-18 month old PDAPP mice received 
intracerebroventricular infusion of antibody 2B3 using osmotic minipumps for a period of 14 days. 2B3 
administration reversed the OiP recognition memory impairment in PDAPP mice. Improved memory 
performance was accompanied by a significant reduction in soluble Aβ40 and βCTF, but not soluble 
Aβ42. Further investigation also revealed that 2B3 significantly reduced the phosphorylation of NMDA 
receptor subunit NR2B at the tyrosine 1472 residue to a level similar to age-matched WT controls. 
Increased phosphorylation of the NR2B residue has been linked with neuronal excitotoxicity and 
impaired cognitive function in other mouse models (Ittner, Ke, Delerue, Bi, Gladbach, van Eersel, 
Wölfing, Chieng, Christie, Napier, et al. 2010).  It is hypothesised that reduced phosphorylation of the 
NR2B following 2B3 administration in PDAPP mice most likely played a significant role in improving 
OiP performance. 
viii
Data from this thesis provides evidence that in vivo administration of 2B3 and inhibition of APP 
metabolism/Aβ production by steric hindrance provides a viable approach for the further development of 
immunotherapies targeting early stage AD pathology. 
In Loving Memory of Frances Maundrell 
1950 - 2016
9Chapter 1: Introduction 
“When Alois Alzheimer revealed the plaques and neurofibrillary tangles under his microscope 
more than a century ago, one wonders whether he anticipated that the proteins forming these lesions 
would have such profound roles and be directly linked in the pathogenesis of the disease”
Lars M. Ittner and Jürgen Götz, 2011  
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1.1 Thesis Overview 
Currently, the clinically available treatments for Alzheimer’s disease (AD) target AD-related 
symptoms only and not the underlying pathological mechanisms or causes. Therefore, there is a 
great demand for the development of these treatments in order to slow the progression or onset 
of AD. Transgenic mouse models have provided a useful tool in which to investigate 
pathological mechanisms associated with AD, as well as to evaluate potential disease-modifying 
compounds. 
This introduction will initially outline the clinical observations of AD prevalence, 
clinicopathology and aetiology (section 1.2). A more in-depth discussion of the molecular 
pathology of AD will then be discussed (section 1.3). A focus will be on the amyloid-β (Aβ) 
peptide. Aβ has been argued to trigger the pathological cascade of events associated with the 
progressive neurodegeneration and cognitive decline reported in AD (Hardy & Allsop 1991; 
Hardy & Higgins 1992; Hardy & Selkoe 2002). Further mechanisms and pathological hallmarks, 
such as neurofibrillary tangles (NFTs) and hyperphosphorylated tau protein will also be 
discussed. This will then lead onto an overview of the current transgenic mouse models of AD-
like pathology (section 1.4). These models are extensively used in order to provide a better 
understanding of the pathological mechanisms and behavioural phenotypes associated with AD. 
A focus will be on the PDAPP model, which was used throughout the research conducted in this 
thesis (Games et al. 1995). A further common use for Tg AD models is to assess novel 
compounds to potentially treat AD. A review of the currently available and developing 
treatments for AD will then be provided in the final section (section 1.5). A focus of this will be 
on immunotherapy, particularly passive anti-Aβ immunotherapies. Despite the success of these 
anti-Aβ antibodies in preclinical studies, little success has been translated in clinical trials 
(Karran & Hardy 2014). The remaining review of developing immunotherapies will focus on an 
anti-APP β-secretase cleavage site antibody, 2B3. 2B3 is able to reduce Aβ in vitro in a range of 
cell lines, including mouse primary cortical neurons (Thomas et al. 2011; Thomas et al. 2013). 
Thus, this introduction will hypothesise that administration of 2B3 in PDAPP mice will reduce 
levels of Aβ and improve memory performance.  
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1.2 An Overview of Alzheimer’s Disease
1.2.1 Prevalence and cost 
Alzheimer’s disease (AD) is the most prevalent neurodegenerative condition afflicting an 
estimated 44 million people worldwide (World Alzheimer's Disease Report 2014). It is the most 
common form of dementia making up 64% of all cases (Alzheimer’s Society: Dementia UK, 
2014).  Within the UK, it is estimated that 850,000 people will have been diagnosed with 
dementia by 2015, which is equal to 1.3% of the entire UK population (Alzheimer's Society: 
Dementia UK update, 2014). Of the cases diagnosed, approximately 1 in 14 people are aged 65 
and above and 1 in 6 people are over the age of 80, indicating that AD is a disease of age. These 
figures appear more aggressive in the United States where 5.2million American citizens have 
been reported to have AD. Of these, 1 in 9 people are over the age of 65 and 1 in 3 are over the 
age of 85 (Alzheimer's Association: Facts and Figures, 2014).  
AD is a debilitating condition not just for the patient, but also the primary care giver. 
Caregivers are reported to be under supported and overworked, collectively spending over 1.3 
billion hours caring for those with dementia in the UK in 2013 (Alzheimer’s Society: Dementia 
UK, 2014). It has further been reported that AD caregivers are susceptible to stress, anxiety as 
well as depression (Ferrara et al. 2008). In addition to this, in 2014, AD had a reported annual 
cost of £26.3 billion in the UK (Alzheimer's Society: Dementia UK update, 2014) and a further 
$214 billion in the US (Alzheimer's Association: Facts and Figures, 2014). These figures are 
estimated to double by 2030 due to modern medicines increasing life expectancy.  For reasons 
such as these, research into the mechanisms of AD are important to identify therapeutic targets, 
as currently there is no preventative treatment. Therefore, there is an ongoing need to continue to 
improve the understanding of AD aetiology and disease mechanisms in order to develop 
potential treatments.
1.2.2 Clinical symptoms 
Clinical symptoms of AD are consistent with the pathological progression of the disease, 
starting initially in the medial temporal lobes (MTL) (i.e., entorhinal cortex (EHC) and 
hippocampus (HPC)), before further progressing into isocortical association areas, including the 
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parietal and frontal lobes (explained in more detail in section 1.3; Braak & Braak 1991; Braak & 
Braak 1995). The earliest clinical symptoms observed in patients with AD are a deficit in MTL-
dependent episodic memory and semantic memory (Hodges et al. 1990; Bondi et al. 2008). 
These deficits are commonly observed in the preclinical phase of AD prior to the development of 
mild AD and mild cognitive impairment (MCI;) (Förstl & Kurz 1999; Bäckman et al. 2001; 
Bondi et al. 2008). As the disease continues to worsen into the moderate and severe stages of 
AD, patients express severe impairment of recent memory and appear to “live in the past” 
(alzheimers.org.uk) and develop further changes in personality, speech and gradual loss of 
everyday activities of daily living (Beatty et al. 1988; Förstl & Kurz 1999). The average duration 
of life following clinical diagnosis of AD is approximately 5-10 years. Despite the relatively 
rapid decline following diagnosis, it is thought that pathological changes in neurochemistry and 
AD biomarkers may precede this stage decades before clinical symptoms present (Förstl & Kurz 
1999; Zanetti et al. 2009; Jack et al. 2010; Jack et al. 2013).  
1.2.3 Diagnosing Alzheimer’s Disease
Criteria for diagnosing AD were originally established in 1984 with the National Institute 
of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) criteria (McKhann et al. 1984). These criteria 
allowed for a “possible” and “probable” diagnosis of AD with a “definite” diagnosis through 
combined clinical and histopathological examination (McKhann et al. 1984). Similar clinical 
diagnostic criteria have since been established including the Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition (DSM-IV) and the International Classification of Diseases, 10th
revision (ICD-10) (World Health Organization, ICD-10, 1992; American Psychiatric 
Association, DSM, 1994; American Psychiatric Association, DSM-IV-TR 2000). The three share 
many approaches to diagnose AD: including mental status exams (MSE) and memory tests. 
These assessments are highly sensitive to cognitive and behavioural symptoms associated with 
AD and allow the progression of decline to be monitored (Schmitt et al. 2000; Salmon & Bondi 
2009). Two of the most frequently used assessments to diagnose cognitive impairment are the 
Mini-Mental Status Examination (MMSE) and the Cambridge Neuropsychological Tests 
Automated Battery (CANTAB) (Folstein et al. 1975; Cockrell & Folstein 1988; Fray & Robbins 
1996; Fray et al. 1996). The MMSE consists of a brief questionnaire able to assess both episodic 
and semantic memory, working memory, as well as attention and orientation to time and place 
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(Folstein et al. 1975; Snyderman & Rovner 2009). CANTAB however, is a non-verbal 
assessment tool, utilizing a touch-screen testing system examining memory, attention and 
executive function (Fray & Robbins 1996). Similar clinical test procedures are also used in order 
to track memory and cognitive decline in AD patients including the Montreal Cognitive 
Assessment, Alzheimer’s Disease Assessment Scale and Logical Memory Test I and II (Rosen et 
al. 1984; Wechsler 1997; Nasreddine et al. 2005). In 1999 a further stage of cognitive decline, 
MCI, was defined as a translational stage between normal cognition (relative to age and 
education) and dementia (Petersen et al. 1999). This definition further helped to define and 
identify those at risk of developing AD (Morris et al. 2001; Petersen 2002). However, AD 
cognitive symptoms alone show much over lap with other dementias, including frontotemporal 
dementia (FTD), and accuracy of diagnoses remains variable until postmortem neuropathological 
examination; which remains the “gold standard” of diagnosis of AD (McKhann et al. 1984; 
Dubois et al. 2007; Beach et al. 2012).  
To better improve AD diagnosis recommendations from the National Institute of Aging 
(NIA) and Alzheimer’s Association workgroups proposed improvements to the diagnostic 
guidelines for AD based on the advances made in understanding AD since 1984 (Dubois et al. 
2007; Jack et al. 2011; Sperling et al. 2011; McKhann et al. 2011; Albert et al. 2011). These 
recommendations focus on detecting AD in its earliest stages by observing a clinical deficit in 
episodic memory as well as at least one or more abnormal biomarkers relative to AD 
neuropathology. These include: molecular neuroimaging with positron emission tomography 
(PET) with Pittsburgh B compound (PiB) to quantify amyloid levels within the brain, structural 
neuroimaging with magnetic resonance imaging (MRI) to assess potential MTL atrophy, as well 
as the analysis of cerebrospinal fluid (CSF) to detect altered levels of amyloid and phospho-tau. 
However, these recommendations appear to target diagnosis of AD predominantly for research 
purposes, while the recommendations for a more clinical criterion remain unfeasible in many 
memory clinics. Due to the relative expense of imaging techniques and the invasive procedure of 
lumbar puncture to obtain CSF, development of screening procedures incorporating blood-based 
biomarkers are being developed. These should allow a more clinically-valid and reliable method 
to diagnosing AD (Burnham et al. 2014; Henriksen et al. 2014; Kiddle et al. 2015).  
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1.2.4 Aetiology of Alzheimer’s Disease
 Two predominant forms of AD have been classified, familial AD (FAD) and sporadic 
AD (SAD). FAD accounts for approximately 1-5% of all cases. SAD accounts for more than 
95% of AD cases. Although causal genetic mutations lead to the development of FAD, no single 
definitive cause has been determined for SAD and it is most likely caused by a combination of 
genetic and environmental factors (Bettens et al. 2013b; Reitz & Mayeux 2014). Despite this 
difference, the clinical and neuropathological cascade of events remains similar across both 
forms of AD (Lippa et al. 1996). 
 FAD is an autosomal dominant inherited form of AD. To date, 260 causal mutations have 
been reported for FAD (http://www.molgen.ua.ac.be/ADMutations). These mutations are divided 
between three genes leading to the clinical and neuropathological onset of AD: APP, PSEN1 and 
PSEN2 (Levy et al. 1990; Goate et al. 1991; Rogaev et al. 1995; Levy-Lahad et al. 1995; 
Sherrington et al. 1995). APP encodes the amyloid precursor protein (APP), which is 
metabolized to generate the neurotoxic β-amyloid (Aβ) peptide, the main component of neuritic 
plaques (Selkoe 2001). PSEN1 and PSEN2 encode presinilin 1 and 2 respectively. These proteins 
help compose a large enzyme complex, γ-secretase, directly related to the production of Aβ (De 
Strooper 2003). These causative mutations commonly result in an increased ratio of Aβ42 to 
Aβ40, where Aβ42 is reportedly a more neurotoxic species of Aβ (Scheuner et al. 1996; Klein et 
al. 1999; Chávez-Gutiérrez et al. 2012). The identification of these mutations acted as a 
foundation of the “Amyloid Cascade Hypothesis” and the generation of Aβ (discussed in detail 
in section 1.3.1), remains the dominant hypothesis for the pathological cascade of events in AD 
(Hardy & Higgins 1992; Musiek & Holtzman 2015;).
 Unlike FAD there have been no causal genetic mutations reported for SAD. However, 
twin studies have predicted that the heritability of SAD may be as high as 80% (Gatz et al. 
2006). Initial genetic studies revealed the APOE ε4 allele as a common risk factor for the onset 
of AD in later age. People who are homozygous for the APOE ε4 allele have a 15 times 
increased risk of developing AD while those who are heterozygous show a three times increased 
risk when compared to homozygotes for APOE ε3, the most common genotype (Farrer et al. 
1997). Due to the continued high risk of developing AD associated with the expression of APOE 
ε4, it was proposed as a semi-dominant inherited gene with moderate penetrance (Genin et al. 
2011). Studies have also indicated that apolipoprotein E (Apo-E) has an important role in Aβ 
metabolism and APOE ε4 genotypes have a greater density of neuritic plaques suggesting it may 
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increase Aβ brain deposition (Klunk et al. 2004; Kok et al. 2009; Liu et al. 2013) However, 
despite these findings, APOE expression is not sufficient to cause AD. More recently, large-scale 
GWAS studies have identified several other risk loci associated with SAD. Single nucleotide 
polymorphisms were initially reported in CLU, PICALM, CR1 and BIN1, while more recent 
studies have further identified PLD3, FRMD4A, EPHA1, ABCA7, CD2AP, CD33 and MSA4
cluster (Harold et al. 2009; Seshadri et al. 2010; Naj et al. 2011; Lambert et al. 2013; Lambert et 
al. 2015). Although the precise biological role of these polymorphisms in AD is yet to be 
defined, functional roles have been reported in lipid processing, immune system regulation, 
synaptic function and endocytosis, functions which are reportedly affected in AD (Lynch et al. 
2003; Tateno et al. 2007; Tebar et al. 1999; Ivanov & Romanovsky 2006; Jones et al. 2010; 
Bettens et al. 2013a). 
 Numerous lifestyle and environmental factors have also been associated with SAD. 
Given that most people diagnosed with AD are 65 years or older, with the risk of diagnosis 
increasing with age, the most significant risk factor of AD is ageing. Other medical conditions 
such as elevated blood-pressure, type 2 diabetes and body weight have also indicated increased 
risk of developing AD ( Leibson et al. 1997; Razay & Vreugdenhil 2005; Whitmer et al. 2005; 
Reitz & Mayeux 2014). However, lifestyle choices have also been reported as protective against 
the onset of AD. For example, Mediterranean-style diets are associated with a reduced incidence 
of AD and MCI (Scarmeas et al. 2009; Gu et al. 2010). Similar effects have also been reported in 
those who undergo regular physical activity as well as engage in cognitively stimulating 
activities (Fratiglioni et al. 2004; Carlson et al. 2008). 
 The identification of both genetic as well as lifestyle/medical-based risk factors 
exemplifies the complexity of SAD. As a result, it is likely that a therapeutic approach using just 
one method of therapy may be insufficient to combat AD and a more multi-targeted strategy may 
be required; based on individual risk profiling. Further research is required to understand how 
these multiple risk factors interact and affect AD-related pathogenic mechanisms.   
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1.3 Alzheimer’s Disease Pathology
The “Amyloid Cascade Hypothesis” has dominated many avenues of AD research since 
its original report in 1992. Following the identification of extracellular senile plaques, composed 
of aggregated Aβ, and intracellular NFTs composed of hyperphosphorylated tau protein, it 
hypothesized that the gradual build up of plaques caused a downstream cascade of events 
including NFT development, neurodegeneration and clinical dementia. The two major 
pathological hallmarks of AD therefore have been intensively studied. This section will start by 
explaining the amyloid cascade hypothesis before further reviewing the current findings 
implicating Aβ and tau in the progressive pathology of AD. Given the focus of this thesis 
concentrating on hAPP overexpression and downstream effects of modulating its metabolism a 
predominant focus will be given to APP metabolism and neurotoxic effects of Aβ, however the 
toxic roles of tau and the pathological relationship between tau and Aβ will also be discussed.
1.3.1 The Amyloid Cascade Hypothesis 
A number of hypotheses have been proposed to explain AD pathology, including 
elevated oxidative stress, the “mitochondrial cascade hypothesis” (declining mitochondrial 
activity), the “calpain-cathepsin hypothesis” (age-related decline in the autophagic-lysosomal 
system) and declining blood-brain barrier (BBB) function (Erickson & Banks 2013; Sutherland 
et al. 2013; Yamashima 2013; Swerdlow et al. 2014). However, the most commonly accepted 
AD hypothesis is the amyloid cascade hypothesis, which has remained a focal point of AD 
research since 1991 (Hardy & Allsop 1991). 
The focus on Aβ followed from its sequencing from meningeal blood vessels of AD and 
Downs syndrome (DS) patients prior to the finding that it was the primary component of senile 
plaques (Glenner & Wong 1984; Masters et al. 1985). It was later discovered that the gene 
encoding the precursor of Aβ, the amyloid precursor protein (APP) was located on chromosome 
21 (Goldgaber et al. 1987; Tanzi et al. 1987). Coupled with the observation that individuals with 
DS express a trisomy of chromosome 21 and frequently develop AD neuropathology in later life 
it was proposed that the generation of Aβ was the primary pathological event of AD (Olson & 
Shaw 1969). It was later discovered that mutations in APP gene locus were causative of FAD 
and lead to increased levels of Aβ (Goate et al. 1991; Mullan et al. 1992). Preliminary studies 
had already reported Aβ-mediated neurotoxicity and further disruption of calcium homeostasis 
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leading to NFT development (Yankner et al. 1989; Mattson et al. 1991; Pike et al. 1991; Mattson 
et al. 1992).  Collectively, these findings provided a genetic and pathological basis for the 
amyloid cascade hypothesis. The amyloid cascade hypothesis stated that the “deposition of 
amyloid β protein, the main component of the plaques, is the causative agent of Alzheimer’s 
pathology and the neurofibrillary tangles, cell loss, vascular damage and dementia follow as a 
direct result of this deposition” (Hardy & Higgins 1992).  
The amyloid cascade hypothesis has fuelled AD research for over 20 years and still 
provides a framework for investigation of putative treatments. However, the findings reported 
over the past two decades have generated considerable controversies and challenges for the 
amyloid cascade hypothesis. The most salient challenges concern the spatiotemporal pathology 
of senile plaques and lack of Aβ plaque correlation with neuronal loss and clinical disease 
progression (Braak & Braak 1991; Serrano-Pozo et al. 2011). Contradicting the amyloid cascade 
hypothesis is the fact that NFT pathology shows a significant correlation with neuronal loss 
(Arriagada, Marzloff, et al. 1992; Gómez-Isla et al. 1997; Serrano-Pozo et al. 2011). However, 
despite this aggregated phosphorylated tau has been reported to be present in the brainstem and 
EHC of young adults who are both cognitively normal and amyloid-free (Braak & Del Tredici 
2011). With age, this aggregated tau becomes ubiquitous in the HPC (Price & Morris 1999; 
Knopman et al. 2003). However, the toxic spread of these tau aggregates into neocortical regions 
is dependent on the presence of plaque and increased amyloid SAD (Price & Morris 1999; 
Knopman et al. 2003; Petersen et al. 2006). Similar to the spread of aggregated tau, only 
individuals with plaque pathology display HPC neuronal loss (West et al. 1994; Gómez-Isla et 
al. 1996). It would therefore seem that despite neuroanatomical discrepancies, Aβ aggregation is 
required to initiate and accelerate the neurotoxic properties of NFTs.  
Research suggests that Aβ deposition may commence over a decade prior to the onset of 
clinical AD (Jack et al. 2013a; Jack et al. 2013b). However, it is argued that despite elevated 
levels of plaques in asymptomatic individuals, this should be considered a “preclinical” phase of 
AD (Jack et al. 2013; Roe et al. 2013; Vos et al. 2013). Interestingly, it has been observed that 
individuals who are ostensibly normal, but show plaque pathology demonstrate subtle deficits 
when using the AD Cooperative Study-Preclinical Alzheimer Cognitive Composite (ADCS-
PACC), which combines tests that assess episodic memory, timed executive function and global 
function, as well as accelerated HPC atrophy compared to plaque free controls (Chételat et al. 
2012; Donohue et al. 2014). This suggests that Aβ deposition may exhibit progressive, mild, 
pathology prior to much more rapid disease progression, following the onset of NFT pathology. 
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In contrast to amyloid plaques, soluble (pre-plaque) forms of Aβ are better correlated with tau 
pathology (Handoko et al. 2013; Lesné et al. 2013). As discussed in more detail below, Aβ 
oligomers can directly initiate tau phosphorylation in vitro and in vivo (Ittner et al. 2010; Choi et 
al. 2014; Zhang et al. 2014;). These findings have led to a revised amyloid cascade hypothesis in 
which soluble Aβ oligomers are responsible for the cascade of neuropathological events 
associated with AD (Hardy & Selkoe 2002) (see Figure 1.1). Despite this revised hypothesis, it 
still remains unclear as to why the long prodromal phase of AD, when plaques are known to be 
present, causes little or no neurodegeneration. 
There are several studies that suggest Aβ production and deposition precedes NFT 
pathology in support of the amyloid cascade hypothesis For example, amyloid-based 
immunotherapies in preclinical mouse models of AD have shown that Aβ monoclonal antibodies 
reduced levels of soluble Aβ and phosphorylated tau, improved cognition and electrophysiology 
markers of synaptic plasticity (Schenk 2002; Oddo et al. 2004; Buttini et al. 2005; Hartman et al. 
2005; Klyubin et al. 2005). In contrast to these positive changes in mouse models, 
immunotherapy has not been successful in clinical trials (Mangialasche et al. 2010). The reasons 
for this discrepancy may be numerous but one important aspect of the data is that patients are 
often treated in the mild-moderate stages of AD when neuronal loss is already manifested (in 
contrast to mouse models). However, more recent results released at the Alzheimer’s Association 
International Conference 2015 revealed promising improvements in cognitive measures and CSF 
biomarkers in Phase III clinical trials for anti-Aβ antibodies Solanezumab and Gantenerumab 
and Aducanumab (Phase Ib trial) treating patients in much earlier stages of AD pathogenesis 
(Qian et al. 2015; Reardon 2015). Current ongoing pharmacological studies and Aβ 
immunotherapy trials using pre-symptomatic FAD cohorts, including the Dominantly Inherited 
Alzheimer’s Network (DIAN) and Alzheimer’s Prevention Initiative (API), will provide a key 
test of the amyloid cascade hypothesis (Reiman et al. 2011; Mills et al. 2013). 
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Figure 1.1: A revised schematic overview of the amyloid cascade hypothesis. This shows the sequence of events 
leading to the clinical onset of AD. The curved arrow represents the theory that soluble Aβ oligomers may directly 
cause synaptic and neuronal injury in addition to the activation of neuroinflammatory mediators. (Hardy and Selkoe 
2002) 
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 The evidence summarized above suggests the early version of the amyloid cascade 
hypothesis that originally focused on plaque pathology, as the cardinal event in AD was 
inaccurate. Aβ appears to gradually accumulate for several years before somehow triggering the 
spread of neurotoxic tau pathology, neuronal loss and cognitive decline. It is likely that 
accumulating Aβ may need to reach a threshold before triggering intermediary signaling and / or 
kinase cascades, declining mitochondrial function or altered immune system function that lead to 
pathological changes in brain function and viability (Musiek & Holtzman 2015). Nevertheless, 
the long preclinical phase of AD offers a window of opportunity to prevent accumulation of 
amyloid and thus slow-down or prevent the cascade of events that ultimately causes neuronal 
loss. Results from the DIAN and API studies will be key to testing whether Aβ-related 
interventions provide a viable method of disease modification/prevention in humans.  
1.3.2 β-Amyloid Production 
APP is a highly conserved single transmembrane protein found in both neuronal and non-
neuronal tissue (Jacobsen & Iverfeldt 2009). Three major APP isoforms (APP695, APP751 and 
APP770) have been reported as a result of alternative splicing of exons 7 and 8 (Moir et al. 1998; 
Tanaka et al. 1989). Of these, APP751 and APP770 are mainly (but not exclusively) expressed 
within non-neuronal tissue. APP695 is the most highly expressed isoform in neurons, and recent 
reports suggest ratios of APP isoform mRNAs to be approximately 1 : 10 : 20 (APP770 :  APP751 : 
APP695) (Tanaka et al. 1989; Haass et al. 1991; Selkoe 2001). APP is metabolised in one of two 
separate pathways (Figure 1.2), the non-amyloidogenic and the amyloidogenic pathway. The 
activation of each pathway is determined by the sequential cleavage of APP by enzyme 
complexes, termed α- and γ-secretase (non-amyloidogenic pathway) and β- and γ-secretase 
(amyloidogenic pathway). (Zhang et al. 2011).  
The non-amyloidogenic pathway sequentially cleaves APP by initial -secretase activity. 
α-Secretase activity is mediated by one or more membrane bound enzymes from the family of 
disintegrin and metalloproteinase domain proteins (ADAM), including ADAM9, 10, 17 and 19 
(Asai et al. 2003; De Strooper et al. 2010). α-secretase cleaves APP in the Aβ encoding domain 
of APP, thus preventing the generation of Aβ in this metabolic pathway. The resulting products 
of α-secretase cleavage are the membrane bound C-terminal fragment, 83 amino acid residues in 
size (CTF83) and an amino (N) terminal metabolite, soluble APP (sAPP), which is released 
into the extracellular domain. The CTF83 fragment is further processed by the intramembrane 
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enzyme complex, γ-secretase which generates a small peptide, p3 and a remaining APP 
intracellular domain (AICD) (Haass et al. 1993; Kojro & Fahrenholz 2005; De Strooper et al. 
2010b). The γ-secretase is composed of enzymes PS1 or PS2, nicastrin, anterior pharynx 
defective, and presinilin enhancer 2, all four of which are reported necessary to reconstitute -
secretase activity (Levitan et al. 2001; Francis et al. 2002; Steiner et al. 2002). 
Figure 1.2: Schematic diagram illustrating the two main pathways of APP metabolism. The non-
amyloidogenic pathway shows sequential APP cleavage by α-secretase, followed by γ-secretase. The amyloidogenic 
pathway shows the sequential APP cleavage initiated by β-secretase, followed by γ-secretase and the production of 
neurotoxic Aβ.
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APP can also be metabolised via the amyloidogenic pathway, which leads to the 
production of the neurotoxic Aβ peptide. The initial cleavage of APP is located 99 amino acid 
residues from the C-terminal of APP by β-secretase, or β-site APP cleaving enzyme 1 (BACE1) 
(Sinha et al. 1999; Vassar et al. 1999; Vassar et al. 2009). The cleavage generates soluble APPβ 
(sAPPβ), which is released into the extracellular space, and a remaining 99 amino acid residue, 
C-terminal fragment (CTF99) or βCTF, which encodes Aβ and remains within the membrane 
compartment. The CTF99 then further undergoes multiple intramembrane cleavages by -
secretase at sites referred to as ,  and  (Gu et al. 2001; Zhao et al. 2004; Kakuda et al. 2006; 
Zhao et al. 2007). The initial cleavage at the -cleavage site allows for the release of the AICD 
fragment into the cytosol. The remaining fragment is processed at the -site prior to the final -
site cleavage to generate A. The -site cleavage occurs at variable positions in the A peptide 
domain, mainly after amino acids 38, 40 and 42. This generates A peptides of varying length, 
which has an important effect on the pathogenicity of A (Walsh & Selkoe 2007). Most A
produced is 40 amino acid residues in size (A40), however, approximately 10% is composed of 
42 amino acid residues (A42). It is A42 that is believed to express the most potent neurotoxic 
effects in vivo and is the most commonly found isoform in amyloid plaques (Jarrett et al. 1993; 
Walsh & Selkoe 2007).   
The non-amyloidogenic pathway accounts for more than 90% of APP metabolism, which 
is thought to occur at the cell surface. Evidence has shown -secretase to be enriched at the 
plasma membrane where it is able to outcompete β-secretase cleavage of APP (Parvathy et al. 
1999; Zhang et al. 2011). Studies have also shown that increased APP trafficking to the cell 
surface or inhibition of its internalisation leads to significant reductions in A (Cataldo et al. 
1997). However, BACE1 cleavage of APP occurs within endocytic vesicles. This is due to the 
optimum activity of BACE1 occurring at low pH and for this reason BACE1 is predominantly 
localised within acidic compartments of the cell, such as endosomes and the trans-Golgi network 
(Vassar et al. 1999; Hook et al. 2002). Impaired APP trafficking to the cell surface or stimulating 
APP internalisation showed an increase in BACE1 cleavage products of APP (Haass et al. 1992; 
Lee et al. 2005). However, despite our understanding of these two metabolic pathways, no 
evidence has yet materialised as to what factors increase the processing of APP down the 
amyloidogenic pathway. 
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1.3.3 β-Amyloid Pathology and Senile Plaques 
Following its production from APP metabolism, Aβ is released into the extracellular 
space in a soluble monomeric form. Although not much is understood about the physiological 
roles of Aβ in the healthy brain, it is thought that Aβ plays a role in modulating synaptic activity 
and promoting neuronal survival (Kamenetz et al. 2003; Plant et al. 2003; Plant et al. 2006; 
Pearson & Peers 2006). Kamenetz and colleagues (2003) reported that evoked activity in 
hippocampal neurons in brain slices increased β-secretase cleavage of APP and stimulated Aβ 
production. This increase in Aβ production was thought to act as a negative feedback mechanism 
to depress synaptic activity and prevent excitotoxicity. γ-Secretase inhibitors supported this 
hypothesis in hippocampal neurons by observing greater excitatory activity as determined by 
excitatory postsynaptic current frequencies (Kamenetz et al. 2003). Regulation of synaptic 
activity was further observed in primary cortical neurons following NMDA receptor stimulation. 
(Lesné et al. 2005). This stimulation inhibited α-secretase APP processing and promoted Aβ 
production. The authors from this study suggested that even a modest deregulation of 
glutamatergic neurotransmission may significantly increase the production of Aβ and plaque 
deposition (Lesné et al. 2005). Plant and colleagues have also reported a significant role in 
physiological Aβ and neuronal survival (Plant et al. 2003). Both γ- and β-secretase inhibitors 
incubated with neuronal cell lines for 24 hours led to an increase in cell death, compared to non-
neuronal cell lines. This effect was prevented by co-incubation with Aβ40. (Plant et al. 2003). 
This effect was later associated with Aβ-mediated regulation of potassium channel Kv4 subunit 
expression and hence, further involvement in neuronal excitability (Plant et al. 2006). 
Collectively, these studies provide evidence that Aβ plays an important role in regulating 
neuronal activity. Deregulation of these mechanisms clearly contributes to the pathogenesis 
observed in AD and understanding Aβ, both at a physiological and pathological level, is greatly 
important. 
In AD Aβ monomers aggregate into oligomeric forms of dimers, trimmers and larger 
soluble aggregates before further aggregating into insoluble protofibrils and amyloid plaques 
(Haass & Selkoe 2007; De Strooper 2010). The spatiotemporal pattern of amyloid deposition has 
been reported in two separate staging systems, initially a three-stage progression distinguished 
by Braak and Braak in 1991. More recently, Thal and colleagues proposed a five stage process 
(Braak & Braak 1991; Thal et al. 2002). Thal and colleagues have reported that the spread of 
amyloid initiates exclusively in the neocortex in stage 1 before progressing into allocortical brain 
regions, including the HPC and EHC in the second stage. Aβ deposits continue to spread to the 
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cholinergic nuclei of the basal forebrain and striatum in phase 3 prior to numerous brainstem 
nuclei in stage 4. Finally, cerebellar Aβ deposits occur in stage 5 (Thal et al. 2002; Serrano-Pozo 
et al. 2011). An interesting observation reported by Thal and colleagues was the anterograde 
pattern by which amyloid spread into regions receiving neuronal projections from those already 
exhibiting Aβ deposition (Thal et al. 2002). It was further confirmed that large areas of amyloid 
accumulation, including in the HPC and EHC can be observed prior to the onset of clinical 
symptoms, such as episodic memory deficits, and suggests that early treatment for AD in 
preclinical stages may prevent the further spread of amyloid and subsequent clinical changes 
(Braak & Braak 1991; Thal et al. 2002). 
In contrast, Aβ in its two opposing forms, soluble monomeric Aβ and insoluble plaques, 
shows relatively low levels of neurotoxicity (Martins et al. 2008). However, an interesting 
hypothesis suggests that plaques may act as an inert “sink” that most likely exist in equilibrium 
with neurotoxic soluble oligomeric Aβ (Benilova et al. 2012; Hefti et al. 2013). Indeed, neurons 
in close proximity of plaques exhibit synaptic loss and changes in neuronal activity in a mouse 
model of amyloid pathology (Bezprozvanny 2009). Moreover it has been reported that soluble, 
toxic species of Aβ appear to “seed” amyloid plaques and return to a soluble state in the presence 
of biological lipids leading to cognitive impairments in mice (Martins et al. 2008; Gaspar et al. 
2010). This is suggestive that it is soluble oligomeric forms of Aβ that act as neuropathological 
triggers in AD pathology. 
Over a decade of research has revealed specific neurotoxic “species” of Aβ (Haass & 
Selkoe 2007; De Strooper 2010; Hefti et al. 2013). The collective term for these species is 
otherwise known as “Aβ-derived diffusible ligands” (ADDL) or “soluble oligomeric Aβ” and 
includes Aβ dimers, trimmers, Aβ*56 and Aβ protofibrils. These studies have examined the 
relative toxicity of different ADDLs generated in a variety of methodologies either from in vitro
culture techniques or from transgenic mouse or human AD brains (Podlisny et al. 1998; Chromy 
et al. 2003; Lesné et al. 2006; Shankar et al. 2008). Evidence supporting the neurotoxic 
properties associated with ADDLs comes from a variety of sources. For example, in vitro
evidence has shown that treatment of hippocampal neurons with soluble Aβ dimers extracted 
from the cortices of AD patients caused aberrant tau phosphorylation and neuritic degeneration; 
which was prevented by co-administration of an Aβ immunotherapy (Jin et al. 2011). 
Furthermore, treatment of rodent HPC slices with soluble Aβ oligomers blocks the induction of 
long-term potentiation (LTP), a model of synaptic plasticity processes thought to underpin 
learning and memory (Bliss & Collingridge 1993; Lambert et al. 1998; Townsend et al. 2006). 
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Observations from Townsend and colleagues (2006) that Aβ oligomers blocked LTP appear to 
be supported by in vivo studies showing intracerebroventricular (ICV) administration of soluble 
oligomeric Aβ in rats as well as in transgenic mice caused memory deficits (Lesné et al. 2006; 
Reed et al. 2009). Finally, soluble Aβ is believed to exhibit high-affinity binding to cell surface 
receptors. These receptors include the nerve growth factor (NGF) receptor, and the Frizzled 
receptor, involved in Wnt signaling, binding to which leads to proapoptotic signaling and 
inhibition of canonical Wnt signaling, involved in hippocampal neurogenesis and synaptic 
plasticity (Yankner et al. 1990; Magdesian et al. 2008; Knowles et al. 2009). Aβ-mediated 
inhibition of Wnt signaling is also implicated in reduced inactivation of tau kinase, glycogen 
synthase kinase 3 (GSK3), which can lead to increased tau phosphorylation and NFT 
development (Magdesian et al. 2008). Other synaptic receptors have been identified as Aβ 
receptors and will be discussed in more detail in section 1.3.5. However, it must be considered 
that ADDL preparation protocols vary considerably and treatment concentrations in vitro are 
often orders of magnitude in excess of the nanomolar Aβ levels believed to be in AD brain. 
Therefore findings from these studies must be treated with caution. Nevertheless, the collective 
studies provide convincing evidence for the presence of soluble oligomeric forms of Aβ in the 
brain and their role in mediating neuronal dysfunction. 
1.3.4 Tau Pathology and Neurofibrillary Tangles 
Similar to amyloid plaques, pathological NFTs spread through the brain in a characteristic 
fashion that is a hallmark of AD. The progressive spread of NFTs was characterized by Braak 
and Braak (1991, 1995) into six neuropathological stages. Pathology is first present in the 
transenterohinal layer (stage I-II), including EHC and HPC, before spreading into the limbic 
system (stage III-IV) and isocortical associated areas (V-VI) (Braak & Braak 1991; Braak & 
Braak 1995). In contrast to plaque pathology, NFTs account for a significant amount of neuronal 
degeneration during disease progression and their presence is highly correlated with the cognitive 
decline in patients (Arriagada, Growdon, et al. 1992; Bierer et al. 1995). It is not surprising 
therefore that a wealth of AD research has focused on understanding the pathogenesis of tau and 
developing tau-based therapy ( Giacobini & Gold 2013; Pooler et al. 2013; Herrmann & Spires-
Jones 2015) 
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Tau is most commonly known for its roles in the central nervous system where it is 
predominantly localized in the cytosol of neuronal axons, but is also present in oligodendrocytes, 
somatodendritic compartments and the plasma membrane (Klein et al. 2002, Ittner et al. 2010, 
Pooler et al. 2012). Tau is a microtubule-associated protein that physiologically stabilises 
microtubules regulated by the phosphorylation/dephosphorylation of serine/threonine (Ser/Thr) 
residues by enzymes GSK3, casein kinase 1 (CK1), cyclin dependent kinase 5 (Cdk5) and 
protein phosphatase 2A (PP2A) (Mandelkow et al. 1992; Baumann et al. 1993; Gong et al. 1994;  
Singh et al. 1995). In AD, this regulated phosphorylation of tau becomes deregulated leading to 
abnormal or hyperphosphorylation of the tau microtubule binding domain to develop a toxic 
loss-of-function (Ballatore et al. 2007). Hyperphosphorylated tau protein aggregates into paired 
helical filaments (PHFs), which aggregate further to form NFTs (Mandelkow & Mandelkow 
1998). This abnormal/hyperphosphorylation of tau is caused by increased activity of specific tau 
kinases, such as GSK3 and cdk5, which are also reported to show increased activity in the 
presence of Aβ (Takashima et al. 1998; Alvarez et al. 2001; Noble et al. 2003). Other dementias 
expressing NFT pathology (known as tauopathies), are independent of Aβ pathology, and include 
Frontotemporal dementia with parkinsonism, which is linked to chromosome 17 (FTDP-17), and 
Pick’s disease (reviewed in Yancopoulou & Spillantini 2003). These tauopathies also show 
abnormally phosphorylated tau, similar to AD (except for the absence of amyloid pathology), and 
therefore implicate tau as a significant factor in neurodegeneration.   
An initial difficulty in studying the neurotoxic properties of tau emerged following a lack 
of NFT development in APP mouse models of amyloid pathology (Schwab et al. 2004; Götz & 
Ittner 2008). Therefore, subsequent models have used causative genetic mutations associated 
with FTD to study neurotoxic properties of abnormally phosphorylated tau protein (as reviewed 
in Götz et al. 2007). Investigation of the relationship between amyloid and tau pathology has
demonstrated a more hierarchical relationship whereby Aβ is able to increase tau 
phosphorylation in vitro and in vivo in APP models. However, there is no evidence of plaque 
pathology in tau mouse models (Greenberg et al. 1994; Busciglio et al. 1995; Stein et al. 2004). 
Moreover, transgenic mice simultaneously expressing FAD mutations and FTD tau mutations 
show exacerbated NFT pathology without any significant change in plaque pathology (Lewis et 
al. 2001; Oddo et al. 2003; Ribé et al. 2005). A common mouse model used to study AD is the 
triple transgenic model (3xTg) containing two FAD mutations and one FTD tau mutation and 
generating both plaque and tangle pathology (Oddo et al. 2003). Aβ immunotherapy in this 
model has been reported to both reduce amyloid pathology as well as reduce levels of 
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hyperphosphorylated tau protein (Oddo et al. 2004). However, tau also acts as a mediator of Aβ 
pathology (Roberson et al. 2007; Ittner et al. 2010). Thus, it appears that both Aβ and tau interact 
and express a synergistic relationship (this will be discussed in more detail in Section 1.3.5).
It has previously been reported in vivo that reduced synaptic density and impaired 
synaptic function precedes NFT formation in the P301S model of tau pathology (Yoshiyama et 
al. 2007). Research into the neurotoxic properties of NFTs and tau has suggested that 
synaptotoxic events and cognitive decline modeled in transgenic tau models are better correlated 
to toxic soluble tau oligomers than PHFs and NFTs (Spires et al. 2006; Berger et al. 2007; 
Sydow et al. 2011). These tau oligomers have been reported to be present in the AD brain at 
levels four-fold higher than present in healthy control brains and are likely to contribute to 
cognitive decline and AD neuropathology (Lasagna-Reeves, et al. 2012a). When extracted from 
AD brains, tau oligomers impair LTP in HPC slices of C57Bl/6 mice and when infused via ICV 
administration into the brains of wild type (WT) C57Bl/6 mice lead to impairment in novel 
object recognition memory (Lasagna-Reeves et al. 2012b). These effects reported by Lasagna-
Reeves and colleagues were not observed in tau knockout (KO) models indicating that 
endogenous tau plays a significant role in mediating oligomeric tau toxicity. It was also observed 
that tau pathology had spread from the initial injection site into HPC as well as cortical 
structures. These results compliment previous findings by both Liu et al and deCallignon et al 
who reported that tau pathology was able to spread in a circuit-based manner both in vitro and in 
vivo (Liu et al.,2012; de Calignon et al.,2012). Interestingly, recent reports have suggested that a 
further physiological function of tau may be as a cell signaling molecule (Pooler et al. 2013; 
Pooler et al. 2014). Pooler and colleagues reported that following glutamate stimulation in vitro
neurons appeared to release tau into the synapse. If these oligomeric forms of abnormally 
phosphorylated tau act as potent toxic aggregates contributing to AD, this mechanism may be a 
significant contribution to the progressive spread of tau pathology in AD. Given that Aβ 
treatment of neurons in vitro caused a reduction in glutamate uptake, this may cause a knock-on 
effect and stimulate a release of toxic oligomeric tau further contributing to AD pathology 
(Lauderback et al. 2001; Fernández-Tomé et al. 2004; Li et al. 2009). It is therefore tempting to 
postulate that combined therapies (targeting both amyloid and tau-mediated pathologies), 
dependent on disease state, may offer a more optimal treatment for AD.  
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1.3.5 Aβ and Tau, a toxic synergy at the synapse 
 For well over a decade now, the synapse has been a prime target of amyloid pathology 
(Selkoe 2002). As discussed above, soluble oligomeric Aβ has been reported to cause a loss of 
synapses as well as altering electrophysiological recordings of neurons as observed by impaired 
LTP and enhanced long term depression (LTD) (Walsh et al. 2002; Walsh et al. 2005; Shankar et 
al. 2008; Li et al. 2009). Aβ has been reported to interact with a number of synaptic receptors, 
including the N-methyl-D-aspartate (NMDA) receptor (NMDAR), metabotropic glutamate 
receptor 5 (mGluR5), and the α7 nicotinic acetylcholine (ACh) receptor (α7nAChR) (Wang et al. 
2000; Renner et al. 2010; Rammes et al. 2011; Shankar et al. 2008). The cellular prion protein 
(PrPc) has also recently been observed to act as an Aβ receptor, altering the interaction between 
the PrPc and NMDAR or mGluR5, leading to neurotoxic downstream events (Laurén et al. 2009; 
You et al. 2012; Um et al. 2013). Studies have also suggested that the precise toxic insult may be 
dependent on the receptor influenced by Aβ. The mGluR5 has been implicated in LTD 
induction, while NMDAR have been more linked to Aβ-mediated spine loss (Shankar et al. 
2008). Collectively, evidence continues to demonstrate a convincing role for Aβ-mediated 
toxicity at the synapse, although synaptotoxicity is also thought to be, at least in part, mediated 
by tau. 
Although Aβ and tau are thought to exert toxicity through separate mechanisms, a more 
synergistic relationship has been reported at the synapse. Aβ-mediated NMDAR excitotoxicity 
appears to be dependent on tau, aspects of which will further be examined in Chapter 5 (Ittner et 
al. 2010). Ittner and colleagues identified a unique interaction between tau and an Src kinase, 
Fyn. It had previously been reported that phosphorylated tau, both in the physiological and 
pathological form, resulted in an increased tau-Fyn interaction influencing the spatial distribution 
of tau in vitro (Lee et al. 1998; Bhaskar et al. 2005). It had also been observed that 
hyperphosphorylated tau accumulates in somatodendritic compartments (Götz et al. 1995). Fyn 
phosphorylates the NMDA NR2B subunit, increasing its interaction with postsynaptic density 
scaffolding protein, PSD95, an event associated with NMDAR-induced synaptic excitotoxicity 
(Salter & Kalia 2004; Ittner et al., 2010). Moreover, tau KO mice are less susceptible to synaptic 
Aβ toxicity (Roberson et al. 2007; Ittner et al., 2010). From these observations Ittner and 
colleagues postulated that this tau-Fyn interaction was required for the translocation of both Fyn 
and tau to the somatodendritic compartments in a manner based on tau phosphorylation. 
Successful completion of this would lead to increased phosphorylation of the NR2B subunit, 
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enhanced PSD-95-NR2B interaction and increased synaptic excitotoxicity, which may be 
mediated by increased levels of soluble Aβ as illustrated in Figure 1.3. Ittner and colleagues used 
both a tau KO mouse model and truncated tau model lacking the microtubule binding domain of 
tau, but maintaining the Fyn binding region in order to test this hypothesis. It was thus reported 
in both models that increased Fyn was observed in the soma and reduced Fyn, tau and 
phosphorylated NR2B in synaptosomal preparations in comparison to WT controls. These 
effects were repeated when these tau models were crossed with an APP model of FAD and 
further showed improved spatial working memory (SWM) performance on a T-maze task (Ittner 
et al., 2010). 
 Collectively these results suggest an initial tau-dependent synaptotoxic mechanism 
influenced by Aβ. However, it is likely that with disease progression, continued exposure of 
neurons to Aβ will lead to increased hyperphosphorylation of tau and an overall downstream 
increase in NMDA-NR2B mediated excitotoxicity. It has also recently been reported that Aβ-
PrPc interaction leads to increased Fyn activation and phosphorylation of the NR2B subunit (Um 
et al. 2012). This effect is likely to further contribute to the synaptotoxic effects of this 
mechanism. These observations highlight the attraction towards the development of tau-based 
therapies as well as the importance of targeting Aβ production early in disease progression.
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Figure 1.3: Schematic illustration demonstrating the interactions between Aβ, tau and Fyn leading 
to neuronal excitotoxicity. Src kinase Fyn interacts with phosphorylated tau protein leading to the 
translocation of both proteins to the post synapse (1-2). Fyn at the synapse phosphorylates the NR2B 
subunit of the NMDAR complex, stabilizing its interaction with PSD95 and expression at the synapse (3-
4). Increased Aβ and enhanced expression of NR2B containing NMDARs at the synapse causes 
disproportionate influx of Ca2+ leading to downstream neurotoxicity. 
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1.4 Modeling Alzheimer’s Disease
 One goal of the research presented in this thesis was to characterize the cognitive 
phenotype of the PDAPP mouse model of amyloid pathology; prior to using the model to test the 
effects of an APP antibody on cognition and pathology. This section aims to provide an 
overview of methods used to model AD pathology and cognitive decline in animal models. 
Given the review of AD pathology described in section 1.3, the main focus will be a summary of 
the behavioural abnormalities observed in transgenic models and their relationship to human AD 
abnormalities.   
There has been extensive use of Tg animals to model the pathological features of AD and 
evaluate potential therapies based the amyloid cascade hypothesis. Tg models were first 
developed on the basis of APP mutations linked with FAD. There are currently 49 APP 
mutations that have been identified, located throughout the APP loci and a further 216 Presinilin 
1 mutations within the PSEN1 loci (http://www.molgen.ua.ac.be/ADMutations). Genetic 
constructs of these human FAD mutations have been expressed under the control of a variety of 
promoters in mice (Capecchi 1989; Kobayashi & Chen 2005; Webster et al. 2014). However, no 
APP animal model has to date replicated all core pathological features of AD patients, including 
amyloid-induced tau pathology and substantial neuronal loss (Lee & Han 2013). Regardless of 
this, these models have been used to provide a more detailed understanding of the effects of 
excess amyloid production on brain function, cognition and the potential of therapeutic 
interventions targeting amyloid processing.  
1.4.1 Human APP mutant models of amyloid pathology 
A number of hAPP mutations in mice result in increased levels of A and age-dependent 
cognitive deficits (see Table 1.1; Games et al. 1995; Kobayashi & Chen 2005; Moechars et al. 
1999; Hsiao et al. 1996). The most commonly used mouse models overexpress the Swedish 
double K670M/N671L mutation, located at the BACE1 cleavage site, the Indiana V717F 
mutation, located at the -secretase cleavage site, and the Arctic E693G mutation, located within 
the A sequence (see Table 1.1; Murrell et al. 1991; Mullan et al. 1992; Nilsberth et al. 2001; 
Games et al. 1995; Hsaio et al. 1996; Mucke et al. 2000). Other Tg models have expressed two 
or more separate hAPP and/or human presinilin mutations in one model in an effort to promote 
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the onset and severity of pathology. Indeed, these models show a more rapid onset of pathology 
and cognitive symptoms (See Table 1.1 for gene mutations expressed and comparison of age-
related pathology; Mucke et al. 2000; Puoliväli et al. 2002; Trinchese et al. 2004; Oakley et al. 
2006). Collectively, these models, similar to human AD patients, show an age-related increase in 
levels of Aβ plaque deposition as well as soluble Aβ, relative to WT littermate controls. 
However, they do not show any apparent NFT pathology, nor MTL atrophy; a feature that has 
been correlated with early episodic and semantic memory deficits in patients (see section 1.2.3).  
Nevertheless, similar to AD patients, most APP models display age-related cognitive 
deficits (as illustrated in Figure 1.4 and the progression of different memory deficits detailed in 
Table 1.2; see also Webster et al. 2014). Generalising across a number of cross-sectional and 
longitudinal designs, one common pattern emerges and that is there is an onset of SWM deficits 
that frequently precedes the onset of deficits in object recognition memory (Webster et al. 2014). 
The precise age at which these pathological and cognitive deficits present varies across AD 
models. However, the precise background strains and nature of the APP and/or presinillin
transgene overexpression likely contributes to this variance. 
SWM will be thoroughly discussed in Chapter 3 and object recognition memory in 
Chapter 4. However, in order to better understand the comparisons of behavioural tasks used to 
determine cognitive deficits in AD models, SWM refers to an animals ability to process spatial 
information within one trial of an experiment, but not for subsequent trials thereafter (Honig 
1978; Olton et al. 1979). Tasks commonly used to assess SWM include the radial arm maze, 
which consists of an eight-arm maze whereby each arm is baited with a food/liquid reward. 
Rodents must forage all rewards before completing the task. Any time an animal enters an arm 
that has previously been visited, this is counted as a working memory error. Many more SWM
tasks are also used, an extensive review of which has been reported by (Dudchenko 2004). The 
tasks that test SWM function show particular sensitivity to hippocampal lesions, which has been 
shown to be critical to the processing of spatial information (Olton & Paras 1979; Aggleton et al. 
1986). AD patients also exhibit visuospatial memory impairment and significant hippocampal 
pathology, which is most likely a cause of the memory disorders in AD (Hyman et al. 1984; Jack 
et al. 1992; Carlesimo et al. 1994). 
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Model Mutation Pathology Cognitive Impairments Synaptic Deficits
PDAPP
(Games et al. 1995)
APP Indiana V717F, 
PDGFβ promoter1
Soluble Aβ and dense core and diffuse Aβ plaques in at 4-6 
months2,3. Dystrophic neurites, gliosis, loss of synaptic 
densities, hippocampal atrophy1,4,5.
Spatial learning6,7,8, Spatial reference 
memory7, spatial working memory6,8, 
object recognition memory6, contextual 
fear conditioning9
Rapid decay of LTP at 4-5 months10. 
Reduced cholinergic signalling11
Tg2576
(Hsaio et al. 1996)
APP Swedish, 695.K670N-
M671L, Hamster PrP 
promoter12
Increased soluble Aβ at 6 months of age, plaque deposition 
by 9-12 months of age13. Astrogliosis, microgliosis and 
dystrophic neurites observed14,15
Spatial reference memory16,17, spatial 
working memory18,19, object recognition 
memory20,21, contextual fear 
conditioning22
Reduced dendritic spine density from 
4 months and impaired LTP at 5 
months in the DG23
APP23
(Sturchler-Pierrat et al., 1997)
APP Swedish, 695.K670N-
M671L, Murine Thy-1 
promoter24
Aβ plaques, astrogliosis and increased phospho-tau at 6 
months of age24 . 14-25% neuronal loss at 18 months of 
age25
Spatial working memory26, spatial 
reference memory26,27,28, passive 
avoidance27, Barnes Maze29
Intact HPC LTP up to 24 months, but 
reduced synaptic transmission at 12 
months30. Behavioural training 
induces a more rapid decay of LTP31
TgCRND8
(Chishti et al., 2001)
APP Swedish, 695.K670N-
M671L, and Indiana V717F, 
Syrian hamster PrP 
promoter32
Aβ deposits at 3 months, dense core plaques by 5 months32. 
Increased microglia activation focussed around Aβ 
plaques33
Spatial learning32, spatial reference 
memory32,34, spatial working memory34,35, 
contextual fear conditioning36
Reduced number of HPC neurons and 
dendritic spine loss37.  Diminished 
LTP38
J20
(Mucke et al., 2000)
APP Swedish, 770.K670N-
M671L and Indiana V717F, 
PDGFβ promoter39
Early increase in Aβ-42 at 2 months of age and plaque 
deposition at 5-7 months39. Increased Aβ*56 at 5-6 months 
of age40,42. Increased astrogliosis41 and phospho-tau42
Spatial reference memory40,41, spatial 
working memory41, object recognition 
memory42, contextual fear conditioning43
Reduced neuronal c-fos in the 
DG40,41, HPC synapses41, impaired 
basal synaptic transmission and LTP44
APP/PS1
(Citron et al., 1997)
APP Swedish, 695.K670N-
M671L, PS1, M146L, 
PDGFβ, PrP promoter45
Amyloid deposits by 3m, abundant plaques by 6-9m45.
Early increase of insoluble Aβ-42 and -40 relative to 
Tg2576 mice from 2 months of age 46. 
Spatial reference memory46, spatial 
learning47 and fear conditioned learning48
Impaired LTP from 3-4 months and 
basal transmission from 6 months47.  
5xFAD
(Oakley et al., 2006)
APP Swedish 695.K670N-
M671L, Florida I716V, 
London V717I, PS1 M146L-
L286V, Thy-1 promoter49.
Aβ-42 accumulation and astrogliosis from 2-3 months49,51, 
reduced whole-brain synaptophysin at 4 months49
Spatial working memory49,51, spatial 
reference memory50, context fear 
conditioning50,52 
Impaired LTP at 6 months and 
reduced basal synaptic 
transmission52,53 
3xTg
(Oddo et al., 2003)
APP Swedish, 695.K670N-
M671L, PS1 M146V, Tau 
P301L, Thy1.2 promoter54.
Aβ deposition (6 months) precedes NFT pathology (15 
months)54. Increased phospho-tau at 6 months55 Elevated 
levels of Aβ*56 by 12 months56. Soluble oligomeric Aβ 
originating intraneuronally at 6 months57
Spatial reference memory55,56, spatial 
working memory59, object recognition 
memory54,58, passive avoidance54
Reduced levels of synaptophysin and 
PSD9560. Impaired LTP and reduced 
synaptic transmission54
34
Table 1.1: Overview of commonly used transgenic mouse models of AD. 1: (Games et al. 1995), 2: (Masliah et al. 1996), 3: (Johnson-Wood et al. 1997), 4: 
(Reilly et al. 2003), 5: (Redwine et al. 2003), 6: (Dodart et al. 1999), 7: (Chen et al. 2000), 8: (Hartmann et al. 2005), 9: (Gerlai et al. 2002), 10: (Larson et al. 
1999), 11: (Bales et al. 2006), 12: (Hsiao et al. 1996), 13: (Kawarabayashi et al. 2001), 14: (Irizarry et al. 1997), 15: (Frautschy et al. 1998), 16: (Kotilinek et al. 
2002b), 17: (Pedersen et al. 2006), 18: (Chapman et al. 1999), 19: (Barnes et al. 2004), 20: (Good & Hale 2007), 21: (Hale & Good 2005), 22: (Corcoran et al. 
2002), 23: (Jacobsen et al. 2006), 24: (Sturchler-Pierrat et al. 1997), 25: (Calhoun et al. 1998), 25: (Vloeberghs et al. 2006), 27: (Kelly et al. 2003), 28: (Lefterov et 
al. 2009), 29: (Prut et al. 2007), 30: (Roder et al. 2003), 31: (Middei et al. 2010), 32: (Chishti et al. 2001), 33: (Chauhan et al. 2004), 34: (Janus 2004a), 35: 
(Lovasic et al. 2005), 36: (Hana et al. 2012), 37: (Steele et al. 2014), 38: (Kimura et al. 2012), 39: (Mucke et al. 2000), 40: (Meilandt et al. 2009), 41: (Galvan et al. 
2007), 42: (Escribano et al. 2010), 43: (Saura et al. 2005), 44: (Saganich et al. 2006), 45: (Citron et al., 1997), 46: (Westerman et al., 2002), 47: (Trinchese et al., 
2004), 48: (Dineley et al., 2002), 49: (Oakley et al. 2006), 50: (Ohno et al., 2006), 51: (Jawhar et al. 2012), 52: (Kimura & Ohno 2009), 53: (Crouzin et al. 2013), 
54: (Oddo et al. 2003), 55: (Clinton et al. 2007), 56: (Billings et al. 2007), 57: (Oddo, Caccamo, et al. 2006), 58: (Filali et al. 2012), 59: (Carroll et al. 2007), 60: 
(Revilla et al. 2014) 
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Object recognition memory refers to an animals ability to discriminate previously 
encountered objects over novel objects that have not previously been encountered (Ennaceur 
& Delacour 1988; Ennaceur 2010). When carried out as originally described by Ennaceur and 
Delacour (animals are presented with two identical objects (A+A) for a short acquisition 
phase then allowed a delay period prior to testing. In the test phase one original object, A, will 
be presented with a new, novel object B) recognition memory has been reported to be 
sensitive to perirhinal cortex (PRC) function, independent of the HPC (Barker & Warburton 
2011). However, manipulations of this task to involve spatial or temporal information 
(detailed in Chapter 4 and outlined in Table 4.1) are able to activate neural circuits that 
involve both the HPC and PRC (Barker & Warburton 2011; Warburton & Brown 2015b). 
Many behavioural tasks used to assess cognition in mouse models of AD require intact 
functioning of specific neuroanatomical structures, including the HPC. They further rely on 
the ability of these structures to process and retrieve information dependent on the function of 
specific neuronal circuits. For example, in object recognition memory, the PRC has been 
observed to be responsible for encoding object information, but the HPC for the spatial 
associative information (Barker & Warburton 2011). Moreover, the ventral CA1/subiculum, 
prefrontal cortex and nucleus accumbens have been reported to play significant roles in 
processing information in the RAM in a delay-dependent manner (Floresco et al. 1997). The 
different anatomical structures and circuits involved in these behavioural tasks allows for the 
investigation of their sensitivity toward pathologies associated with Tg AD mouse models and 
potentially how these circuits may be affected in AD. Table 1.1 outlines the onset of amyloid 
pathology in multiple Tg models used to investigate AD. Table 1.2 displays the progressive 
cognitive deficits observed within individual memory systems determined by behavioural 
tasks that are able to assess these types of memory (i.e. RAM – SWM, novel object 
recognition – object recognition memory) and also allows for a comparison of these memory 
types and their decline with age in Tg mouse models. The data presented in Tables 1.1 and 1.2 
suggest that certain neuroanatomical structures and/or circuits are more susceptible to amyloid 
pathology in Tg models based on a similar progressive pattern of deficits illustrated in Figure 
1.4. 
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Figure 1.4: Overview of the progressive cognitive decline in AD. The pattern of cognitive deficits is 
illustrated in order of clinical AD disease severity (A) and cognitive impairment in murine models of AD (B). 
(Webster et al., 2014)   
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Model
Memory Type
AgeWorking 
Memory
Reference 
Memory
Fear 
Conditioned 
Memory
Object 
Recognition 
Memory
PDAPP
≤ 2 months
2, 3 2 2 3-5 months 
1* 2 2 1, 2 6-10 months
1, 2, 3 2 1 2 11-15 months
1, 3 1 ≥ 16 months
Tg2576
≤ 2 months
5 7 4*, 5 3-5 months
5 6 7* 4, 5 6* 6-10 months
7* 11-15 months
6, 7 6* ≥ 16 months
APP23
8 8 ≤ 2 months 
8 9* 8, 9 3-5 months
8 8 6-10 months
11-15 months
9 9 ≥ 16 months
TgCRND8
10 ≤ 2 months
10 11 3-5 months
10 11 6-10 months
11 11-15 months
≥ 16 months
J20
≤ 2 months
12 14 12 15 3-5 months
13, 14 12 15 6-10 months
13 11-15 months
12 ≥ 16 months
APP/PS1
16 ≤ 2 months
16 17* 3-5 months
16 17 6-10 months
11-15 months
≥ 16 months
5xFAD
18 ≤ 2 months
18 20 19* 3-5 months
20 19 6-10 months
20 11-15 months
≥ 16 months
3xTg
21, 22 21, 22 21 ≤ 2 months
23 22 22 3-5 months
23 21 22* 21 22* 21 6-10 months
23 21 21 21 11-15 months
≥ 16 months
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Table 1.2: Overview of the progressive cognitive decline observed in Tg models of AD from 
longitudinal and cross-sectional studies. Tg Models of AD show a pattern of progressive cognitive 
decline within individual tasks, but also across different memory tasks/systems. Earlier deficits are 
commonly observed in spatial working and reference memory tasks and later deficits in object 
recognition memory.  All studies referred to in this table assess cognitive performance at two or more 
age points in either cross-sectional or longitudinal design protocols. Boxes in a light shade of grey 
represent a time point when Tg mice show no significant difference to age-matched WT littermates. * 
Represents Tg mice showing a deficit in any manipulation of the behavioural task being tested, e.g., 
increased retention period prior to test. Those in darker shades represent a deficit when compared to 
WT controls across all manipulations. Numbers in boxes refer to referenced studies reported below. 
All other deficits not reported here are reported in table 1.1, which were taken at one age point only. 
Working memory measures are taken from reported T/Y-maze (Y-M) and specific MWM protocols as 
detailed in (Chen et al. 2000). Reference memory deficits are taken from RAM, or probe trial results 
of RAWM or MWM following repeated acquisition. This measure from MWM has previously been 
defined as reference memory following the escape platform remaining in the same location during the 
repeated acquisition trials (Frick et al. 1995). Fear conditioned memory measures are reported from 
context association and conditioned stimulus (CFC) as well as passive avoidance (PA) of aversive 
stimulus experiments associating either a context of tone with a foot shock. Finally, object recognition 
memory measures an animal’s ability to discriminate novel objects (or object novelty (ON)) from 
those previously encountered. Studies reported here: 1: MWM, ON (Chen, Chen, Knox, Inglis, 
Bernard, Martin, Justice, Mcconlogue, et al. 2000), 2: RAM, ON (Dodart et al. 1999), 3: MWM 
(Hartman et al. 2005), 4: CFC (Dineley et al. 2002), 5: Y-M, CFC (King et al. 1999), 6: Y-M, BM, 
ON, OL (Yassine et al. 2013), 7: MWM (Westerman et al. 2002), 8: MWM, PA (Van Dam et al. 
2003), 9: MWM, PA (Kelly et al. 2003), 10: MWM (Hyde et al. 2005), 11: CFC (Hanna et al. 2012), 
12: MWM, CFC (Saura et al. 2005), 13: RAWM (Du et al. 2008), 14: RAWM (Arancio et al. 2004), 
15: ON (Escribano et al. 2009), 16: RAWM (Trinchese et al. 2004),  17: CFC (Dineley et al. (2002), 
18: Y-M (Oakley et al. 2006), 19: CFC (Kimura & Ohno 2009), 20: Y-M (Shukla et al. 2013), 21: 
MWM, PA, ON (Clinton et al. 2007), 22: MWM, PA (Billings et al. 2005), 23: Y-M (Carroll et al. 
2007).    
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It is intriguing that there is a lack of evidence to suggest a worsening of the cognitive 
deficits once they become apparent. As these deficits are thought to be caused by increasing 
deposition of Aβ, it would be logical that the severity of the deficit should increase with time. 
A numerical age-related worsening of SWM is observed in the PDAPP mouse model at 17-19 
months of age following an initial deficit at 4-6 months of age (Hartman et al. 2005). 
However, Hartman and colleagues fail to show any increase in levels of Aβ at 4-6 months, but 
do report a small increase at 10-12 and much greater deposition by 17-19 months of age. One 
interpretation of this pattern is that the initial deficit is due to an effect of APP
overexpression, whereas Aβ deposition may contribute to the later decline in memory at 17-
19 months of age (Hartman et al. 2005). A further two studies in the Tg2576 and 5xFAD 
models also suggest an age related worsening of memory potentially related to accumulating 
levels of amyloid (Westerman et al. 2002; Shukla et al. 2013). Westerman and colleagues 
demonstrated an initial decline in spatial reference memory at 6-11 months of age. This 
deficit was ameliorated in mice up to the age of 12-18 months by reinforcement of spatial 
reference information (by increased training), however older cohorts  (20-25 months) 
remained impaired. Further analysis revealed that these deficits in older mice were 
significantly associated with levels of insoluble Aβ (Westerman et al. 2002). Similar to this, 
other studies have also demonstrated that increased stimulus (e.g. increased number of foot 
shocks received in a fear conditioned response task), training to criterion protocols in the 
Morris Water Maze (MWM) or simplification of a task can change the age of which a 
cognitive deficit manifests (Chen et al. 2000; Dineley et al. 2002; Kelly et al. 2003; Daumas 
et al. 2008). However, no further studies present evidence that age-dependent increases in 
levels of amyloid lead to progressive cognitive changes. 
The absence of evidence suggesting Aβ-mediated worsening of memory may be due a 
lack of sensitivity in behavioural tests. Alternatively, the absence of severe tau pathology in 
hAPP models may also restrict the severity of cognitive change. Indeed, in human studies, a 
much stronger correlation is reported between tau biomarkers and cognitive decline (Jack et 
al. 2010; Jack et al. 2013). Moreover, cognitive tasks more closely associated with memory 
deficits observed in AD may provide a closer parallel for AD-related cognitive deficits. For 
example, AD patients display episodic memory deficits; an inability to recall events in 
relation to their content and temporal-spatial information (Tulving 1972; Butters et al. 1987; 
Greene et al. 1996). Rodent cognitive tasks have been able to assess an analogue of episodic-
like memory that determine an animals ability to exhibit a memory of “what” happened, 
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“where” and “when”. These tasks include adaptations of object-based and fear conditioned 
memory paradigms (Good et al. 2007; Iordanova et al. 2008; Iordanova et al. 2011). Tg2576 
mice have been reported to express “episodic-like” deficits in an object-based memory task 
(Good et al. 2007). However, no study has yet assessed episodic, or episodic-like memory 
across a range of ages in Tg models of AD. Collectively, these data suggest that Tg models 
provide an important tool for understanding the neural circuits and anatomical structures 
sensitive to AD pathogenesis. The tasks commonly used to assess cognition in mouse models 
of AD have been extensively characterised and it is clear that although there is critical 
involvement of the HPC in these tasks (discussed in Chapter 3 and 4), other circuits and 
structures are also required for the processing of information. For example, fear conditioned 
memory tasks rely on an anxious response to a foot shock in order to form the required 
memory. This task has been shown to be sensitive to both HPC function and the amygdala 
(Phillips & LeDoux 1992; Nader et al. 2000). Increased fear response has been reported in 
PDAPP, J20 and 3xTg mice previously, which was associated with Aβ pathology in the 
amygdala (España et al. 2010). Therefore, when assessing memory in Tg models, appropriate 
control measures or prior assessment of emotionality is advised in order to carry out the most 
optimal cognitive task and provide more reliable conclusions to the structures and circuits 
effected by AD pathogenesis and possible pharmacological intervention. 
1.4.2 The PDAPP Model 
The PDAPP model was originally reported in 1995 by Games et al., and has since 
been used widely in AD research (Games et al. 1995). The transgene, otherwise known as the 
hAPPV717F mutation, expresses a point mutation located around the γ-secretase cleavage site, 
leading to an altered amino acid structure of APP at Valine 717 (Murrell et al. 1991). The 
expression of this transgene is driven by the platelet-derived growth factor (PDGF) β-
promoter, which targets the expression of this mutant transgene to neurons (Sasahara et al. 
1991). The overexpression of hAPP generates a total APP protein level 10-fold higher than 
the amount of endogenous brain murine APP (Games et al. 1995). 
The PDAPP model has traditionally been bred on a mixed background with Swiss-
Webster, DBA/2 and C57Bl6 (Games et al. 1995). However, variations in behaviour have 
been reported to occur between different genetic backgrounds (Brooks et al. 2005; Kobayashi 
& Chen 2005). Brooks and colleagues assessed several mouse strains commonly used as Tg 
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background strains, including DBA/2 and C57Bl/6. Brooks (2005) reported differences in a 
range of behavioural tasks, including novel object recognition task (described and used in 
Chapter 4). One interesting observation was that the total exploration time of objects in the 
novel object recognition memory task was greatest in DBA/2 and BALB/c mice, which 
significantly differed from the 129S2/Sv strain. C57Bl/6 mice also appeared to show reduced 
contact time with objects relative to the DBA/2 strain, of which both of these strains are used 
in the mixed PDAPP background (Games et al. 1995; Brooks et al. 2005). Interestingly, when 
comparing the behavioural data between different labs using the PDAPP model differences in 
object recognition memory have been reported (Dodart et al. 1999; Chen et al. 2000). Dodart 
and colleagues (1999) reported an age-dependent deficit in object recognition memory, where 
as Chen et al (2000) showed no deficit in object recognition memory across all ages tested. 
These mice were generated from different colonies and no data were provided to determine if 
each colony had an equal contribution of each strains phenotype, which may have lead to 
altered behavioural phenotypes. This question of age-related changes in object recognition 
memory in the PDAPP model will be further evaluated in chapter 4. Gender-specific 
differences of behavioural performance have also been reported within background strains, 
including C57Bl/6 (Võikar et al. 2001; Frick & Gresack 2003; Gresack & Frick 2003). 
Studies by Frick and Gresack have revealed that male C57Bl/6 mice showed greater object 
recognition memory performance and lower SWM and reference memory errors in the radial 
arm maze when compared to female C57Bl/6 mice (Frick & Gresack 2003; Gresack & Frick 
2003). For these reasons, in this study, we have bred the PDAPP model on a C57Bl/6 
background and used only male mice to increase the potential of any alteration in behaviour 
between wild type and transgenic to be a phenotype of the hAPPV717F mutation. 
The neuropathology of this model has previously been characterised, both on the 
original mixed background, and C57Bl/6 background only. In summary PDAPP mice have 
shown increased soluble amyloid levels at ages as young as 4 months and plaque development 
from approximately 6-8 months; which significantly increase with age (Games et al. 1995; 
Johnson-Wood et al. 1997; Fryer et al. 2003; Redwine et al. 2003; Reilly et al. 2003; Basak & 
Holtzman 2011). These effects were not observed quite as early in PDAPP mice on a C57Bl/6 
background (Hartman et al. 2005). Hartman and colleagues observed plaque pathology at 10-
12 months of age in the HPC of PDAPP mice, which increased significantly by 17-19 months 
of age (Hartman et al. 2005). This age-related increase in soluble and aggregated plaque 
pathology appears similar to ages reported in Tg2576 mice (6 months soluble, 9 months 
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insoluble) and APP23 mice (6 months of age) (Struchler-Pierrat et al. 1997; Kawarabayashi et 
al. 2001). However, more rapid plaque pathology appears to be common in Tg APP mice 
expressing 2 or more FAD APP genes, including the TgCRND8 (plaque pathology at 3 
months) and 5xFAD (amyloid deposits at 2 months of age; Chishti et al. 2001; Oakley et al. 
2006). However, although these latter models offer a more rapid onset of pathology, multiple 
FAD mutations have not been reported in patient populations and therefore offer an 
unrealistic model compared to those expressing single FAD APP mutations. Thus, the more 
progressive onset of amyloid pathology in the PDAPP mouse model offers a more realistic 
parallel to model AD pathology. 
 The hAPPV717F mutation causes a significant shift in the production of Aβ42 over 
Aβ40, most likely causing the increased propensity for Aβ aggregation in PDAPP mice 
(Suzuki et al. 1994; Zerbinatti et al. 2004). This differs in comparison to other models such as 
the Tg2576, which exhibit a greater level of Aβ40 than Aβ42 and may therefore offer a tool to 
investigate differences in amyloid pathology, aggregation and cognitive effects based on 
individual FAD mutations (Kim et al. 2007). Nonetheless, Aβ deposits appear initially in the 
cingulate cortex before accumulating in the molecular layer of the dentate gyrus (DG), CA1 
region of the HPC, the EHC and further progressing into cortical structures in brains of 
PDAPP mice (Games et al. 1995; Irizarry et al. 1997; Johnson-Wood et al. 1997; Su & Ni 
1998;). No deposition has been reported in the thalamus and cerebellum. The areas of greatest 
deposition are the DG and EHC suggesting the perforant pathway to be most susceptible to 
Aβ pathology (Irizarry et al. 1997; Johnson-Wood et al. 1997). This pathway has been 
reported to show plaque pathology in human AD and is most likely a cause of cognitive 
deficits in tasks sensitive to HPC function (Lippa et al. 1992; Hyman et al. 1986). 
As reported in Tables 1.1 and 1.2, PDAPP mice exhibit age-related cognitive deficits. 
However, age-independent deficits in spatial reference memory have also been reported as 
early as 3 months of age, which precedes plaque pathology (Dodart et al. 1999; Hartman et al. 
2005). Moreover synaptic changes have also been reported early on in PDAPP mice. Mice at 
4-5 months of age show a rapid decay in LTP compared to WT controls (Larson et al. 1999). 
They also exhibit a reduced basal level of acetylycholine (ACh), and reduced ACh release 
following pharmacological stimulation. The latter is consistent with an early impairment in 
cholinergic signalling (Bales et al. 2006). This is most likely an effect of hAPP
overexpression. It has been reported that an overall 12% reduction in total HPC volume of 
PDAPP mice can be observed at 3 months of age (Weiss et al. 2002; Redwine et al. 2003; 
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Reilly et al. 2003). This HPC atrophy is likely to contribute to early age-independent 
cognitive deficits in this model (Dodart et al. 1999; Hartman et al., 2005). Some studies have 
reported age-related changes in object recognition memory and SWM (Dodart et al. 1999; 
Chen et al. 2000; Hartman et al. 2005). These age-related cognitive deficits are associated 
with insoluble Aβ and plaque deposition. Furthermore, treatment with Aβ-immunotherapy has 
showed significant improvement in both object recognition memory and SWM suggesting 
these age-related cognitive deficits observed in PDAPP mice are caused by Aβ accumulation 
(Dodart et al. 2002; Hartman et al. 2005). A more thorough evaluation of SWM and object 
recognition memory will be provided in Chapters 3 and 4 respectively.  
Further differences in PDAPP and WT controls have also been reported. PDAPP mice 
exhibit lower body temperatures with age, compared to WT controls (Huitrón-Reséndiz et al. 
2002). These reduced body temperatures complicate behavioural paradigms using water maze 
protocols, such as the MWM, which would require set water temperatures to prevent 
hypothermia in mice, which has previously been reported to cause impaired learning and 
memory in the MWM (Rauch et al. 1989). PDAPP mice also exhibit increased locomotor 
activity in younger ages (3-5 months) during dark period (active period) of the 12hour light 
dark cycle, but not the light period (Huitrón-Reséndiz et al. 2002). A confounding observation 
was reported that this effect was no longer observed in aged PDAPP mice (20-26 months of 
age), to which the authors provided no explanation of how this effect was likely reversed 
(Huitrón-Reséndiz et al. 2002). Alternative Tg models have also been reported to exhibit 
increased locomotor activity, including 3xTg and Tg2576 mice (Ognibene et al. 2005; Knight 
et al. 2013). Hyperactivity has been associated with impaired spatial learning and memory in 
cognitive tasks including the MWM and RAM (Cain et al. 1996; D’Hooge & De Deyn 2001). 
Therefore considerations must be made when using cognitive tasks to assess memory in Tg 
models of AD, whether underlying behavioural phenotypes, such as hyperactivity, impact on 
impaired memory function reported in these models. 
The data discussed above provide evidence that PDAPP mice model an age-related 
increase in amyloid levels, which are associated with progressive cognitive decline. Early 
cognitive deficits have been reported from 3 months of age, which precede amyloid pathology 
and are likely an effect of APP overexpression (Johnson-Wood et al., 1997; Dodart at el. 
1999). These early changes in behavioural performance must be considered when using 
PDAPP mice to study pharmacological interventions for AD as well as amyloid pathology in 
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this model. However, the PDAPP model provides a useful tool for studying age-related 
cognitive decline associated with amyloid pathology.  
Collectively, Tg models of AD, despite not recapitulating the full human AD 
pathology, have been invaluable in studying the neurotoxic properties of tau and amyloid in 
AD as well as other dementias. These models demonstrate age-related increases in soluble Aβ 
and plaque pathology, which have been correlated to the onset of cognitive deficits. They 
have also provided an in vivo system to test pharmacological compounds or antibody-based 
therapies as well as potential amyloid/tau based therapies. However, from the studies carried 
out thus far it is apparent that a number of considerations must be made before using Tg 
animals in these types of experiments. For example, if characterising the cognitive phenotype 
of a Tg model, it is ideal to have a starting age at which both Tg and WT mice perform at 
relatively equal levels in at least one behavioural task. As amyloid levels increase with age it 
allows the observation of these age-related effects instead of any early developmental effects 
of transgene overexpression. Moreover, it presents an age point to test whether 
pharmacological intervention may reverse or prevent this amyloid-induced deficit. Thus, for 
both cognitive phenotyping and pharmacological assessment of compounds in vivo
considerations of precise model, pathologies reported, age of onset of cognitive deficits and 
sensitivity to relative difficulty of specific cognitive tasks must all be carefully considered for 
appropriate completion of these studies.  
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1.5 Current and Developing Treatment for Alzheimer’s Disease
 In this final introductory section, an overview of the current and developing treatments 
for AD will be discussed. The focus will be on therapies targeting amyloid production and 
Aβ. Given that one of the main aims of this thesis is to test the in vivo effects of 2B3, an anti-
APP BACE cleavage site antibody, a more thorough description of BACE1 inhibitors and 
modulators will be provided in chapter 6. However, current therapy strategies including γ-
secretase inhibitors, passive and active immunotherapies will be discussed below. 
1.5.1 Current Alzheimer’s Disease Treatment
Despite promising therapeutic results from in vivo data, currently only symptomatic 
treatments are approved for AD (NICE Guidelines 2011).  There are currently two main types 
of pharmacological intervention for AD patients. The first major group of pharmacological 
compounds, and the first line of treatment available for AD, are anticholinesterase inhibitors; 
donepezil (Aricept; Pfizer), rivastigmine (Exelon; Novartis) and galantamine (Reminyl; 
Janssen), which act to enhance ACh levels by targeting acetyl cholinesterase, the enzyme 
involved in the breakdown of ACh. Despite all three compounds having similar mechanisms, 
all are reported to be variable in their pharmacology and pharmacokinetics (Scarpini et al. 
2003).  
Galantamine has been further reported to enhance cholinergic neurotransmission 
through postsynaptic mechanisms (Scott & Goa 2000). Rivastigmine is also reported to 
inhibit butyrylcholinesterase as well as acetyl cholinesterase. Butyrylcholinesterase is thought 
to contribute to cholinergic pathology in AD and this may therefore be a further beneficial 
effect of rivastigmine (Arendt et al. 1992; Perry et al. 1978). Memantine is a moderate-to-
severe stage treatment (Ebixa; Eli Lilly), and is an NMDA receptor antagonist (Scarpini et al. 
2003). Memantine disrupts neuronal death mediated by the deregulation of Ca2+ homeostasis, 
caused by excess extracellular glutamate via activation of NMDA receptors (Greenamyre & 
Young 1989; Danysz & Parsons 2012). Drug trials with memantine in advanced AD patients 
reported a significant reduction in deterioration in cognitive and functional measures (Tariot 
et al. 2003). However, all these treatments only target symptoms of AD and are thought to 
modify disease processes per se. For these reasons, scientific research has continued to 
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explore methods to promote clearance, modify processing and/or accumulation of amyloid, as 
well as tau-based interventions (for review please see Pedersen & Sigurdsson 2015) 
1.5.2 Non-immunotherapy-based treatments 
Secretase Inhibitors 
Given the role of β- and γ-secretase in the metabolism of APP and production of Aβ 
they have both been attractive targets for therapeutic intervention. Both targets have 
undergone clinical trials in forms of secretase inhibitors, currently of which 4 clinical stage 
II/III trials are being carried out for BACE1 inhibitors (Qian et al. 2015). A more detailed 
discussion of β-secretase inhibition as a therapy for AD will be reserved until Chapter 6. The 
next section will consider γ-secretase based therapies. 
Early studies indicated that selective mutation or deletion of PS1 (γ-secretase) 
complex prevented transmembrane APP cleavage and significantly reduced levels of Aβ 
(Wolfe et al. 1999; De Strooper et al. 1998). Soon after, pharmacological γ-secretase 
inhibition was reported to reduce Aβ in vitro as well as in vivo, including total Aβ in the brain 
(Dovey et al. 2001). However, the initial preclinical success of γ-secretase inhibitors was not 
reflected in clinical trials. Semagacestat (Eli Lilly) was discontinued following a phase III 
trial due to a lack of cognitive improvement in patients with probable AD, as well as high 
levels of adverse effects, including skin cancer (Doody et al. 2013). A similar failure of 
avagacestat (Bristol-Myers Squibb) was also reported following clinical stage II trials, with 
adverse reaction at higher doses that included skin cancers (Coric et al. 2012). These adverse 
reactions are most likely due to the fact that both γ- and β-secretases are involved in multiple 
physiological pathways (Haass 2004). Indeed, γ-secretase has been reported to have a role in 
Notch signalling, which when disrupted has been linked to oncogenic changes (De Strooper et 
al. 1999; Shih & Wang 2007). 
 The presence of adverse reactions with γ-secretase inhibitors have lead to the 
development of more selective γ-secretase inhibitors, specifically targeting γ-secretase 
cleavage of APP, while have no or limited impact on Notch or other substrates. γ-secretase 
modulation modifies PS1 conformation allowing for altered APP processing and can lead to 
reduced levels of Aβ42 (Lleó et al. 2004; Crump et al. 2013). Second generation γ-secretase 
modulators with increased potency have recently been synthesized and have reduced Aβ42 
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production and improved cognitive measures in Tg2576 mice, without any alteration in Notch 
signalling (Kounnas et al. 2010; Rogers et al. 2012). Whether this strategy will prevent the 
adverse reactions observed with older γ-secretase inhibitors as well as show cognitive benefit 
will be a key question for current and future clinical trials. 
Anti-Aggregation Therapy 
Aβ monomers secreted at physiological pico-nano molar ranges show no signs of 
neural toxicity. An alternative strategy developed for AD treatment prevents the toxic 
aggregation of monomeric Aβ into soluble oligomeric and aggregated forms of amyloid 
(Haass & Selkoe 2007; Selkoe 2013). Early reports showed that a naturally occurring 
glycolipid, scyllo-inositol was able to inhibit Aβ aggregation in vitro (McLaurin et al. 1998). 
Later in vivo studies with TgCRND8 mice showed that scyllo-inositol derivatives reduced Aβ 
plaques and improved spatial memory on the MWM (McLaurin et al. 2006). Scyllo-inositol 
also prevented Aβ-mediated inhibition of LTP in the hippocampus, and prevented cognitive 
deficits in rats receiving ICV administered of Aβ (Townsend et al. 2006). Following these 
positive animal studies, a clinical phase II trial assessed the beneficial effects of ELND005 
(Elan/Transition Therapeutics), a stereoisomer of scyllo-inositol, in mild-moderate AD 
patients. Reports showed a significant reduction in CSF Aβ, however the end point targets of 
improved cognition and activity of daily living were not met (Salloway et al. 2011). This 
compound continued into a clinical phase 2/3 with investigation into secondary aggressive 
and aggitative symptoms in moderate AD patients. In October 2015 it was announced that 
results from this trial had shown significantly reduced aggressive/aggitative behaviours in 
severe AD patients (Transition Therapeutics Press Release, October 2015). This compound is 
now seeking clinical phase III assessment. 
1.5.3 Immunotherapy in Alzheimer’s Disease
In 1996 Beka Solomon’s group suggested that anti-Aβ antibodies could prevent Aβ 
fibril formation in vitro (Solomon et al. 1996; Solomon et al. 1997). This work was later 
demonstrated in vivo following active immunisation against full length Aβ-42 in young, pre-
plaque, and old PDAPP mice with Aβ plaque pathology (Schenk et al. 1999). This study 
demonstrated that immunisation prevented the build up of Aβ plaques in younger mice and 
significantly reduced Aβ-mediated pathology in older mice (Schenk et al. 1999). Soon after, it 
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was reported that systemic delivery of anti-Aβ monoclonal antibodies showed similar effects 
in PDAPP mice; crossing the BBB, binding Aβ plaques and leading to plaque clearance via 
Fc receptor mediated microglial phagocytosis (Bard et al. 2000). Following the publication of 
these two original studies, immunotherapy has been a popular therapeutic strategy. 
β-Amyloid Passive Immunotherapy 
Swiftly following the early success of active Aβ vaccination, Bard and colleagues 
were able to demonstrate significant reduction of amyloid pathology in the PDAPP model, a 
large amount of research has focussed on the removal of A from the brain with the use of 
passive Aβ immunotherapy (Bard et al. 2000; Lemere 2013; Wisniewski & Goñi 2015). 
Passive immunotherapies targeting different A epitopes have reported variable clearance of 
aggregated and soluble A, but often show improved cognition (Solomon & Frenkel 2010; 
Lemere 2013). Peripheral administration of m266, a monoclonal antibody binding the central 
region of A, in the PDAPP model showed improved cognition in object recognition memory 
and SWM (Dodart et al. 2002). Furthermore, following m266 treatment, PDAPP mice were 
reported to show increased serum A, suggesting increased clearance from the brain. 
However, no effects on amyloid burden were observed in the brain (DeMattos et al. 2001; 
Dodart et al. 2002). Similar to this study, Kotilinek and colleagues treated Tg2576 mice with 
BAM-10, an antibody directed against the N-terminal region of A, and reported improved 
spatial learning and memory, without showing a significant reduction in soluble or insoluble 
forms of A (Kotilinek et al. 2002a). A further study utilising the PDAPP model, peripherally 
administered 10D5, an N-terminal directed anti-Aβ antibody (Hartman et al. 2005). Hartman 
et al reported that chronic treatment with 10D5 showed improved spatial learning in the 
MWM, but not on spatial reference memory performance. Mice also showed improved 
hippocampal LTP as well as increased plasma A levels and overall reduced plaque and A
SAD in the HPC (Hartman et al. 2005).  
Collectively the above summary shows that passive immunotherapy improved 
cognitive deficits in multiple transgenic models of amyloid pathology. However, the 
mechanism for the improvement in cognition and how Aβ is cleared from the brain remains 
unclear. Several hypotheses have been proposed for the mechanism by which Aβ is removed 
from the brain, including the peripheral sink, microglial-mediated phagocytosis, antibody-
mediated alteration of Aβ aggregation and neutralization of Aβ toxicity (Fu et al. 2010). 
These mechanisms will be discussed in more detail in chapter 6. A further observation to note 
49
is that different species of ADDLs and localisation of Aβ may be contribute to the impaired 
cognition in Tg models (Billings et al. 2007). Billings and colleagues observed that 3xTg 
mice, that received extensive behavioural training performed better on the MWM and showed 
reduced insoluble Aβ42, but increased soluble Aβ42 when compared to 3xTg mice naïve to 
any behavioural training (Billings et al. 2007). This study also reported that Aβ*56 was 
significantly reduced in 3xTg mice with extensive training, despite the overall increase in 
soluble Aβ42. This pattern of results suggests that precise species of soluble Aβ may 
contribute to the onset of cognitive deficits in the 3xTg model. A study prior to this also 
reported that the accumulation of intraneuronal Aβ was responsible for the onset of cognitive 
deficits in the 3xTg model (Billings et al. 2005). Following ICV administration of anti-Aβ 
immunotherapy, spatial reference memory deficits were reversed and levels of intraneuronal 
Aβ were significantly reduced. A more recent study by Liu et al., (2015) showed that different 
models of AD show different levels of Aβ*56, which may be related to the extent of cognitive 
deficits in each models (Liu et al. 2015). The lack of changes in total soluble Aβ discussed 
above argues for caution when interpreting/analysing changes to Aβ in whole brain extracts 
following an immunotherapy. It may be conceptually more informative to investigate changes 
in different soluble Aβ species. 
Although immunotherapies targeting A directly have shown promising results in 
preclinical studies, early clinical trials provided little support for their use in in humans 
(Winblad et al. 2014; Wisniewski & Goñi 2015). Bapineuzemab (Pfizer), the humanised 3D6 
antibody, was one of the first passive immunotherapies to pass through clinical phase I, II and 
III. Despite showing a reduction in Aβ burden in the brain following PET imaging, little 
clinical benefit was observed in terms of neuropsychological assessment in patients with 
mild-moderate AD (Rinne et al. 2010; Lemere 2013). The Bapineuemab clinical phase III 
trial was terminated in 2012, for reasons believed to be related to little clinical benefit 
(www.clinicaltrials.gov). The humanized m266, Solanezumab (Eli Lilly), is currently in an 
extended clinical phase III trial (www.clinicaltrials.gov). Initial results of Solanezumab 
clinical phase III trial failed to report improved cognition in mild-moderate AD patients. 
However, in 2012, promising results were shown when Lilly combined data of mild AD 
patients only across two separate phase III clinical trials and reported slowed cognitive 
decline (Lilly press release 2012). Clinical phase III trials are now continuing in mild AD 
patients only. Clinical data reported at the Alzheimer’s Association International Conference 
(AAIC) 2015 revealed reduced disease progression and cognitive rating scores 34% better 
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than placebo treated patients (Qian et al. 2015; Reardon 2015). However, these are 
preliminary data of the 108-week time point and not the study end point, which will be 
available following study completion in October 2016. Improved cognitive measures and CSF 
biomarkers were also reported at the AAIC 2015 conference for clinical phase III trials of 
Crenezumab (Roche/Genetech/AC Immune) and Gantenerumab (Roche/Genetech) and 
clinical phase Ib trial data of Aducanumab (Phase Ib trial) (Qian et al. 2015; Reardon 2015). 
These current clinical Aβ immunotherapy trials focus on the prevention as well as treatment 
of AD patients in earlier disease stages. Further prevention trials are also currently 
commencing in individuals with FAD. These include a consortium of Lilly, Roche and the 
Alzheimer’s Association, (The Dominantly Inherited Alzheimer’s Network; DIAN) as well as 
the Alzheimer’s Prevention Initiative partnered by Genetech, the Banner Institute and the 
National Institute of Health (www.nia.nih.gov/alzheimers/clinical-trials). 
2B3, an Anti-Amyloid Precursor Protein Antibody 
Despite the predominant target of immunotherapies being the Aβ peptide itself, other 
groups have focussed on targeting APP and its metabolism by antibody-induced steric 
hindrance of the BACE1 cleavage site of APP (Arbel et al. 2005; Thomas et al. 2006; Thomas
et al. 2011). Thomas et al date developed a novel monoclonal antibody, 2B3, which binds to 
the BACE1 cleavage site of APP, and showed that it reduced the production of A by steric 
hindrance (Thomas et al. 2011). Targeting APP processing has advantages over other 
immunotherapies that target A directly. For example, by targeting the BACE1 cleavage site 
of APP, 2B3 avoids direct inhibition of BACE1. This feature of 2B3 avoids interference with 
BACE1 activity in its alternate processes and pathways, thus reducing the risk of adverse 
reactions (Vassar et al. 1999; Cole & Vassar 2007; Hunt & Turner 2009; Vassar et al. 2009). 
APP metabolic products other than Aβ (e.g., β-CTF) are also believed to express neurotoxic 
properties that may induce behavioural abnormalities (Griffin 2010; Pimplikar et al. 2010; Xu 
et al. 2015;). Moreover, proteolytic cleavage of A has been reported to produce several 
isoforms with truncated N- and C-terminus, which exhibit different pathological properties 
(Pike et al. 1991; Pike et al. 1995; Tekirian et al. 1999; Cleary et al. 2005). Therefore, the 2B3 
or steric hindrance approach avoids issues related to targeting specific forms of A.  
Thomas et al. (2011) showed that 2B3 reduced levels of A in a concentration- and 
time-dependent manner in human astrocytoma (MOG-G-UVW) cells, which express 
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endogenous APP (Thomas et al. 2011). More recently, the reduction in levels of Aβ with 2B3 
administration has been shown in primary cortical neurons derived from a transgenic model 
of AD expressing the hAPP London mutation (Thomas et al. 2013). These data indicate that 
2B3 may also bind to APP in vivo, reduce levels of A and potentially improve cognitive 
function in mouse models of amyloid pathology. 
To date, only one other APP immunotherapy, using BBS1, has been reported in vivo 
(Rakover et al. 2007; Rabinovich-Nikitin et al. 2012). These studies were carried out in 2 
different mouse models, Tg2576 and the 3xTg model, respectively. Both studies reported 
differing effects on levels of A. Rakover et al do not report a reduction in A, but 
Rabinovich-Nikitin et al did. This may be due to differences in BBS1 delivery.  Rakover and 
colleagues administered treatment via peripheral administration, whereas Rabinovich-Nikitin 
and colleagues delivered BBS1 via ICV infusion direct into the brains. However, both studies 
reported improved object recognition memory following BBS1 treatment. However, it must 
be noted that the study using 3xTg mice used a very small number of mice in the treatment 
group (n=3). Given the variability in amyloid production shown by transgenic lines, these 
results should be confirmed in a larger sample of mice (Dodart et al. 1999; Chen et al. 2000; 
Dodart et al. 2002; Hale & Good 2005; Rabinovich-Nikitin et al. 2012). A further point of 
concern is that Rabinovich-Nikitin et al. (2012) did not report data from a WT control group 
to establish baseline levels for behaviour or normal physiological levels of protein. For this 
reason, data from this study must be considered with caution. Further assessment of anti-
BACE1 cleavage site antibodies is still required to validate this strategy as a useful 
therapeutic tool. Assessment of 2B3 in vivo will provide further information of the effects of 
targeting APP metabolism as a treatment for AD and further show any alterations of brain 
biochemistry and cognitive performance regarding this approach.
β-Amyloid Active Immunotherapy 
 Following the successful preclinical results reported by Schenk and colleagues in 
1999, subsequent studies have confirmed reduced amyloid pathology and improved cognition 
in APP transgenic mice following β-amyloid active immunotherapy (for review see Lemere & 
Masliah 2010). Studies also revealed differential biding epitopes of B and T cells. The B cell 
epitopes were located in the first 15 amino acid residues of the Aβ sequence and T cell 
epitopes were located in the mid- and C-terminal region of Aβ (Lemere et al. 2000; Cribbs et 
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al. 2003; Lee et al. 2005). The first clinical trial assessing active immunisation, AN1792, in 
moderate to severe AD patients was comprised of full length Aβ-42, a strong adjuvant (QS-
21) and polysorbate 80, which increased the stability and solubility of the vaccine. This trial 
was ceased because 6% of the treatment group developed meningoencephalitis (Gilman et al. 
2005). Whilst 19% of patients generated plaque-binding anti-Aβ antibodies, those that came 
to autopsy still showed severe cognitive impairment determined by MMSE (MMSE 
scores=0), despite reduced Aβ deposition in the cerebral cortex (Holmes et al. 2008). These 
results indicated that perhaps plaque removal in late stage AD was not an appropriate strategy 
given the level of established NFT pathology and neuronal loss. Although the precise reason 
for the meningeoencephalitis is unknown, there was evidence that an overactive Th1 response 
was present surrounding a number of plaques. This suggested that immunization with the full 
Aβ42 peptide may have induced an autotoxic T cell reaction (Boche & Nicoll 2008). 
 This initial problem in active immunisation triggered interest in passive 
immunotherapy, but also generated a surge in second generation active vaccines focussing on 
the B cell epitope, consisting of the first 15 amino acid residues of the Aβ peptide (Winblad et 
al. 2014). Currently, seven active immunotherapies are in development and under clinical 
trials (www.clinicaltrials.gov; Winblad et al. 2014; Wisniewski & Goñi 2015). Two of the 
most advanced in these trials are CAD106 (Novartis) and ACC-001 (Janssen/Pfizer). Both of 
these vaccines are currently being tested in clinical phase II trials (www.clinicaltrials.gov). 
Currently, no adverse reactions similar to those originally reported with AN1792 have been 
observed and high antibody titres have so far been reported over a chronic vaccination period 
(Hagen et al. 2011; Winblad et al. 2012; Winblad et al. 2014). Cognitive measures in these 
studies are yet to be reported. 
While both active and passive immunotherapies demonstrated positive changes in 
preclinical AD studies, both methods have their limitations. Active immunotherapy engages 
the cellular and humoral immune system to generate and maintain the production of anti-Aβ 
antibodies. This immunisation process uses an antigen (either full length Aβ, or a small 
fragment) that can be delivered with an adjuvant to stimulate high antibody titres. Whilst this 
approach can induce a more chronic antibody production and offer a cost-effective method of 
treatment, the active vaccine can also induce T cell activation and stimulate a pro-
inflammatory response. This adverse reaction can then take a long period of time to stop, 
leading to potentially extensive autoimmune damage. (Gilman et al. 2005; Winblad et al. 
2014; Wisniewski & Goñi 2015). Passive immunotherapy on the other hand focuses on the 
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peripheral delivery of monoclonal antibodies designed to target specific epitopes. This 
approach has the advantage of prompt reversal, should any adverse reactions occur. In 
addition, it has the advantage of being highly specific in terms of targeting individual species 
or conformations of Aβ without disrupting other forms of the protein. However, this method 
of treatment requires more routine administration and is a much more costly method of 
treatment. Moreover, chronic treatment with humanized monoclonal antibodies may lead to a 
gradual development of anti-antibodies, neutralizing the anti-AD treatment effects 
(Brüggemann et al. 1989; Lemere 2013). 
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1.6 Thesis Summary, Aims and Hypotheses 
This chapter has provided an overview of the clinical and pathological hallmarks of 
AD as well as providing a review of some of the systems adopted to model this 
neurodegenerative condition. The current therapies in clinical trials have also been discussed. 
To-date, no significant success has been translated from in vivo studies to clinical trials 
(Karran & Hardy 2014). For this reason, further efforts into developing effective treatments 
that may be translated to the clinical levels are still under investigation. Results so far using 
anti-APP β-secretase cleavage site antibodies 2B3 and BBS1 have shown promising results 
by reduction of Aβ levels in vitro and BBS1 has been reported to have shown this effect in 
vivo with further improved memory performance in Tg models (Arbel et al. 2005; Rakover et 
al. 2007; Arbel-Ornath et al. 2009; Thomas et al. 2011; Rabinovich-Nikitin et al. 2012; 
Thomas et al. 2013). However, this assessment of 2B3 in vivo has not yet been carried out. 
Therefore, to assess the in vivo effects of 2B3 administration, PDAPP mice were 
characterised in terms of behavioural and biochemical phenotype across a range of ages in 
order to determine an optimal age to assess whether 2B3 would be able to improve memory 
performance in vivo and replicate reductions in Aβ as reported in vitro (Thomas et al. 2011; 
Thomas et al. 2013).  PDAPP mice were tested on a foraging-based task, which assessed 
SWM, in Chapter 3, prior to object recognition memory and object-place associative memory 
assessment in Chapter 4. Aβ pathology in the HPC of PDAPP mice was also determined in 
Chapter 4. A hypothesis was determined that PDAPP mice would show an age-dependent 
decline in memory performance that would be associated with an increase in Aβ pathology. 
Once an age-dependent impairment was observed, PDAPP mice were administered 2B3 as 
reported in Chapter 5. Chapter 5 thus tests the main hypothesis of this thesis that inhibition of 
APP metabolism at the β-secretase cleavage site by 2B3 will inhibit Aβ production and 
improve memory performance in PDAPP mice. 
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Chapter 2: General Methods  
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2.1: Introduction 
This chapter details the methods used to breed, maintain and characterise the 
behavioural phenotype and pathological hallmarks of the PDAPP colony, used throughout this 
thesis. It further describes the procedures and experimental design used to characterise 
behavioural phenotypes in PDAPP mice. The biochemical techniques used to analyse and 
quantify protein levels in brain tissue from PDAPP & WT mice are also described. Protocols 
that are specific to individual Experiments are described in the relevant Chapter.  
2.2 Maintenance and breeding of the PDAPP colony 
2.2.1 Housing conditions 
All mice used were housed in standard conditions in cages measuring L 48cm x W 15 
cm x H 13cm with an opaque plastic base and a wire top. The cage floors were covered in 
sawdust, approximately 1cm deep, and contained a cardboard tube, wooden gnawing block 
and approved nesting material. Holding rooms were maintained at a stable temperature and 
relative humidity levels at around 21oC ± 2oC and 60 ± 10% respectively. Mice were given ad 
libitum access to food and water, unless otherwise stated as part of a behavioural test, and 
were kept on a 12hr light/dark cycle. All behavioural testing was carried out during the light 
hours. All animals were health-checked weekly and maintained according to UK Home Office 
and EU regulations and the Animal Scientific Procedures Act (1986). 
2.2.2 PDAPP Breeding 
PDAPP mice have been previously bred on a mixed triple background comprised of 
Swiss-Webster, DB2 and C57Bl/6 to maintain the hAPPV717F genetic mutation (Games et al. 
1995, Eriksen & Janus, 2007). However, the PDAPP colony used throughout this work was 
maintained on a C57Bl/6 (Harlan) background. Heterozygous male PDAPP mice were 
crossed with female C57Bl/6 (Harlan) mice.  At approximately 5 weeks of age pups were 
weaned and males from the litter were group housed or individually housed depending on 
numbers of males in the litter. It was not possible to house two individual males from 
different litters due to aggressive behaviours.  An ear-biopsy was then taken from each mouse 
for genotyping. 
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2.2.3 Genotyping using polymerase chain reaction 
In order to identify the PDAPP mice, a polymerase chain reaction (PCR) was used to 
amplify the hAPP V717F transgene DNA (Figure 2.1). A tissue sample (ear clip) was 
collected from each mouse at 6-8 weeks of age and stored at -20oC. Tissue was digested and 
DNA extracted using DNeasy Blood and Tissue kits (Quiagen, UK). To carry out the PCR, 
5µL of DNA was added to 20µL of Master Mix on ice in DNase, RNase-free aliquots. A 
20µL measure of Master Mix contained 15.425µL nuclease free water (Fisher), 2.5µL 10x 
PCR Buffer (InVitrogen, Paisley, UK), 0.5µL 50mM MgCl2 (InVitrogen, UK), 1.25µL 
deoxynucleotide tri-phosphates (dNTPs, GE Healthcare, Little Chalfont, UK), 0.05μl of each 
primer at a concentration of 100pmol, and 0.125µL of Taq polymerase (InVitrogen, UK). 
Two sets of primers were used in the APP (V717F) Master Mix to target and amplify APP
and Actin. The primers 2010 (Eurofins MWG Operon; 5’ -
ATCTGGCCCTGGGGAAAAAAG- 3’) and 2011 (5’ -GATGTCCTTCCTCCTCTGTTC- 3’) 
targeted and amplified the hAPP V717F mutation, whilst primers MusA-ActinF1 (Eurofins 
MWG Operon; 5’ -CACCACACCTTCTACAATGAGCTG- 3’) and MusA-ActinR1 (5’ -
TCATCAGGTAGTCAGTGAGGTCGC- 3’) targeted Actin. Samples were immediately 
transferred from ice to a thermocycler (MJ Research, Massacheusettes, USA) for 
amplification and run at the following conditions: 72oC for 2 minutes, 36 cycles at 94oC for 1 
minute for DNA denaturing, 60oC for 1 minute for primer annealing, and 72oC for 2 minutes 
to allow for strand elongation. Following these cycles, samples were incubated at 4oC 
overnight. 
DNA products were separated by gel electrophoresis on a 1% agarose gel in TAE 
buffer (Pierce) in an ethidium bromide-free docking system (Bio-Rad, Hertfordshire, UK). 
Prior to separation, 20µL of DNA product was loaded with a loading dye, “Novel Juice” 
(GeneDirex, Newmarket, UK) at 1 part novel juice to 5 parts sample. Samples were run at 
100V for 120minutes and were run alongside a 100bp DNA ladder (GeneDirex), a water 
control, containing nuclease-free H2O in place of DNA and a negative and a positive control 
from mice of a known genotype. Products were visualised using (Olympus X3 camera to 
capture the image and Alpha DigiDoc to process the image) and sized against the DNA 
ladder. The hAPPV717F transgene DNA product is approximately 900bp and appears in 
transgenic (Tg) samples only, whilst the Actin DNA product appears as a band at 
approximately 500bp in each both wild type (WT) and Tg samples containing genomic DNA. 
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Figure 2.1: Example of visualised DNA bands following PCR and gel electrophoresis to identify 
wild type and PDAPP mice. Transgenic mice produce 2 bands of approximately 900 and 500 bp 
representing the hAPP V717F mutation and Actin, whilst wild-type mice produce only the band 
representing Actin. 
2.3 Characterising the behavioural phenotype of male PDAPP mice 
2.3.1 Design 
Heterozygous male PDAPP mice were subjected to three separate tasks to assess 
memory across a range of ages. A full scientific justification for the use of these tasks will be 
reserved for the appropriate empirical chapters; here I describe the basic procedures. These 
tasks tested object-novelty memory, object-in-place (OiP) memory and spatial working 
memory (SWM) in a foraging-based task. All three behavioural tasks were run in a 
counterbalanced design at 6-8, 10-12 and 14-16 months of age (Figure 2.2). Mice were 
divided into to 2 groups, A and B; counterbalanced for age, and genotype. Initially, both 
groups underwent 3 days of habituation. Group A was then subjected to object novelty 
memory assessment, followed by SWM assessment and finally OiP memory. Group B 
underwent this sequence of memory tasks counterbalanced to group A to prevent order effects 
(Figure 2.2). All mice were previously trained at 3-4 months of age as detailed in the tasks 
below to habituate them to handling, the behavioural room, test arena and task-specific details 
(objects and foraging apparatus). 
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Figure 2.2: Schematic diagram illustrating the counterbalancing of the behavioural design to 
characterise memory in PDAPP mice across a range of ages. The same design was used at each age 
point (6-8, 10-12 and 14-16 months of age) in the experiment. ON – object novelty; OiP – object in 
place; SWM – spatial working memory. 
Subjects: 
Heterozygous male PDAPP mice expressing the hAPPV717F genetic mutation and 
WT littermate control mice (all maintained on a C57Bl/6 genetic background (Harlan) as 
previously described (Hartman et al. 2005)) were used in the present study. There were a total 
of 16 Tg and 16 WT littermate controls at the start of this study. Therefore, 8 Tg and 8 WT 
mice were in group A and an equal proportion in group B.  However, due to attrition, the final 
time point assessed cognitive function of 14 Tg mice and 15 WT mice. The same mice were 
used across all tests and ages examined. During this longitudinal study, the aim was to 
maintain mice in group housing conditions although, due to attrition, 3 mice were re-housed 
individually. 
2.3.2 Object Recognition Memory 
Apparatus: 
 A square arena measuring 60cm x 60cm with 40cm high walls was used for all tasks 
in this study. The walls were made of clear Perspex and covered externally with white card. 
The arena was placed on a stand that elevated it 50cm above floor level and was situated in 
the centre of a quiet testing room. The room contained a variety of extra-maze visual cues 
(e.g., wall posters, shelving, equipment etc.) around the walls of the test room at a height 
observable from inside the arena. The position of the extra-maze cues, the experimenter and 
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recording equipment remained constant throughout the study. The floor and walls of the arena 
were wiped clean with 70% ethanol wipes after each sample and test phase to remove odour 
cues. Each trial was recorded using a camera (VM-904K, Shiba Electrics Ltd, Hong Kong) 
suspended above the centre point of the arena connected to a DVD recorder (Panasonic), and 
interaction with the objects was recorded with an electronic stopwatch (Thermo Scientific, 
UK) by the experimenter.
Objects:  
Objects were obtained from a variety of sources. They were matched in size and were 
made of materials such as ceramic, glass and plastic. Objects included garden gnome, vinegar 
bottle an empty salt/pepper grinder. They were weighted appropriately to withstand the 
investigative behaviour of mice. Objects were of a height and shape that made it difficult for 
mice to climb onto them. All objects were wiped clean with 70% ethanol wipes after each 
sample and test phase to reduce the use of differential odour cues.   
Scoring: 
 Object exploration was defined according to the methods described by Ennaceur & 
Delacour, (1988). The time spent actively interacting with an object; this included sniffing, 
gnawing and pushing at a distance no greater than 2cm. Object exploration was not scored if 
the animal was using the object to explore extra-maze environment or was within the 2cm 
area of the object, but not facing it. Time spent exploring objects was recorded across all 
testing with an electronic timer. A discrimination ratio (DR) was used to index the animals’
discriminative performance that was independent of individual differences in contact times; 
this was calculated as follows: 
As each trial was carried out twice, this score was averaged across both trials. DR 
sores above 0.5 indicate a preference to explore novel over familiar objects. 
Total Time Spent Exploring Novel Object (A)
Total Time Spent Exploring Novel and Familiar Objects (A+B)
= Discrimination Ratio 
(DR)
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Procedures:   
Object Recognition Task 
Habituation: Mice were always transferred from a holding cage into the centre of the 
test arena. The start location remained constant throughout all testing in these procedures. 
Mice were allowed to explore freely for 10 minutes on Day 1 in an empty arena. Mice were 
then further habituated for 2 consecutive days to the arena containing 2 identical objects for 
10 minutes each day. Objects were positioned approximately 30cm apart and were positioned 
in a different location on each day. A different pair of objects was used each day and across 
all ages tested.  
Novel-object memory: To assess object novelty memory two identical objects were 
placed in the centre of the arena and mice were allowed to explore the objects for 10 minutes 
during the sample phase (see Figure 2.3A). Preliminary experiments revealed that 3 sample 
phases produced robust recognition across delays. Thus, following each sample phase, the 
mouse was removed from the arena and placed in a holding cage for a delay period of 5 
minutes. Following the third sample phase, mice received either a 5 minute and 24 hour delay 
period in a counterbalanced order. Subsequently, one familiar and one novel object were then 
replaced in the arena (Figure 2.3A). The mouse was returned to the arena for 10 minutes 
during the test period. For both sample and test phases the animals’ exploratory behaviour 
was assessed as described above. Time spent exploring objects in both sample and test phases 
was recorded by an experimenter out of view of the animal. Animals received 2 consecutive 
days of testing for each delay period, which occurred immediately following the 3 
consecutive days of habituation. No sets of objects were re-used for an individual mouse. 
Object-in-Place memory: Four different objects were placed in the centre of the arena 
in a square formation (see Figure 2.3B). Each object was approximately 15cm from the walls 
and 25cm apart from each other. Mice were placed in the centre of the arena and exposed to 
the four different objects for three separate 10 minute sample phases as described for object 
novelty memory. Time spent exploring these objects was recorded. Following the 10-minute 
sample phase, mice were removed from the arena and returned to their home cage for a 5-
minute retention interval. Following the third sample phase, mice underwent either a 5-minute 
or 24-hour delay period before the test phase, whereby the position of one set of two objects 
positioned diagonally opposite each other were switched. Mice were then given a 10-minute 
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test phase and time spent exploring the familiar and novel location of objects was recorded. 
Animals received 2 consecutive days of testing for each delay period. Counterbalancing was 
conducted for the order of objects animals were exposed to and the novel spatial location of 
objects.  
Figure 2.3: Illustration to demonstrate object recognition memory testing paradigms. A) Object 
novelty memory was assessed following 3 sample phases, each separated by a 5-minute retention 
delay indicated by the arrow. Following a delay of 5 minutes or 24 hours mice were subjected to a test 
phase. In the test phase mice were presented with one familiar object and one novel object for a period 
of 10 minutes. B) Object-in-Place memory was assessed in an identical manner as object novelty, 
however, animals were presented with 4 different objects during the sample phase. In the test phase 
the spatial orientation of 2 of these objects was changed. 
2.3.3 Data Analysis 
Data were analysed using Microsoft Excel for calculation of means, DR scores, 
standard deviations and standard error of the mean.  IBM SPSS statistics was used for all 
statistical data analysis as described below. 
Statistical Analysis
IBM SPSS Statistics software was used to statistically analyze all data. An -level of 
0.05 was used for all measures showing statistical significance. All data were checked for 
violations of normality by Shapiro-Wilk test and violations of equal variance by Levene’s 
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test. Due to high levels of variability in contact times, violations of these tests were observed 
(p<0.05). Therefore, data that violated these tests were subjected to transformation based on 
the level of positive/negative skew and reassessed. Data that showed no (further) violations of 
any tests of normality were analysed by mixed measures analysis of variance (ANOVA), 
One-Way ANOVAs and students’ t-tests (one sample, independent samples and paired 
samples) where appropriate. All significant main effects and interactions were obtained 
following Bonferroni correction to adjust for multiple post hoc comparisons. Any data where 
transformation were either not possible or did not prevent violations were analysed by non-
parametric equivalent tests; Mann-Whitney U (Independent Samples t-test), Kruskal-Wallis H 
Test (One-Way ANOVA), Wilcoxn-Signed Rank (Paired-Samples t-test), Friedman Test 
(Repeat Measures ANOVA). Any further statistical analysis carried out in experimental 
chapters will be described in the relevant chapter. 
2.4 Biochemical Analysis of PDAPP and Wild-Type Brains 
2.4.1 Preparation of Brain Samples for Biochemical Analysis 
Brain Dissection 
Mice were culled by cervical dislocation and brains were removed immediately. 
Brains were then dissected bilaterally and the hippocampus removed. Samples were snap 
frozen on liquid nitrogen. Dissected samples were stored at -80oC until further processing.  
Protein Extraction 
Brain samples of each mouse were homogenised in 2% sodium dodecyl sulphate 
(SDS) in dH20 with 1% inhibitor cocktail (Millipore) at 75mg/ml of wet tissue weight. The 
samples were homogenised using a Precellys 24 Dual (Bertin technologies, Montigny
le Bretonneux, France) at 6000rpm for 2*30 seconds with a 30 second delay. The 
homogenate was rotated at 4oC overnight. Homogenate was removed and centrifuged at 100 
000Xg (28 300rpm) for 1 hour at 4oC. The supernatant was carefully removed and diluted 
either in 1:5 EC Sodium Buffer (All chemicals were purchased from Fischer Scientific, 
Loughborough, UK unless otherwise stated; 20mM Na2HPO4/NaH2PO4, 0.2mM EDTA, 
0.4M NaCl, 0.2% (w/v) bovine serum albumin (BSA; Sigma Aldrich, UK), 0.05% (w/v) 
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CHAPS (Sigma Aldrich, UK), 0.05% (w/v) NaN3 at pH 7) or 2:3 in 3 X sample buffer (SB) 
(6.3mMTrisBase, 0.8% (w/v) SDS (BioRad, UK) 20% (v/v) Glycerol, 10% (v/v) -
mercaptoethanol, 2% (v/v) bromophenol blue, dH2O to 50ml). Samples were stored at -20oC.
The insoluble pellet was further dissolved in 70% formic acid (Sigma Aldrich, UK) 
at 150mg/ml original wet tissue weight. Samples were centrifuged again at 100 000xg (28 
300rpm) for 1 hour at 4oC. The supernatant was carefully removed and added 1:20 to a 
neutralising buffer (1M Tris, 0.5M Na2HPO4, pH 11) and stored at -20oC.
Bicinchonic Acid Protein Assay 
A bicinchonic acid (BCA) protein assay kit (ThermoScientific, UK) was used to 
determine the protein concentration of soluble fractions. Diluted bovine serum albumin 
standards (Pierce) were prepared ranging from 2 - 0.003mg/ml in a serial dilution. All 
standards samples and blanks were analysed in duplicate on a 96 well plate. The standards 
and negative blank control (dH2O) were loaded at a volume of 25uL, and samples and 
sample blanks (2% SDS) at 1uL to ensure protein concentrations could be determined by the 
standard curve. A volume of 200μl BCA Working Reagent consisting of 50 parts Reagent A 
and 1 part Reagent B was further added to wells. The plate was mixed thoroughly for 30 
seconds on a plate shaker and incubated at 37o C for 30 minutes. The plate was read at 
absorbance 540nm using a spectrophotometer. Protein concentration of each sample was 
then calculated using Microsoft Excel from the standard curve generated by the BSA 
standards.  
2.4.2 Western blotting 
Samples were diluted 1:3 with 3x Sample Buffer and heated at 70oC for 40 minutes 
to reduce samples prior to first use in Western blot analysis. Samples were then re-frozen for 
subsequent use when they were briefly thawed at 70oC for five minutes before loading. 10μL 
of the molecular weight marker (Precision Plus Protein Standards marker, Bio- Rad 
Laboratories, Hercules, California, USA) were loaded and samples were loaded at 20μg onto 
a 10% polyacrylamide gel (H2O, 3.3% (v/v) acrylamide, 1.25% (v/v) (BioRad) Tris.HCl, 
0.1% (v/v) SDS, 0.05% (BioRad) APS, 0.005% TEMED (Sigma Aldrich, UK)) and 
separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) in 
running buffer (25mM Tris base, 190mM glycine, 0.05% SDS, pH 8.3). The separated 
proteins were then blotted on to a 0.2μm nitrocellulose membrane (Amersham Biosciences, 
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Little Chalfont, UK), before being washed in Tris-buffered saline with Tween 20 (TBST, 2 
mM Tris, 15 mM NaCl, 0.1% Tween-20, pH 7.5) and blocked for 1 hour at RTP in 5% (w/v) 
blotto (non-fat milk powder; Tesco). Membranes were washed three times in TBST for five 
minutes and incubated in 1% blotto with primary antibody prepared as described in Table 
2.1. Membranes were incubated overnight on a roller. The membranes were washed as 
above in TBST. Membranes were then incubated for 2 hours at RTP in secondary antibody, 
conjugated to horseradish peroxidase (HRP; according to primary antibody species, Table 
2.2) prepared in 1% blotto. Membranes were washed again in the same fashion. Bands were 
visualised using enhanced chemiluminescent detection (Super Signal, West Dura, Perbio 
Science, UK) and exposed to high performance chemiluminescent X-ray film (Amersham 
Biosciences). Films were scanned and analysed using ImageJ software. 
Table 2.1: Primary antibodies used in this thesis for Western blot analysis. Species, dilution 
factor and antibody distributor are described. 
Table 2.2: Secondary antibodies used in this thesis for Western blot analysis. Species, dilution 
used and distributor are also described. 
Primary Antibody Species Dilution Source
APP (22C11) Mouse 1:1000 Millipore
NMDAR1 Mouse 1:1000 BD Biosciences
NMDAR2B Rabbit 1:500 Millipore
NMDAR2B Y1472 Rabbit 1:750 Millipore
PSD95 Rabbit 1:1000 AbCam
GAPDH Pre-Conjugated 1:50,000 Sigma
Secondary 
Antibody
Species Dilution Factor Source
Anti-Mouse Horse 1:15,000 Pierce
Anti-Rabbit Goat 1:15,000 Pierce
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2.4.3 Enzyme linked immunosorbent assay (ELISA) 
Amyloid Precursor Protein (APP) ELISA
 APP levels were determined using human APP DuoSet ELISA (R&D Systems, 
Abingdon, UK). A detailed protocol can be found at https://www.rndsystems.com/. In brief, a 
96-well plate (Greiner Bio-One, Frickenhausen, Germany) was coated with the “Capture 
Antibody” at a concentration of 4μg/ml, prepared in phosphate-buffered saline (PBS) 
(137mM NaCl, 2.5mM KCl, 8mM Na2HPO4 and 1.5mM KH2PO4) and incubated overnight at 
RTP. Wells were then washed four times with 0.05% (v/v) PBS-Tween (PBST). Unbound 
sites were blocked by adding 200μL/well of “Reagent Diluent” (RD) (PBS with 1% w/v 
bovine serum albumin (BSA)) with 5% (w/v) sucrose for 60 minutes at RTP. Wells were 
washed and aspirated four times with PBST. Standards and samples were prepared in RD. 
Standards were prepared in two-fold serial dilutions ranging from 20-0.625ng/ml. Samples 
were diluted 1:50 in RD. Standards and samples were loaded at 100μL/well in duplicate and 
incubated at RTP for 2 hours. Wells were then washed four times in PBST. “Detection 
Antibody” was prepared at 300ng/ml and loaded at 100μL/well and incubated for 2 hours at 
RTP. Wells were washed and aspirated four times with PBST. Enzyme-labelled HRP 
Strepavidin was then loaded at 100μL/well and incubated for 20 minutes at RTP in the dark. 
Wells were washed and aspirated four times with PBST. Each well was then loaded with 
“Enzyme Substrate” (0.02M Citric Acid, 0.03M Phosphate, 20mg OPD (o-phenylenediamine 
dihydrochloride; Sigma Aldrich, UK), 0.012% (v/v) H2O2 and incubated at RTP for 30 
minutes in the dark. “Stop Solution” (2.5M H2SO4) was loaded at 50μL/well to stop any 
further colour change. Wells were read at 492nm using a plate reader. Concentrations of APP 
were determined using GraphPad Prism 4.0 and Microsoft Excel and normalised to the total 
protein concentration of each sample.
Amyloid-β (Aβ) 40 (Non-Commercial)
The methods utilised to determine the levels of soluble and insoluble Aβ40 were as 
previously described by Thomas et al., (2006, 2011). A 96-well plate (Greiner Bio-One, 
Frickenhausen, Germany) was coated in the anti-N-terminal human Aβ monoclonal antibody 
(MAb) 6E10 (Covance, Princeton, USA) at a concentration of 0.167μg/ml, diluted in 
carbonate/bicarbonate buffer (15mM Na2CO3, 35mM NaHCO3, pH 9.6) overnight at 4oC. The 
plate was aspirated and washed with PBST (137mM NaCl, 2.5mM KCL, 8mM Na2HPO4, 
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1.5mM KH2PO4, 0.05% Tween20) in between each stage. All incubations were at room 
temperature (RT). Unbound sites were blocked with 1% non-fat milk powder (Tesco) in PBS 
for 30 minutes. Standards and negative controls were prepared in an identical final buffer 
solution as samples (eg. Where samples were diluted 1:10, the PBST was 9 parts to 1 part 
sample preparation buffer; 1 part 2%SDS, 4 parts EC sodium buffer as described in 2.4.1). 
Samples were prepared in PBST. Samples and standards were loaded at 100μl per well in 
duplicate for 2 hours. Standards (Invitrogen) ranged from 10-0.019ng/ml in doubling 
dilutions. Samples of the soluble fraction were prepared at 1:10. Insoluble fraction samples 
were prepared 1:20. Negative controls included the final buffer used to prepare standards. The 
detection antibody, BAM401AP (affinity purified, Autogen Bioclear, Calne, UK), an affinity-
purified antibody specific to the C-terminal of the Aβ40 peptide was used as the detection 
antibody at a concentration of 0.45μg/ml in PBST for 1.5 hours. BAM401AP has been 
verified as specific through western blotting work within the laboratory group (Thomas, 
unpublished data). The secondary HRP-labeled anti-rabbit IgG (Pierce Thermo Scientific) 
was applied at 0.33μg/ml in PBST for 1 hour. The enzyme substrate, o- phenylenediamine 
(OPD), in 0.1M citrate-phosphate buffer (24mM citric acid, 51mM Na2HPO4, pH5) was 
applied and incubated for approximately 20 minutes in the dark. The reaction was stopped 
using 50μl 2.5M H2SO4 and read at 492nm using a spectrophotometer. The ELISA protocol 
provides a lower sensitivity limit of around 0.1ng/ml (Thomas et al., 2006). The concentration 
of Aβ40 was then determined using GraphPad Prism 4.0 and Microsoft Excel and normalised 
to the total protein concentration of each sample.
Aβ40 ELISA (IBL)
A commercial Aβ40 ELISA kit (IBL International GmbH, Hamburg, Germany) was 
used to determine smaller changes in amyloid levels following 2B3 administration in PDAPP 
mice, Chapter 5. A detailed protocol may be found at http://www.ibl-international.com/. In 
brief, standards were prepared in “Assay Buffer” in 2 fold serial dilutions ranging from 100-
1.56pg/ml. Samples were prepared at a 1:4 dilution in “Assay Buffer”. Samples and standards 
were loaded at 100μL/well onto a microtitre plate (pre-coated with Anti-Human Aβ35-40 
(1A10)) and incubated at 4oC overnight. Each well was then washed and aspirated thoroughly 
7 times. “Enzyme Conjugate” (HRP conjugated Anti-Human Aβ NH2 terminus (82E1)) was 
loaded at 100μL/well and incubated for 60 minutes at 4oC. Wells were washed again in an 
identical fashion. “TMB Substrate” was then loaded at 100μL/well and incubated at RTP for 
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30 minutes in the dark. “TMB Stop Solution” was then added at 100μL/well in order to stop 
any further colour change. Change in colour went from blue to yellow. Wells were read in a 
plate reader at 450nm and data analysed in an identical fashion as described above. 
Aβ42 ELISA (Invitrogen)
All assays to quantify levels of soluble and insoluble Aβ42 were carried out using a 
human Aβ42 ELISA kit (Invitrogen Corporation, California, USA). A detailed protocol for 
this kit can be found at www.invitrogen.com. In brief, standards and samples were prepared in 
Standard Diluent Buffer. Standards were prepared in serial two-fold dilutions with a range 
from 1000-15.63pg/ml. Soluble and insoluble samples were diluted at 1:10 in Standard 
Diluent Buffer.  50μL of standards and samples were loaded to the appropriate wells on the 
microtitre plate (Aβ Antibody Coated Wells (antibody targeted the NH2 terminus region of 
Aβ)). 50μL of the Human Aβ42 Detection Antibody was loaded and mixed on a plate shaker. 
The microtitre plate was incubated at 4oC overnight. Wells were washed and aspirated 
thoroughly four times. Anti-Rabbit IgG HRP Working Solution was then added at 100μL/well 
and incubated for 30 minutes at RTP. Wells were washed and aspirated thoroughly again 
before adding Stabilized Chromogen at 100μL/well. Plates were incubated at RTP for 30 
minutes in the dark. 100μL Stop Solution was then added to cease any further colour change 
leading to a change from blue to yellow. Wells were read in a plate reader at 450nm. Data 
were analysed as described above. 
β Carboxy Terminal Fragment ELISA (IBL)
A commercial βCTF ELISA kit (IBL International GmbH, Hamburg, Germany) was 
used to determine changes in βCTF levels following 2B3 administration in PDAPP mice, 
Chapter 5. A detailed protocol may be found at http://www.ibl-international.com/. In brief, 
standards were prepared in “EIA Buffer” in 2 fold serial dilutions ranging from 12-
0.19pmol/L. Samples were prepared at a 1:10 dilution in “EIA Buffer”. Samples and 
standards were loaded at 100μL/well onto a microtitre plate (pre-coated with Anti-APP-C 
Rabbit IgG) and incubated at 4oC overnight. Each well was then washed and aspirated 
thoroughly 9 times. “Labelled Antibody Solution” (HRP conjugated Anti-Human Aβ NH2
terminus (82E1)) Mouse IgG) was loaded at 100μL/well and incubated for 60 minutes at 4oC. 
Wells were washed again in an identical fashion. “Chromogen” was then loaded at 
100μL/well and incubated at RTP for 30 minutes in the dark. “Stop Solution” was then added 
at 100μL/well in order to stop any further colour change. Change in colour went from blue to 
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yellow. Wells were read in a plate reader at 450nm and data analysed in an identical fashion 
as described above. 
2.4.4 Data analysis 
ImageJ software was used to quantify Western blot images. GraphPad Prism software 
was used to analyse all ELISA data presented in this Thesis. All data were further analysed in 
Microsoft Excel and SPSS statistics as described in Section 2.3.3. 
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Chapter 3: Characterising Foraging Behaviour in PDAPP Mice 
71
Chapter Overview 
Chapter 3 describes a foraging-based task that aimed to determine spatial working 
memory (SWM) performance in PDAPP mice across a range of ages. The task used was 
based on a design previously carried out to assess SWM in pigeons, which was shown to be 
sensitive to hippocampal function (Pearce et al. 2005). Pearce and colleagues presented 
pigeons with eight baited pots in different spatial locations in a training arena. To assess WM, 
pigeons had to forage the food reward from all eight pots and any return visits to pots during 
the trial was considered a WM error. In the task used in this chapter, six pots were placed in a 
radial formation, each containing a small liquid reward. Mice were trained to forage rewards 
and during testing were assessed on their ability to forage all six pots. Errors were determined 
as a mouse returning to a pot, which had already been foraged. However, to date, no 
published data have yet been presented using this task in mice in order to show sensitivity to 
hippocampal (HPC) function in the processing of spatial information.  
The first two experiments in this chapter therefore aimed to assess if the successful 
completion of this foraging-based task required HPC function. Male C57Bl/6 mice received 
either bilateral HPC lesions or sham procedures and were assessed on this task in an 
environment enriched with extra-maze spatial stimuli (Experiment 1) and without 
(Experiment 2). The final experiment (Experiment 3) of this chapter determined the 
performance of PDAPP mice on this task across a range of ages to investigate how foraging 
behaviour was affected by age and amyloid pathology in this mouse model. Results from 
these experiments will be discussed with reference to the involvement of the HPC in 
processing spatial information in SWM tasks and other foraging behaviours.  
3.1 Chapter Introduction  
Working memory (WM) was first described by Werner Honig in 1978 as stimulus 
information that is used during one trial of an experiment, but not for subsequent trials 
thereafter (Honig 1978). One of the most common tasks used to assess WM is the radial arm 
maze (RAM), which was first described by David Olton and Robert Samuelson in 1976, 
(Olton & Samuelson 1976). In this task, eight arms radiate from a central platform. At the end 
of each arm is a small food (or liquid) reward, which is readily consumed by rodents. Olton 
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and Samuelson initially observed that rats would retrieve all eight rewards with minimal re-
entries to previously baited arms. Subsequent experiments were carried out testing the theory 
that rats completed the task using WM, as opposed to exploiting kinaesthetic strategies (such 
as simply entering a series of adjacent arm or through the use of odour cues in previously 
visited arms) (Olton et al., 1979; Olton & Samuelson, 1976;  Olton et al., 1977). These 
experiments provided evidence that rats would complete the task by remembering which arms 
had been visited in a single session. However, this information was not transferred between 
sessions when arms were re-baited. It was therefore concluded that rats used a type of WM to 
complete the RAM (Olton et al., 1979). 
Animals use spatial navigation processes to manoeuvre quickly and safely through 
their environments when foraging and/or exploring, as described by Vorhees & Williams 
(2014). In order to reduce energy expenditure and predatorial risk whilst doing so, animals 
must form a memory or cognitive map. The capacity to navigate effectively relies on two 
main navigation systems. Allocentric navigation uses environmental, or distal, cues, whereas 
egocentric navigation relies more on the internal cues generated by the animal’s movement 
and/or proximal cues. The use of allocentric navigation is believed to be supported by the 
hippocampal (HPC) formation (O’Keefe & Nadel 1978; O’Keefe & Conway 1978; Olton & 
Collison, 1979; O’Keefe & Kraemer et al., 1983; Morris et al., 1986; Speakman 1987; Morris 
et al., 1990). Since the early reports by O’Keefe and colleagues, more recent studies have 
revealed distinct contributions of HPC sub-regions, as well as specific receptors, in the 
processing of spatial WM (SWM) information (Steele & Morris 1999; Bannerman et al. 2004; 
van Strien et al. 2009; Sanderson et al. 2010; Murray et al. 2011; Sahay et al. 2011). For 
example, GluA1 receptor knock out mice have been observed to show impaired SWM, but 
not spatial reference memory in a modified version of the six-arm RAM, whilst HPC lesion 
mice showed impairment in both measures (Schmitt et al. 2003). Furthermore, HPC NMDA 
receptor NR2B subunit knockout mice showed impaired SWM performance as determined by 
reduced spontaneous alternation in the T-maze, but intact spatial reference memory 
performance on the MWM (von Engelhardt et al. 2008). Collectively, these observations 
showed that the HPC plays a key role in the processing of spatial information for these tasks, 
however different neuronal mechanisms within the HPC appear to support the processing of
different types of information.
WM deficits are commonly observed in patients with AD and are clinically assessed 
with tests such as the Mini-Mental Status Examination (MMSE), the Montreal Cognitive 
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Assessment (MCoA; Folstein et al. 1975; Nasreddine et al. 2005; Snyderman & Rovner 
2009). These tests lend themselves well to study the progressive cognitive decline associated 
with AD over a longitudinal period. Ideally, cognitive testing in rodents would assess 
identical cognitive functions in paradigms matching those mentioned above. Although not 
identical, SWM tasks provide a method to assess WM in rodent models of dementia. 
Although no current AD model fully recapitulates the full pathology of AD, Aβ-
induced HPC pathology is observed in models expressing FAD mutations in APP and/or 
Presinilin (Games et al. 1995; Hsiao et al. 1996; Sturchler-Pierrat et al. 1997; Holcomb et al. 
1998). Studies have shown significant HPC involvement in WM and the processing of spatial 
information in these tasks and it is therefore not surprising that many of the rodent dementia 
models show age-related cognitive impairments in these types of tasks (Chapman et al. 1999; 
Chen et al. 2000; Minkeviciene et al. 2008; Wirths et al. 2008). Interestingly, the SWM 
deficits in AD models often manifest before the onset of other cognitive deficits, such as 
associative learning and recognition memory impairments, similar to the progressive decline 
of cognitive functions in clinical AD (Webster et al. 2013; Webster et al. 2014). For reasons 
such as these, SWM tasks provide a valuable tool to study the effects of AD-related 
pathologies and their effect on cognition.
Cognitive deficits related to AD-like pathology are sensitive to age, therefore, the 
nature of the tasks and the time it takes to run is an important consideration. Many SWM 
memory tasks require either multiple trials in one day, such as the T-maze and MWM (Steele 
& Morris 1999; Dudchenko 2001). This can be highly time consuming with larger cohorts of 
animals. Furthermore, tasks such as RAM require extensive training with long testing 
protocols lasting over 14 days (Olton et al., 1977; Hodges, 1996). In fact, it has been reported 
that mice have varying levels of performance on the RAM and require extensive training for 
successful performance (Foreman & Gillett 1998; Foreman & Ermakova 1998).  In order to 
promote learning, a water-based version of the RAM (the radial arm water maze; RAWM) is 
often used to assess SWM (Alamed et al. 2006). In this version of the task, mice must swim to 
the end of each arm in order to find a submerged platform. Any re-visits to arms already 
explored is a measure of WM error.  
Water-based tasks exert high levels of stress on animals as observed by increased 
levels of corticosterone and glucocorticoids (Francis et al. 1995; Harrison et al. 2009). The 
HPC has a dense population of glucocorticoid receptors, which have been associated with 
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altered cognitive performance following a stressful episode (Francis et al. 1995; Magarin & 
McEwen 1995; Lupien & McEwen 1997). The results of these tasks may therefore be 
confounded with stress effects on cognition and potential interaction with on-going 
pathological processes. Moreover, extended periods of stress in AD models has been 
associated with increased levels of Aβ production and accelerated learning and memory 
deficits (Green et al. 2006; Jeong et al. 2006; Srivareerat et al. 2009). For this reason the 
differences between control animals and AD models must be treated cautiously. Finally, 
specific tasks require equal performance in other behaviours influencing task performance to 
more thoroughly assess the memory systems involved in successful task completion. For 
example, motor performance as well as anxiety and motivation are non-cognitive based 
behaviours that are associated with these tasks (Kobayashi & Chen 2005; Webster et al. 
2014). These behaviours are affected differentially across AD models. Therefore careful 
consideration must be made when choosing the precise behavioural task(s) for a given mouse 
model of AD.  
 With the above points taken into consideration, we have developed a foraging-based 
task that was designed to provide efficient and effective assessment of SWM. The original 
basis of this task was taken from an avian foraging task reported by Pearce and colleagues 
(Pearce et al. 2005). In this study, pigeons were presented with eight baited pots in different 
spatial locations in a training arena. To assess WM, pigeons had to forage the food reward 
from all eight pots and any return visits to pots during the trial was considered a WM error. I 
adapted this task for mice using an open arena containing six pots positioned in a similar 
formation as the reward locations in a RAM (Figure 3.1). Extra maze stimuli surrounding the 
test arena were available to assist spatial navigation. In each session, the mouse was placed in 
the centre of the arena and was allowed to freely explore and forage the six rewards available 
in the pots. Each pot was baited with a single liquid reward and was not replenished during 
the trial. Mice were required to consume all six rewards in order to complete the task. The 
most efficient behaviour was to visit each pot only once during the session. This required the 
animals to remember within a given trial which pots had been foraged in relation to their 
spatial location. Within a trial, the difficulty of task increased with each successful forage. 
The animals received 4 trials in total, 1/day. A WM error was scored within a trial when a 
mouse returned to a pot previously visited in that session. As well as WM errors, additional 
measures included total time to complete the task, and time taken to engage with the task 
(indices of motivation and motor performance).  
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In order to validate the task as one that requires a functionally intact HPC, the first 
experiment examined the effects of excitotoxic lesions of the HPC in male C57Bl/6 mice on 
the foraging task (Experiment 1). It was hypothesised that HPC lesioned mice would show a 
significant increase in the number of WM errors compared to control animals. Experiment 2 
was designed to determine whether any disruption caused by HPC cell loss was restricted to 
conditions under which animals used extramaze (i.e., spatial) information. All distal 
extramaze cues were removed by drawing a black curtain around the arena and the forging 
pots were each made visually distinctive by the addition of a unique pattern on the outside of 
each pot. The task was then carried out in an identical fashion. To the extent that the HPC 
contributes to processing spatial information but not to a visual discrimination, it was 
predicted that mice with HPC lesions would perform at a similar level to control mice. 
Experiment 3 examined foraging behaviour in PDAPP mice across different age ranges. 
Based on results from previous studies assessing SWM in PDAPP mice, it was hypothesised 
that PDAPP mice would show an age-related deficit in efficient performance of the foraging 
task.    
3.2 Experiment 1: The effects of hippocampal cell loss of foraging behaviour 
3.2.1 Introduction: 
Assessment of the effect of HPC lesions on SWM was carried out on 6-month-old 
C57Bl/6 male mice. C57Bl/6 mice used were wild-type (WT) littermate controls taken from 
PDAPP breeding line to ensure that the mice used to assess HPC involvement in the foraging 
task were as similar as possible to the PDAPP background strain.  
3.2.3 Methods: 
Subjects: 
A total of 26 male C57Bl/6 mice aged 6 months were used to assess HPC involvement 
in this foraging-based WM task. 13 mice received bilateral HPC excitotoxic lesion surgery 
and 13 received control (SHAM) surgery (as described) 3 weeks prior to behavioural 
assessment.  
All mice in experiment 1 and 2 were maintained on a 12-hour light/dark cycle. Two 
days before training and throughout test days, all mice were water deprived to 85% of their 
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original body weight and allowed access to water for only 2 hours per day after testing, but 
maintained on ad libitum food throughout. 
Surgery:  
Mice were anaesthetised with Isoflurane [2-chloro-2-(difluromethoxy)-1, 1, 1-
trifluoro-(ethane)] in O2 during stereotaxic surgery. The skull was exposed by a scalp 
incision. Two holes were drilled on opposite sides of the midline at the appropriate 
coordinates (see Table 3.1). Infusions of 0.09mM N-Methyl D-Aspartic Acid (NMDA, 
Sigma-Aldrich, UK) in sterile phosphate were delivered at a rate of 0.3μl per minute into each 
hemisphere using a 30G cannulae microinjection 2μl Hamilton #75 syringe (Hamilton 
Company, Reno, USA). Following each infusion, the needle was left in place for 2 minutes 
before being retracted slowly. Upon completion, the wound was sutured and the animal was 
given a subcutaneous injection of glucosaline to aid rehydration. In SHAM-operated mice, 2 
holes were drilled in accordance to the stereotaxic coordinates in table 3.1 before being 
sutured. Each mouse was then placed in a 30oC temperature controlled recovery chamber with 
monitoring until the mouse was deemed alert and mobile. Following this mice were returned 
into a new home cage containing a sawdust bedding, covered in tissue paper to prevent any 
sawdust entering the wound. Mice were also provided with sweetened porridge (ReadyBrek) 
and ad libitum supply to food and water.  
Perfusion: 
 Mice were given an intraperitoneal (IP) injection of 0.2ml 200mg/ml pentobarbitol 
(Euthetal, Merial, Harlow, UK) to induce terminal anaesthesia. A cannula was inserted into 
the left ventricle of the heart whereby approximately 50ml of 0.1M PBS (pH 7.4) was pumped 
through the circulatory system. Following this, approximately 100ml of 4% paraformaldehyde  
in 0.1M PBS (PFA) was further pumped through the circulatory system to initially fix brain 
tissue. The brain was then extracted and post-fixed in 4% PFA at room temperature (RTP) for 
6 hours before being transferred to 30% reagent grade sucrose in dH2O. The brain remained in 
sucrose until sinking, indicating it was fully saturated (approximately 48 hours). Brains were 
then sliced using a freezing microtome. 40μm coronal sections were mounted on gelatinised 
slides in 0.1M PBS. Slides were left to dry for 48 hours. 
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Site
Stereotaxic Coordinates
Anterior/Posterior 
(-) 
Lateral
( )
Ventral
(-)
Volume
(uL)
1 1.2 1.0 2.0 0.15
2 1.7 1.0 2.0 0.15
3 1.7 1.5 2.0 0.15
4 2.2 1.0 2.0 0.15
5 2.2 2.0 2.0 0.15
6 2.5 1.5 2.0 0.15
7 2.5 2.2 2.2 0.15
8 3.0 3.0 4.2, 3.0, 2.5 0.15
9 3.6 3.0 4.0, 3.0, 0.15
Table 3.1: The stereotaxic coordinates for bilateral HPC lesions outlined as mm from bregma 
(anterior posterior), from the midline (lateral) and from the dura (ventral). 
Cresyl violet staining:
 Staining of coronal sections was carried out by immersing slides in xylene for 4 
minutes before immersion into descending concentrations of ethanol (100%  90%  70%) 
for 2 minutes per ethanol concentration. Slides were then immersed in dH2O for 2 minutes 
before 0.005% Cresyl violet was applied for 3 minutes. Slides were then further immersed in 
dH2O for 30 seconds before dehydrated in an ascending concentration of ethanol (70% 
90%  100%  100%) for 3 minutes per immersion. Slides were given two final exposures 
to xylene, each for 5 minutes. Finally, slides were cover-slipped with DPX Mounting media 
and allowed to dry for 48 hours. Sections were then imaged using a Leica DMRB microscope 
and images were captured using an Olympus DP70 camera and the programme analySIS-D.  
Apparatus: 
All training and testing was carried out in the same testing room as described in 
2.3.3. Initial training of the task was carried out in identical homecages (L 48cm x W 15 cm x 
H 13cm) with a 1cm deep bed of sawdust covering the floor. White ceramic pots (Lakeland, 
UK) with a diameter of 6.5cm and a depth of 3.5cm were mounted on a wooden cube base 
measuring 3x3x6cm. Pots were secured to the floor of the cage/arena with blue-tac. Following 
initial training, mice were exposed to the same pots in the same arena used in 2.3.3. The floor 
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of the arena was also covered in sawdust, approximately 1cm in depth. In the arena pots were 
arranged approximately 20cm apart. Each trial was recorded using a camera (VM-904K, 
Shiba Electrics Ltd, Hong Kong) suspended above the centre point of the arena connected to a 
DVD recorder (Panasonic DMR E50EBS), and time taken to complete the task was measured 
with an electronic stopwatch (Fischer Scientific, UK) by the experimenter. 
Procedure: 
Training (homecage): Throughout the training and test phase mice were water-
deprived to approximately 90% of their pre-training weight. Water was given for 2 hours 
immediately after training or testing each day.  The first stage of training focussed on mice 
associating a reward with a ceramic pot. During this training the mice had to learn to forage 
the ceramic pots to gain a liquid reward of 1:3 sweetened condensed milk (Nestle) solution 
(prepared in water; H20).  During initial training, mice were removed from their home cage 
and placed into an identical home cage with sawdust bedding together with one ceramic pot 
placed in the centre of the cage for three successive trials. The cage wire lid was removed to 
increase exploration and paper was taped around the edges of the cage to prevent climbing 
out as shown in Figure 3.1A. Between each mouse, pots were wiped clean with 70% ethanol 
wipes to remove any odour cues, and the milk solution replenished accordingly. On the first 
day, the ceramic pot was baited with lowering volumes of milk solution (50, 10 and 5ml) to 
initially engage mice and to encourage interaction with the pot. Once a mouse had foraged a 
small volume of the liquid reward it was removed immediately from the cage and returned to 
its home cage. Mice were given no more than 10 minutes per trial. When mice had 
successfully demonstrated foraging behaviour with the volumes used above, 30uL was 
pipetted into the centre of the pot, the volume used for the remainder of training and testing. 
This process was repeated until each mouse had consumed the 30uL reward in all trials for 2 
consecutive days.  
Training (Test Arena): Mice continued training in the test arena. Mice were 
initially exposed to an empty arena with sawdust covering the base for 10 minutes to allow 
free exploration. For the following consecutive days of training, 2 baited pots were placed 
diagonal across from one another in the arena, 40cm apart (Figure 3.1B). On each day, the 
location of the pots was moved to prevent the development of a spatial bias in the test phase. 
Mice were placed into the centre of the arena and allowed to explore until they had 
consumed both rewards or a 10-minute time limit was reached.  After this the mouse was 
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returned to its home cage.  This process was repeated until all mice foraged in both pots in 
less than 3 minutes.  
Testing: Mice were then tested over the next four consecutive days with one 
session per day.  During these sessions the arena was set up with six pots arranged in a 
circular shape, each 20cm apart (Figure 3.1C). Each pot contained 30uL of milk solution. 
Each mouse in turn was taken from their home cage and placed in the centre of the arena 
always facing away from the experimenter.  The mouse was allowed to explore the arena 
and forage pots until they had consumed the reward in all 6 pots or until 10 minutes had 
elapsed from when the first pot was foraged. Following the trial, mice were returned to their 
home cage. The pots were then wiped clean with 70% ethanol wipes and the milk solution 
replenished before the next mouse.  All test sessions were recorded onto a DVD player using 
an overhead camera.  
Scoring
A score of foraging behaviour was defined as a mouse jumping onto the rim of a pot 
and directing its nose in toward the bottom to consume a reward. A number of error scores 
were taken from this task to assess SWM performance and foraging behaviour. They are 
detailed in Table 3.2 below. It was hypothesized that mice in this task would adopt a win-shift 
strategy whereby a pot that has been foraged from should not be returned to, as no further 
reward will be obtained. A win-shift strategy on the RAM implies that rats will search for 
food in different spatial locations (or maze arms) once foraging a reward from a given arm 
(Olton & Schlosberg 1978). Win-stay implies that rats will return to the same arm to obtain a 
further reward. Olton and Scholberg (1978) determined that rats adopted a win-shift over a 
win-stay strategy when being tested on the RAM (Olton & Schlosberg 1978). Mice have also 
been reported to exhibit win-shift foraging behaviour in both RAM and RAWM protocols 
(Hyde et al. 1998; Anagnostaras et al. 2003). This would suggest that mice would be likely to 
adopt a win-shift foraging strategy for successful task completion. Therefore, WM should 
prevent mice from returning to pots where a liquid reward has already been consumed.  
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Figure 3.1: Figure to illustrate pots and the pot arrangement through training and testing. (A) 
Shows an individual pot in a homecage used for initial training. (B) Two pots placed opposite each 
other in the arena-training phase. (C) Six pots are placed in a radial formation for the test phase of the 
foraging task.  
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Error 
Measurement
Definition Example of behaviour
Error A mouse returning to a pot where the 
reward was previously consumed.
A mouse forages a reward from 
pot A and leaves pot A. The 
mouse then returns to pot A 
(Error).
Repeat Error A mouse returning to a pot where an 
error was already made. Hence, 
repeating the error.
A mouse forages a reward from 
pot A, and leaves pot A. The 
mouse then returns to pot A 
(error). It leaves pot A again, 
forages in pot B before 
returning to pot A (repeat 
error). 
Error in neighbouring  
pot
A mouse making an error 
immediately in the same pot or the 
neighbouring pot to which it has just 
foraged (if this pot has already been 
foraged in).
A mouse forages a reward from 
pot A. The mouse then forages in 
pot B before foraging in pot A
Error in distal pot A mouse making an error in a pot 
one or more distant from a pot it has 
just foraged or made an error in.
A mouse forages in pot A. The 
mouse then forages in pot C 
before retuning to pot A.
Chaining Response When a mouse forages pots in a 
sequence of 3 or more pots 
immediately adjacent to one another
A mouse forages in pot A, B, and 
C etc. until the sequence is 
broken. 
Perseverative Error A mouse returning to a pot 
immediately after receiving a 
reward, or immediately after making 
an error.
A mouse forages in pot A. The 
mouse leaves pot A and 
immediately returns to pot A.
Table 3.2: Overview of the types of errors scored to assess SWM in a foraging-based task. Errors are 
defined and examples of when these errors are scored are described.
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In this scoring procedure, “total error” acts as a baseline measure of SWM function. 
As described in Table 3.2, further measures were used to assess within-trial behaviours, such 
as foraging strategy, perseveration and factors representing more severe working memory 
deficits. 
A repeat error was scored as a mouse returning to a pot where an error had already 
been made during the trial. This type of error was independent of the perseverative error 
described, as it was not an immediate return to a pot that had just been foraged. As total error 
incorporated all types of errors made within the trial, the repeat error was able to provide a 
more distinctive WM error measure.  
A measure of chaining response was recorded to determine whether mice foraged in a 
random sequence or had a tendency to alternate pot choices within a given trial. This measure 
aimed to establish if animals adopted different foraging strategies to complete the task. The 
spatial distribution of errors was also assessed to compliment the measure of chaining 
response. Errors made in pots neighbouring a pot that had just been foraged or distal to those 
just foraged were recorded. This score was calculated as a ratio against total errors made by 
each mouse to give a measure that was unbiased by differences in total errors between groups. 
Perseverative errors were also scored when a mouse returned immediately to a pot it 
had just successfully foraged in or made an error in. Perseverative errors were recorded as this 
behaviour has been observed in HPC lesioned animals and have further been reported in AD 
patients and mouse models (Lamar et al. 1997; Huitron-Resendiz et al. 2002; Wang & Cai 
2006; Yoon et al. 2008).
Further measures were taken to look at motor performance as a measure of total time 
taken to complete the task from when the mouse was placed into the arena to when the final 
reward was consumed. Lastly, the time taken to observe engagement with the task (i.e. the 
time taken from when the mouse was placed into the arena to when it foraged the first pot) 
was recorded. This measure was thought to reflect the effect of anxiety or motivation on 
engagement with the task. 
Statistical Analysis
Data were analysed using Microsoft Excel for calculation of mean number of 
errors, times and standard error of the mean. IBM SPSS Statistics software was used to 
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analyse all data statistically. An -level of 0.05 was used for all measures showing statistical 
significance. All data were checked for violations of distribution and homogeneity of 
variance by Shapiro-Wilk test and Levene’s test respectively. Due to high levels of 
variability in data sets, and a large number of zero scores in the error measures, violations of 
these tests were observed (p<0.05). Therefore, data that violated these tests were subjected to 
transformation (i.e. Square root, log-10) based on the level of positive/negative skew and 
reassessed. Data that then showed no further violations of distribution were analysed by 
repeat measures ANOVA and independent samples t-test. In t-tests that reported violations 
of Levene’s test for equality of variance, results reported were from a modified t-test, the 
Welch t-test, which accommodates for unequal variances. Data that could not be transformed 
due to the presence of zeros in the data were analysed using non-parametric statistics. Mann-
Whitney U Tests were used to compare between group factors and Wilcoxon Signed-Rank 
Tests or Friedman’s test with Bonferroni correction to adjust for multiple post hoc 
comparisons were used to compare within subject factors.  
3.2.4 Experiment 1 – Results: 
Histology: 
An example of bilateral HPC lesions are presented in figure 3.3 and the maximum 
and minimum tissue damage obtained as a result of excitotoxic lesions are displayed in 
Figure 3.3 and 3.4 respectively. In this study 2 lesioned animals were removed from the 
study following histological analysis due to completely intact ventral hippocampal structure. 
Eight mice showed a complete lesion of the HPC with the exception of the most posterior 
ventral DG (mostly observed unilaterally) and small sparing of the ventral pyramidal cell 
layer of the HPC. Three mice showed complete removal of the dorsal HPC with further 
bilateral damage to the ventral HPC. As observed in Figure 3.4, the minimal lesion effect 
showed intact ventral HPC structure unilaterally at the most posterior reference. However 
damage was observed in the ventral DG. Cortical damage around the infusion site was 
observed in all lesioned animals, predominantly of the parietal association cortex and visual 
cortex. No HPC damage or other damage was present in the SHAM control mice except two 
mice that displayed a small amount of damage unilaterally to the visual cortex. Further 
damage observed was not focussed around the craniotomy site and was likely related to 
mechanical damage during tissue sectioning.  
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Figure 3.2: Cresyl stained example of hippocampal lesion and SHAM control mice. HPC lesions 
(right) show a significant loss of the HPC structure compared to intact HPC formation in the SHAM 
control mice (left). 
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Figure 3.3: Schematic illustration of the maximum hippocampal lesion. The level of HPC (and 
cortical) damage is illustrated by the shaded areas. Each section is denoted from the distance posterior 
to bregma.
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Figure 3.4: Schematic illustration of the maximum hippocampal lesion. The level of HPC (and 
cortical) damage is illustrated by the shaded areas. Each section is denoted from the distance posterior 
to bregma. 
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Time Taken:
The mean measurements of time taken across all 4 trials can be observed in Table 3.3. 
Lesion mice showed very similar times to SHAM controls for the total time taken to complete 
the task as well as the time taken to engage with the task. This was confirmed following 
independent samples t-tests. Total time taken showed no significant difference between 
groups, t(22)=-0.15, p>0.5. Time taken to engage with the task also showed no significant 
difference between groups, t(22)=0.83, p>0.1. These results indicate that any changes in 
memory performance between these two groups are not an effect of gross motor and/or 
motivational changes. 
Perseverative Errors:
Lesion mice appear to show a greater number of perseverative errors as observed in 
Table 3.3. Data were analysed using Mann-Whitney U Test, which confirmed that HPC 
lesioned mice made a greater number of perseverative errors when compared to sham-control 
mice, U=118.5, z=2.7, p<0.01. 
Chaining response: 
 To determine if HPC lesioned mice showed any difference in strategy to complete the 
task, chaining responses were determined (Table 3.3). HPC lesioned mice showed a greater 
number of chaining responses compared to SHAM controls as determined by Mann-Whitney 
U test, U=113.0, z=0.1, p<0.05. 
Time Measure Treatment
SHAM Lesion
Mean SD Mean SD
Total Time (s) 190.8 56.10 194.4 64.33
Engagement Time (s) 43.1 24.57 36.1 19.15
Perseverative Errors 0.73 0.61 2.80 3.53
Chaining Response 0.69 0.36 1.06 0.36
Table 3.3: Results table showing motor and foraging behaviours in the foraging task. Means and 
standard deviation (SD) in HPC lesion mice (n=11) and SHAM controls (n=13) are reported.  
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Total Errors:
To determine if there was any main effect of lesion on total errors and task acquisition, 
a repeated measures ANOVA with the between subject main effect of lesion and within-
subject main effect of trial was used to assess the number of errors recorded across the 4 
trials, as observed in Table 3.4 and Figure 3.5A. Results showed no significant main effect of 
trial, F(3, 66)=0.48, p>0.5 and no significant trial * group interaction, F(3, 66)=0.03, p>0.5 
when assessing with-subjects factors. However, a main effect of treatment was reported, F(1, 
22)=154.2, p<0.05.  
Trial Treatment
SHAM Lesion
Mean SD Mean SD
Trial 1 4.38 2.33 6.75 5.96
Trial 2 4.69 2.84 7.08 3.88
Trial 3 4.15 2.19 6.17 3.88
Trial 4 3.54 3.13 6.17 3.56
Table 3.4: Table showing the mean number of errors made in each trial by HPC lesion mice (n=11) 
and SHAM controls (n=13).
Repeat Errors:
Inspection of Figure 3.5B showed that HPC lesioned mice displayed a greater number 
of repeat errors. This was confirmed following analysis by independent samples t-test, 
t(16.29)=-2.86, p<0.05. 
Ratio of Neighbouring and Distal errors to Total errors:
The number of errors in neighbouring and distal pots are presented as a ratio of total 
errors, corrected for perseverative errors (Figure 3.5C). Independent samples t-test revealed 
that HPC lesion mice have a significantly higher ratio of error scores in neighbouring pots 
than SHAM controls, t(22)=2.14, p<0.05. HPC lesion mice further made less errors in distal 
pots when compared to SHAM control mice, t(22)=2.14, p<0.05.  
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Figure 3.5: Foraging behaviour in HPC lesion mice. Measures of SWM in SHAM control (n=13) 
and HPC lesion mice (n=11). Data were averaged across four trials for each mouse and mean score 
for each group is reported. Error bars represent the S.E.M. A) Total number of errors. B) Total 
number of repeat errors. C) The ratio of neighbouring and distal errors to total errors made. *p<0.05. 
90
3.2.5 Discussion 
Results from Experiment 1 demonstrate that lesions of the HPC impair performance of 
the foraging task. HPC lesion mice made a greater number of total errors and repeat errors, 
which were used to determine WM performance in this study. This result agrees with previous 
HPC lesion experiments assessing SWM function in both rats and mice in WM tasks (Nadel 
& Moscovitcht 1997; Cassel et al. 1998; Deacon et al. 2002; Winters et al. 2004). However, 
interestingly previous studies in SWM assessment have reported task acquisition over a 
period of trials or days on maze-based WM tasks (Cassel et al. 1998; Morgan et al. 2000; 
Richter et al. 2013; Wilson et al. 2015;). This was not observed in this task by either sham-
controls or HPC lesioned mice. This indicates a validity to compare means of HPC lesion 
mice and sham-controls across all four trials, which are unbiased by any changes across trials. 
The analysis of the distribution of errors showed that HPC lesioned mice made a 
greater portion of their errors in adjacent pots than in distal located pots. This result was 
consistent with the observed increase in chaining foraging responses in HPC lesioned mice 
whereby mice would forage three of more pots immediately adjacent to one another before 
breaking this response and foraging in a pot in a more distal location. Thus, HPC lesioned 
mice appeared to adopt a different foraging strategy in order to complete the task by foraging 
in a sequential pattern and in pots with adjacent locations, whereas SHAM control mice 
appeared to forage pots in neighbouring and distal locations in an equal ratio, likely using the 
extra-maze spatial stimuli to complete the task.  
HPC lesioned mice showed no difference in total times and latency to engage with 
foraging compared to SHAM controls. This suggests that performance was not affected by 
gross motoric or motivational changes following the lesion. HPC lesioned mice showed a 
greater level of perseverative behaviours. This result is further in agreement with other reports 
observing this type of behaviour in HPC lesion animals (Olton & Werz, 1978; Johnson et al., 
1996; Whishaw & Tomie, 1997; Pouzet et al., 2002).  
Collectively, the data from the present experiment indicated that the HPC was required 
for effective foraging behaviour. Experiment 2 evaluated whether the changes in total errors, 
response perseveration and pattern separation were restricted to circumstances where 
performance did not rely on processing extra-maze cues.  
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3.2 - Experiment 2:  Assessment of non-spatial WM in HPC lesion mice 
3.2.1 Introduction: 
To test that the deficits in the foraging task were due to impaired processing of spatial 
information, a non-spatial version of this task was carried out. Two distinct types of 
navigation have been reported, allocentric and egocentric. Egocentric navigation employs the 
use of more internal cues such as self-movement or internal markers of the environment and 
therefore is not considered as spatial information. Allocentric navigation relies strongly on the 
use of distal cues or landmarks in order to form a cognitive map and has been associated with 
HPC function (Morris et al. 1986; Morris et al. 1990; Vorhees & Williams 2014). It is 
hypothesized that mice used allocentric navigation in order to complete the foraging task in 
Experiment 1. 
To test this hypothesis, in Experiment 2, extramaze cues were removed by drawing a 
black curtain around the arena and pots were each given a novel pattern. Mice therefore relied 
upon non-spatial cues in order to complete the foraging task. Studies have previously found 
conflicting results when assessing HPC involvement in non-spatial memory tasks (Olton & 
Feustle 1981; Aggleton & Road 1986; Morris et al. 1986; Raffaele & Olton 1988; Ennaceur & 
Meliani 1992). For instance, Olton and Feustle examined non-spatial WM through the use of 
an enclosed 8-arm RAM where each arm was given a distinctive discriminative stimuli. Rats 
with fimbria-fornix lesions showed working memory impairments relative to sham controls 
(Olton & Feustle 1981). However, Aggleton and Road used a three-arm Y-maze delayed non-
matching-to-sample task, which revealed that rats with HPC lesions were able to learn and 
perform the task similar to sham controls (Aggleton & Road 1986). Precise reasons for these 
differences remain speculative and are likely influenced by factors including task difficulty, 
levels of proactive interference, maze type etc. Despite conflicts between studies implicating 
the HPC in non-spatial WM tasks, experiment 2 aims to test a hypothesis that the working 
memory deficits reported in experiment 1 were due to impaired processing of spatial 
information instead of a more total WM impairment. 
3.2.2 Design: 
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The same mice used in experiment 1 were used in experiment 2. In this task each pot 
was given a novel design and all visual spatial extra-maze cues were obscured.  
Apparatus: 
All apparatus used was identical to that used in experiment 1. A black curtain was now 
drawn around the test arena to remove the distant spatial cues in the testing room. The pots 
were also changed. The size and shape remained identical, however, each pot was now 
individually designed and patterned distinctively from one another (Figure 3.6). 
Figure 3.6: Novel pot designs used in experiment 2. All 6 pots were given a novel design (4 are 
shown in this figure). Position of the pots was changed each day, but the radial formation remained. 
Procedure: 
  No pre-training was carried out and animals received training as follows:  
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Test Phase: Following testing in the spatial version of the task, mice were then 
subjected to a non-spatial WM assessment. An identical testing procedure was used as 
described above, however a black curtain was drawn around the test arena to remove all 
visual extra-maze cues. All pots were placed in the same arrangement as previously described, 
but each pot now had a unique design (Figure 3.6). To prevent any familiarity in the pattern of 
the pots occurring across the 4 days of testing, pots were swapped in their location each day 
so that no individual pot was neighbouring the same 2 pots on any test day. 
3.2.3 Experiment 2 - Results: 
Time Taken:
The mean measurements of time taken across all 4 trials can be observed in table 3.5.  
HPC lesion mice showed very similar times in both total and engagement times to SHAM 
control. This was confirmed following independent samples t-tests. There was no significant 
difference in total time taken to complete the task between groups, t(22)=-0.28, p>0.5, or for 
animals to engage with the task, t(22)=0.20, p>0.5. 
Perseverative Errors:
Initial observation of Table 3.5 shows a greater number of perseverative errors made 
by HPC lesion animals. This observation was supported by independent samples t-test 
statistical analysis, which revealed a significant difference between SHAM controls and HPC 
lesioned mice, t(22)=-0.97, p<0.05. 
Chaining strategy
 HPC lesioned mice showed a greater chaining response when compared to SHAM 
control mice as determined by independent-samples t-test, t(22)=-4.20, p<0.001 (Table 3.5). 
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Time Measure Treatment
SHAM Lesion
Mean (s) SD Mean (s) SD
Total Time 169.85 71.02 178.06 69.87
Engagement Time 40.12 16.51 38.77 15.99
Perseverative Errors 0.75 0.51 1.65 1.53
Chaining Response 0.62 0.47 1.44 0.45
Table 3.5: Results table showing non-WM measures made by HPC lesion mice (n=11) and SHAM 
controls (n=13). 
Total Errors:
To determine if there was any overall mean difference in total errors and task 
acquisition, a repeated measures ANOVA with the between subject main effect of lesion and 
within-subject main effect of trial was used to assess the number of errors recorded across the 
4 trials, as observed in Table 3.6 and the total mean in Figure 3.7A. Results showed a non-
significant difference between lesion group, F(1, 22)=131.4, p>0.1, a non significant within-
subjects main effect of trial, F(3, 66)=2.44, p>0.05, and a non-significant trial * treatment 
interaction, F(3, 66)=2.42, p<0.05.  
Trial Treatment
SHAM Lesion
Mean SD Mean SD
Trial 1 4.23 3.14 7.92 3.49
Trial 2 4.31 2.53 4.23 3.85
Trial 3 4.77 4.95 3.92 1.94
Trial 4 3.77 1.54 4.15 2.10
Table 3.6: Table showing the mean number of errors made in each trial by HPC lesion mice (n=11) 
and SHAM controls (n=13). 
Repeat Errors:
No significant difference between groups was reported for mean repeat errors (Figure 
3.7B), as determined by Mann-Whitney U Test, U=89.0, z=1.02, p>0.1. 
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Neighbouring/Distal Errors:
The ratio of neighbouring and distal errors are presented as a ratio to total errors made 
(figure 3.7C) to assess the pattern of errors in lesion and SHAM control mice. An independent 
samples t-test reported that HPC lesioned mice made a greater number of errors in 
neighbouring pots, t(22)=-3.04, p<0.01 and less in distal pots,  t(22)=3.58, p<0.01 when 
compared to SHAM control mice. 
Figure 3.7: Foraging behaviour in HPC lesion mice. Measures of SWM in SHAM control (n=13) 
and HPC lesion mice (n=11). Data were averaged across four trials for each mouse and mean score 
for each group is reported. Error bars represent the S.E.M. A) Total number of errors. B) Total 
number of repeat errors. C) The ratio of neighbouring and distal errors to total errors made. *p<0.05. 
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3.2.4 Discussion: 
 Results from this experiment indicated that HPC lesion mice displayed a similar WM 
performance to SHAM control mice when spatial stimuli were removed. Similar to 
experiment 1, no differences were observed in the times taken to complete the task or engage 
suggesting the removal of spatial cues did not affect states of emotion in these mice or motor 
performance differentially. Moreover, perseverative behaviour was observed in HPC lesion 
mice across both spatial and non-spatial versions of the foraging task.  
Two further group differences that were observed in experiment 1 continued to 
present in experiment 2; chaining response and the greater ratio of errors made around a 
previous search location in mice with HPC lesions. The former effect showed that HPC 
lesion mice continued to display a chaining response pattern, ie, animals would tend to 
simply forage in the adjacent pot (1, 2, 3) regardless of whether this pot had had previously 
been foraged in or not. Complimentary of this response, HPC lesioned mice also continued 
to show a greater level of errors made in pots adjacent to where they had just foraged. 
Collectively, as discussed in experiment 1, these differences imply that HPC lesion mice 
adopted a different strategy for task completion compared to SHAM control mice. Given a 
continued response across both experiments, this strategy is likely independent of spatial 
stimuli.  
Despite HPC lesion and SHAM mice displaying apparent different strategies, mice 
performed at comparable levels in regards to total errors and repeat error measures. These 
results indicate that HPC lesion mice were more able to use local cues to guide overall 
performance in this version of the foraging task and performed at a comparable level to 
SHAM controls. Moreover, these results suggest that inhibition of processing of spatial 
information by HPC ablation was responsible for impaired performance in experiment 1. 
 The results of experiment 2 show that HPC lesion mice are able to perform the 
foraging task at levels that are similar to sham-control mice. This would suggest that HPC 
lesions have minimal involvement in non-spatial WM processes in the foraging task. 
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3.4 - Experiment 3: Assessing foraging behaviour in PDAPP mice 
3.4.1 Introduction: 
To date, little work has been carried out to assess SWM in the PDAPP model. The 
only existing data were reported by Dodart et al., who showed age-independent WM deficits 
in the 8-arm RAM from as early as 3 months of age, which appeared to worsen with age by 
9-10 months of age (Dodart et al., 1999). Similar to reports by Dodart et al. (1999), PDAPP 
mice have also been observed to exhibit early spatial learning deficits on the circular Barnes 
maze at 3-5 months of age (Huitrón-Reséndiz et al. 2001). Evidence of perseverative 
behaviour and different search strategies were also reported. These deficits appeared to 
worsen with age and by 22-26 months of age PDAPP mice displayed a greater number of 
total trial errors, perseverative behaviour and showed impaired spatial search strategies with 
a greater tendency to display random search strategies (crossing the arena) compared to WT 
littermate controls (Huitrón-Reséndiz et al. 2001). Chen et al., reported an age-dependent 
deficit in spatial learning following a training to criterion protocol of the MWM (Chen et al., 
2000). This study predominantly focussed on the PDAPP models ability to learn a spatial 
location following multiple trials in order to meet a performance criterion (3 successive trials 
with a mean escape latency of <20 seconds). Results of this procedure showed an age-
dependent worsening in spatial learning from 6-9 months to 13-15 months of age (Chen et 
al., 2000). Further studies have since confirmed these observations of age-dependent effects 
in the processing of spatial information in the MWM and confirmed the significant 
involvement of Aβ in PDAPP mice (Hartman et al., 2005; Daumas et al., 2008). However, 
still no study to date has determined age-dependent effects of SWM in the PDAPP model.  
Reports in alternate APP and APP + PS1 models have reported age-related 
worsening in SWM performance in tasks such as the T-Maze and RAWM (Chapman et al. 
1999; Wirths et al. 2008; Webster et al. 2013). Age-dependent cognitive effects also appear 
to be relative to the distribution of Aβ in the HPC (Chapman et al., 1999; Westerman et al., 
2002). Given that PDAPP mice are reported to show age-dependent increases in levels of 
Aβ, particularly in areas such as the HPC, it is likely that SWM performance of PDAPP 
mice will be sensitive to aging (Games et al. 1995; Reilly et al. 2003; Hartman et al. 2005). 
Following evidence that the foraging task is sensitive to HPC function in experiment 1 it was 
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hypothesised that PDAPP mice would show an age-dependent decline in SWM performance 
on the foraging task. 
3.4.2 Design 
Design and subjects are fully described in section 2.3. PDAPP mice were not tested 
on the non-spatial version of this task due to time restraints as described in section 2.3. For 
this reason, all PDAPP and WT littermate control mice were initially trained on the foraging 
task at 4 months of age and were re-trained at each age point starting in the test arena, not in 
the home cage. 
3.4.3 Methods 
The apparatus, procedure and scoring used in this experiment were as described in 
experiment 1 (3.3.3).  
Statistical Analysis: 
The statistical analysis and treatment of data (transformations etc.) carried out in this 
experiment were as described in 4.3.3. However, because PDAPP mice were assessed across 
a range of ages, a further factor of age was analysed in all subsequent analyses. When 
violations in data distribution were observed by Shapiro-Wilk test, that were not rectified by 
transformations, the non-parametric Friedmans test of multiple within-subject comparisons 
was used. Post-hoc comparisons were made with appropriate Bonferroni corrections for 
multiple comparisons. This method is a more conservative non-parametric statistical test 
than multiple within-subject comparisons using only Wilcoxon signed order rank tests.  
3.4.4 Results 
Time Taken:  
Initial inspection of the time measures (Table 3.8) suggests that on average PDAPP 
mice took numerically longer to complete the foraging task than their WT littermate 
controls. A repeat measures ANOVA comparing the main between subject factor of 
genotype and within subject factor of age was used to analyse these data. Analysis of total 
time revealed a non-significant main effect of genotype, F(1, 27)=3.48, p>0.05, a non-
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significant main effect of age, F(1.56, 42.13)=2.62, p>0.05 and no significant age * 
genotype interaction, F(1.56, 42.13)=0.19, p>0.5. 
Engagement Time:
 Repeated measures ANOVA of engagement times (Table 3.8) revealed no significant 
main effect of genotype, F(1, 27) = 3.88, p>0.05 when comparing engagement times with 
the first pot in the foraging task. There was a a significant main effect of age, F(1.64, 44.37) 
= 3.57, p<0.05, but no significant age * genotype interaction, F(2, 54) = 0.67, p>0.5. This 
analysis revealed that with age, engagement time decreased, but this effect was not different 
between genotype. 
Perseverative Errors:
Inspection of the number of perseverative errors in Table 3.8 across the age range 
reveals that while WT mice have varying levels of perseverative behaviour, PDAPP mice 
show an age-related increase. These measures were analysed with non-parametric Mann-
Whitney U Tests for between-subject analysis and Friedman Test for within subject effects 
of age. Man-Whitney U Tests revealed no significant main effect of genotype at 6-8 months, 
U=104.5, z=-0.2, p>0.5, 10-12 months, U=129.5, z=1.09, p>0.1, but a significant main effect 
of genotype at 14-16 months of age, U=174.5, z=3.09, p<0.01. A Friedman test reported that 
there was a significant within-subject effect of age in WT mice, X2(2)=6.70, p<0.05. 
Pairwise comparisons were then performed with a Bonferroni correction for multiple 
comparisons and revealed no significant differences between any individual age range. A 
significant within-subject effect was also obtained in PDAPP mice, X2(2)=6.37, p<0.05. 
Pairwise comparisons further revealed a significant difference between perseverative errors 
made at 6-8 months and 14-16 months of age, p<0.05, but no other age comparisons. 
Chaining response:
 Analysis of chaining response as observed in Table 3.8 in PDAPP mice was carried 
out using a repeated measures ANOVA. Analysis revealed a main effect of genotype, F(1, 
27) = 39.77, p<0.001, a main effect of age, F(2, 54) = 5.18, p<0.01 and no significant age * 
genotype interaction, F(2, 54) = 1.09, p>0.1. 
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Measure Genotype
Age
6-8 Months 10-12 Months 14-16 Months
Mean SD Mean SD Mean SD
Total Time 
(s)
WT 135 11.9 114 17.7 100 10.9
PDAPP 175 26.1 134 23.9 141 19.9
Engagement 
Time
WT 26.95 20.30 23.92 30.03 12.48 13.45
PDAPP 38.40 29.14 40.31 40.10 32.09 36.98
Perseverative 
Error
WT 0.38 0.06 0.65 0.12 0.25 0.07
PDAPP 0.39 0.09 0.91 0.17 1.25 0.32
Chaining 
Response
WT 0.67 0.36 0.83 0.43 0.82 0.52
PDAPP 1.08 0.48 1.45 0.48 1.63 0.44
Table 3.7: Results table showing motor and foraging behaviours in WT (n=15) and PDAPP (n=14) 
mice across all ages tested. 
Total Errors:
Initial observation of Table 3.8 and Figure 3.8A suggested a trend that PDAPP mice 
showed a greater number of total errors with age. A repeat measures ANOVA was used to 
ascertain if mice showed any overall changes in total errors made or acquisition to the 
foraging task, which may be affected by age and/or genotype (Mean values reported in Table 
3.6). In this analysis, the between-subject factor remained as genotype and within-subject 
factors were age and trial. Results revealed a non significant main effect of genotype, F(1, 
27)=1.84, p>0.1, a non significant main effect of age, F(2, 54)=0.13, p>0.5, a non significant 
age x genotype interaction, F(2, 54)=2.50, p>0.05, a non significant main effect of trial, 
F(2.09, 56.52)=0.23, p>0.5, a non significant trial x genotype, F(3, 81)=0.71, p>0.5, a non-
significant age x trial interaction, F(6, 162)=0.60, p>0.5 and a non-significant age x trial x 
genotype interaction, F(6, 162)=0.46, p>0.5. 
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Genotype Age
Trial
1 2 3 4
Mean SD Mean SD Mean SD Mean SD 
6-8 WT 4.27 2.49 4.73 2.22 5.20 3.53 4.47 2.29
PDAPP 4.29 3.07 4.64 5.05 4.57 3.25 4.57 3.20
10-12 WT 5.53 2.75 3.40 2.59 5.00 2.70 4.73 3.06
PDAPP 5.00 2.72 5.64 4.92 4.86 4.02 4.79 5.31
14-16 WT 3.67 2.16 3.07 2.12 3.20 2.91 4.67 3.96
PDAPP 7.07 8.26 6.14 5.40 4.71 5.20 5.93 5.57
Table 3.8: Mean numbers and standard deviation of working memory errors across trials in 
the foraging task in wild type (n=15) and PDAPP mice (n=14).
Repeat Errors:
A similar observation can be made of figure 3.8B as with total errors. These data 
were assessed using non-parametric Mann-Whitney U test (between-subjects) and 
Friedman’s test (multiple within-subjects comparison) due to violations of Shapiro-Wilk test, 
p<0.05 and inability to transform data due to a number of zero scores in the data set. Results 
from Mann-Whitney U test revealed no significant differences between genotypes at 6-8 
months of age, U=104.5, z=-0.22, p>0.5, 10-12 months of age, U=139.5, z=1.52, p>0.1, but 
a significant difference between WT and PDAPP mice at 14-16 months of age, U=150.5, 
z=1.99, p<0.05. Within-subjects analysis revealed no significant effect of age in WT mice, 
X2(2)=1.2, p>0.5, or in PDAPP mice, X2(2)=2.33, p>0.1. 
Neighbouring/Distal Errors:
The number of errors in neighbouring and distal pots were converted to a ratio of total 
errors (figure 3.8C) to assess group differences in the pattern of errors. These data were 
analysed with a repeated measures ANOVA. Analysis of errors in neighbouring pots revealed 
a significant main effect of genotype, F(1, 27) = 20.51, p<0.001, a significant main effect of 
age, F(2, 54) = 7.39, p<0.001 and no significant age * genotype interaction, F(2, 54) = 0.41, 
p>0.5. Analysis of the ratio of distal errors revealed a main effect of genotype, F(1, 27) = 
18.54, p<0.001, a main effect of age, F(2, 54) = 7.01, p<0.01, but no significant age * 
genotype interaction, F(2, 54) = 0.33, p>0.5. Collectively this analysis revealed that PDAPP 
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mice make a greater portion of errors in neighbouring pots and less in pots in distal locations 
when compared to WT controls at each age tested.  
Figure 3.8: Foraging behaviour and SWM performance in PDAPP (n=14) and WT control mice 
(n=15). Data were averaged across four trials for each mouse and mean score for each group is 
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reported. Error bars represent the S.E.M. A) Total number of errors. B) Total number of repeat errors. 
C) The ratio of neighbouring and distal errors to total errors made. 
3.3.5 Discussion 
The results of experiment 3 demonstrate an overall general decline in SWM 
performance in PDAPP mice with age. Although numerically different, no significant 
differences were observed when comparing time taken to complete or engage with the task. 
The latter result suggests that gross changes in motor performance, motivation or anxiety did 
not influence the performance of PDAPP mice on this task. However, perseverative behaviour 
was observed by 14-16 months of age. This finding is similar to results observed with PDAPP 
mice in a holeboard maze and 3xTg mice using a touchscreen-based 5-choice serial reaction 
time-task (Huitrón-Reséndiz et al. 2002; Romberg et al. 2011a). Previous evidence showing 
that HPC lesions displayed similar behaviour, as well as observations from experiments 1 and 
2, suggests that this pattern of deficit may reflect an age-dependent impairment in HPC 
function in PDAPP mice (Wang & Cai 2006; Yoon et al. 2008). The differences observed in 
the mean total number of errors, although by eye appearing to worsen with age, showed no 
significant difference in PDAPP mice at any age compared to WT mice. Nevertheless, 
PDAPP mice made a greater number of repeat errors compared to WT mice at 14-16 months 
of age.  
PDAPP mice were also observed to use a chaining response during the foraging task. 
This was complimented by an overall increase in the number of errors made in pots adjacent 
to those that had just been foraged in. PDAPP mice have shown altered strategies from a 
young age (3-5 months) in a circular holeboard maze (Huitrón-Reséndiz et al. 2002). Huitrón-
Reséndiz (2002) observed an age-related change in escape strategy in the holeboard maze in 
PDAPP mice at 20-26 months of age. Altered escape patterns were also observed in PDAPP 
mice in the MWM up to 18-21 months of age (Chen et al. 2000). This different pattern of 
response appears to worsen with age in PDAPP mice in the foraging task by 14-16 months of 
age, although no age * genotype interaction was observed and a main effect of age appears to 
effect foraging behaviour similarly between both PDAPP and WT control mice. This suggests 
that overexpression of APP, prior to the significant onset of amyloid pathology observed at 15 
months (chapter 4) leads to altered foraging strategies in PDAPP mice from 6-8 months of 
age.  
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Collectively, these data were consistent with age-related impairments in the processing 
of SWM previously reported in PDAPP mice (Dodart et al. 1999; Chen et al. 2000; Hartman 
et al. 2005; Daumas et al. 2008). Levels of amyloid have been reported to increase from as 
early as 6 months and continue to rise with age (Dodart et al. 2002; Dodart et al. 2000; Games 
et al. 1995; Hartman et al. 2005; Reilly et al. 2003). Data reported in Chapter 4 showed that 
PDAPP mice showed a significant increase in the levels of soluble and insoluble Aβ42 in the 
HPC at 15 months of age. This age-dependent increase in levels of Aβ in the HPC is likely to 
impair the processing of spatial information required for the successful completion of the 
foraging task and influence the behaviour of mice reported in experiment 3. 
3.4 Chapter Discussion  
The main aim of this chapter was to determine an age-dependent profile of SWM 
performance in the PDAPP model. To do this, a foraging based task was used that was less 
aversive than other water or fear motivated tests, and promoted rapid acquisition suitable for 
within-subject longitudinal designs. In order to evaluate the role of the HPC to this form of 
spatial working memory, Experiments 1 and 2 tested the hypothesis that mice with excitotoxic 
lesion of the HPC would show a selective deficit in the foraging task when extramaze cues 
guided performance compared to a similar task in which intramaze cues guided successful 
foraging. 
The results from experiments 1 determined that HPC ablation caused impaired 
foraging behaviour, most likely because of a deficit in processing extramaze spatial 
information. This was further confirmed by a non-spatial manipulation of the foraging task 
(experiment 2) whereby all distal spatial cues were removed to prevent allocentric navigation. 
Despite evidence from experiments 1 and 2 suggesting a role for the HPC in this foraging-
based task, alternative factors may influence task performance, such as the use of odour cues, 
which was not controlled for in this task. Rodents have been shown to use odour trails to aid 
navigation in water-escape and other WM tasks previously (Means et al. 1992; Hughes 2004). 
However, Olton and Collison (1979) reported that in the RAM, intramaze cues including 
odour trails were insufficient to govern accurate choice behaviour (Olton & Collison, 1979). 
Olton and Collison determined this by rotating the maze after each choice and food was either 
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kept in the same arm to determine if intramaze cues were used or food was kept in the same 
location to determine if extramaze cues were used to govern behaviour. Results from the 
study by Olton and Collison concluded that the use of extramaze stimuli governed accurate 
choice behaviour in rats (Olton & Collison, 1979). Thus, a further manipulation of the task 
described in this chapter, similar to that described by Olton and Collison, could be used in 
order to confirm whether mice used odour trails to navigate foraging behaviour, whereby the 
spatial locations of foraged pots could be changed half way through the trial (Olton & 
Collison, 1979). 
Across both experiment 1 and 2 HPC lesion mice were observed to show a greater 
number of errors in pots adjacent to those just foraged in, which was complimented by a 
significantly greater chaining response. This reported behaviour to alternate in a preferred 
direction has previously been reported in foraging tasks such as the RAM (Olton & Werz 
1978; Timberlake & White 1990). Contradicting to the results reported in experiment 1, 
Olton and Werz reported that HPC lesioned rats showed a more random response pattern and 
showed a preference for foraging in arms far away from the arm where they had just 
received a reward, whereas control rats showed a preference in foraging adjacent baited arms 
(Olton and Werz, 1978). This difference in behaviour may be influenced by the open arena 
design of the foraging task reported in this chapter compared to the radial arm design of the 
RAM whereby rodents must always return to a central platform prior to making their next 
choice. Interestingly, HPC lesioned rats have been reported to exhibit circling search 
strategies in the MWM in order to find the hidden platform (Pouzet et al. 2002). These 
results indicate that different types of maze may cause altered search strategies in rodents in 
order to successfully complete the given task. The differences in foraging strategy observed 
in this chapter and in HPC lesioned rats in the RAM and other spatial tasks may thus be an 
effect of the differences in maze type and/or the stimulus driving the goal-response (ie. food-
reward/escape from aversive stimulus). This observation further adds to the caution that 
must be taken when comparing results of spatial memory and foraging behaviours across a 
range of tasks.  
 Collectively, evidence from experiments 1 and 2 suggest 3 main conclusions. First, 
the HPC plays a significant role in the processing of spatial-based allocentric information in 
the foraging task. Secondly, the processing of extra-maze information is likely sensitive to 
proactive interference as determined by the increase in number of total errors and repeated 
error choice made by HPC lesion mice. Thirdly, impaired HPC function can lead to altered 
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foraging behaviours and strategies in both the spatial and non-spatial versions of the foraging 
task. 
The findings from experiment 1 and 2 provided a task with rapid acquisition and 
testing periods on which to assess SWM in PDAPP mice across a range of ages. To date, no 
study has used a within-subject longitudinal design to assess SWM performance in the 
PDAPP model; other studies have used cross-sectional designs (Dodart et al. 1999). Due to 
the evidence of age-dependent increases in Aβ production and deposition, particularly in the 
HPC, and the evidence of age- and Aβ-related cognitive deficits, it was hypothesised that 
PDAPP mice would display an age-related deficit in the foraging task (Games et al. 1995; 
Chapman et al. 1999; Dodart et al. 2002; Hartman et al. 2005). In experiment 3 no significant 
difference was reported when observing mean total errors only as a measure of SWM 
performance. However, differences were observed with age in regard to repeated errors. This 
identified a SWM deficit in 14-16 month old PDAPP mice only, relative to WT littermate 
controls. As total errors take into account all forms of “error” across the foraging task, repeat 
errors allow for the identification of a more severe WM deficit as mice repeat an error already 
made. Although speculative, one possible reason for increased repeat errors is an increased 
sensitivity to proactive interference. PDAPP mice have been reported to show age-dependent 
deficits in spatial learning at 13-15 months of age in a manipulation of the MWM, which 
could be reversed following Aβ immunotherapy (Chen et al. 2000; Hartman et al. 2005;
Daumas et al. 2008). This spatial learning deficit was further shown to be sensitive to 
interference (Daumas et al. 2008). Daumas and colleagues showed that as the number of 
spatial locations learned in the MWM increased, the ability of PDAPP mice to recall them 
reduced in mice at 5-6 months of age and thus concluded that PDAPP mice were sensitive to 
spatial interference (Daumas et al. 2008). It was hypothesised that earlier deficits would most 
likely be an effect of soluble oligomeric forms of Aβ that had been implicated in disrupted 
neuronal function and preceded overt plaque deposition (Walsh et al. 2005; Lesné et al. 2006;
Daumas et al. 2008). The sensitivity to interference observed by Daumas and colleagues 
presents an interesting comparison to the observations of patients with AD who show faster 
forgetting on recall tasks and remote memory and hence, examining memory interference in 
AD may be sensitive to earlier diagnosis (Kopelman, 1985; Christensen et al.,1998). A similar 
approach to Daumas and colleagues may better test the sensitivity of proactive interference in 
PDAPP mice in the foraging task by increasing the number of pots placed in the open arena. 
107
This would require a greater level of spatial information to be processed within-trial in order 
to remember the spatial locations of pots already foraged and further confirm this observation.  
Across all experiments in this chapter HPC lesion mice and PDAPP mice displayed a 
greater tendency to show a chaining response in foraging behaviour. This was further 
complimented by a significant increase in the ratio of errors made in pots adjacent to those 
just foraged in. Altered foraging responses and escape strategies have previously been 
reported in HPC lesioned mice and Tg models of amyloid pathology, including PDAPP mice 
(Olton & Werz 1978; Chen et al. 2000; Huitrón-Reséndiz et al. 2002; Janus 2004). In 
PDAPP and TgCRND8 models of amyloid pathology altered search strategies in the Barnes 
maze and MWM have been associated with age and with age-related increases in amyloid 
pathology (Johnson-Wood et al. 1997; Chishti et al. 2001; Huitrón-Reséndiz et al. 2002; 
Janus 2004). However, PDAPP mice also displayed age-independent, non-spatial search 
strategies in the Barnes maze from 3-5 months of age (Huitrón-Reséndiz et al. 2002). Similar 
to this, chaining strategies were observed in the foraging taging task in PDAPP mice from 6-
8 months of age. This preceeded the significant increase in levels of Aβ in the HPC of 
PDAPP mice (Chapter 4, experiment 6). It has previously been observed that 100-day old 
PDAPP mice have a reduced HPC volume, an effect likely caused by APP overexpression 
(Redwine et al. 2003). It is probable that these early detrimental effects of the HPC play a 
role in spatial search strategies in spatial memory tasks and may be a reason for the early 
differences in foraging behaviours observed in PDAPP mice at 6-8 months of age in 
experiment 3. 
  The significant increase in errors made in adjacent pots may not purely be an effect 
of chaining response. It is difficult to distinguish the extent to which the reported increase in 
errors made in the adjacent pots is a direct effect of this chaining strategy used by HPC 
lesioned and PDAPP mice. It may reflect a deficit in pattern separation ability. Spatial pattern 
separation is the process in which memory components containing similar or overlapping 
spatial information are separated to form independent, distinguished memories (Rolls 2013). 
This process in believed to occur through inputs to the HPC and subsequent processing of 
information in the DG and CA3 (Gold & Kesner 2005; Yassa & Stark 2011). Pattern 
separation is reportedly effected by age, but more significantly by the pathological effects of 
AD (Stark et al. 2010; Holden et al. 2012; Ally et al. 2013; Stark et al. 2013). However, to 
date, no study has reported any specific deficits in pattern separation in any transgenic model 
of AD. Interestingly, one report has predicted aberrant processing of information within 
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DG/CA3 networks based on differential c-fos expression in Tg2576 mice following exposure 
to novel spatial stimuli in a familiar arena setting (Palmer & Good 2011). Palmer and Good 
further predicted that, based on these results, APP overexpression would likely impact on 
pattern separation processes supported by the DG/CA3 region. In this study, PDAPP mice 
made a significantly greater proportion of errors in pots adjacent to one another in comparison 
to WT littermate controls; an effect that was also observed in mice with HPC cell loss. This 
overall distribution of errors appeared to be age-independent, however, numerically a greater 
proportion of errors were made in adjacent pots with age. It has previously been reported that 
100-day old PDAPP mice have a 12.3% reduction in total HPC volume as well as a localized 
28% volume reduction in the DG compared to age-matched WT controls (Redwine et al. 
2003). Thus, APP overexpression and reports of HPC morphological abnormalities may 
contribute to the overall increase in errors made in adjacent pots as reported in experiment 3. 
Furthermore, evidence from fMRI studies have reported hyperactive signals in the CA3 and 
DG and hypoactive signals in the EHC in patients with MCI (a preclinical marker of AD) 
undertaking a pattern separation task (Petersen et al. 1999; Yassa et al. 2010). Although 
speculative, a significant increase in levels of insoluble Aβ40 and a numerical increase in 
Aβ42 were observed in the HPC of 7-month old PDAPP mice (Chapter 4, experiment 6), 
which may have also contributed to this early change in error distribution. None-the-less, this 
measure and speculative hypothesis of pattern separation deficits requires further 
examination, independent of the reported chaining response. Therefore, more specific task 
manipulation that may inhibit chaining responses, or more precise lesions or pharmacological 
intervention of the HPC sub regions would be required to confirm this pattern separation 
hypothesis in this task.  
In summary, the aims of this experimental chapter were to validate a new behavioural 
assay that was sensitive to HPC function to assess SWM performance in PDAPP mice. The 
main features of this task was that it would act to be less aversive than tasks such as the 
MWM and RAWM, and require less repeated training and extensive testing protocols, as is 
necessary for example, in the RAM. The results from this study demonstrate that the HPC 
played a significant role in forging behaviour when animals were able to use extramaze 
information. PDAPP mice showed altered foraging behaviour and strategies as well as an age-
related WM deficit. Due to the age-dependent increase in levels of Aβ in the PDAPP model 
(Chapter 4), it would appear that the foraging task acts as a unique tool for testing SWM 
performance that may be sensitive to amyloid burden. However, further characterisation and 
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evaluation of the task is required in order to provide a more conclusive understanding of the 
deficits and foraging behaviours observed in mice during this task. This task therefore 
presents itself as a rapid and unique assay in which to test age-related effects of SWM 
performance and foraging behaviours in animal models of progressive neurological disorders, 
such as AD.   
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Chapter 4: Characterising object recognition memory and age-related 
amyloid pathology in PDAPP mice 
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Chapter Overview 
 This chapter describes experiments that evaluate object recognition memory in the 
PDAPP model across a range of ages. The main aim of these experiments was to identify any 
age-dependent deficit that could be used as a behavioural target for in vivo administration of 
the anti-APP antibody, 2B3. Two versions of the object recognition procedure were used. The 
first was the object novelty recognition memory task. The second task was the object-in-place 
(OiP) procedure. The former task was used to assess the encoding and memory for object 
information, the latter to assess encoding of object-place associations. An age-related profile 
of soluble and insoluble levels of Aβ40 and Aβ42 was also carried out by ELISA in order to 
establish the relationship between age-related behavioural phenotypes and pathological 
hallmarks of excess amyloid production in the hippocampus (HPC) of the PDAPP model. The 
first section of the chapter will provide an overview and rationale for the use of object 
recognition memory paradigms. Subsequently, a succinct review of the current literature 
regarding age related changes in recognition memory in the PDAPP mouse model and other 
transgenic lines will be provided. In summary this chapter reports that PDAPP mice showed 
intact memory for object novelty/familiarity across age and delay intervals, but impaired OiP 
memory that manifested at 14-16 months of age. The latter appeared to be related to a 
significant increase in levels of Aβ in the hippocampus (HPC). The results are discussed with 
reference to previous findings and how they contribute to our understanding of recognition 
memory processes in PDAPP mice.  
4.1 Chapter Introduction 
The novel object recognition procedure was originally developed in 1988 by 
Ennaceur and Delacour as a one-trial task to examine recognition memory in rats. The task 
exploited the natural tendency of rodents to explore objects (Ennaceur & Delacour 1988). 
This task removed the need for explicit training and food deprivation (Aggleton 1985; 
Rothblat & Hayes 1987). In the basic procedure, rats are first placed in an arena with two 
identical objects. This sample trial (T1) lasted for 3 or 5 minutes before varying delays of up 
to 24 hours were introduced prior to the test trial. In the test trial (T2), rats were presented 
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with one identical object that had been previously encountered in T1 and one novel object that 
had never been seen before. The total time spent exploring/interacting with the novel and 
familiar objects were recorded. Exploration was defined as directing the nose at a distance of 
≤2cm to the object and/or touching the object with the nose. Any further interaction with the 
object that was not directly exploring the object, ie, sitting on the object, was not considered 
exploring the object and was not scored. Findings from this study reported that rats showed a 
preference for exploring novel objects, which was highly influenced by the total time given in 
T1 to explore the sample objects and the interval between T1 and T2 (Ennaceur & Delacour 
1988). This task therefore offered itself as a novel, more rapid one-trial memory testing 
protocol without the necessity for explicit training or positive/negative reinforcement.  
Since the original report, the novel object recognition procedure has been used in 
many studies to assess recognition memory in a range of rodent models of neurological 
disorders, pharmacological studies, as well as studies designed to understand the 
neuroanatomical substrates of recognition memory (Antunes & Biala 2012; Warburton & 
Brown 2015a). The basic procedure has been extended to test memory for other features of 
objects, such as their spatial location (Figure 4.1 and Table 4.1). Results of this work are a 
comprehensive literature that has described major roles for three interconnected brain 
systems, the perirhinal cortex (PRC), HPC and medial prefrontal cortex (mPFC). Given that 
the experiments carried out in this chapter focus on object novelty memory and object-in-
place (OiP) memory, the neural systems supporting information processing relative to these 
tasks will be the main focus. The object-location task will also be considered due to the HPC 
sensitivity in the processing of spatial information in this task (Barker et al., 2011). A more 
detailed review of the neural substrates of the temporal order memory can be found in 
Warburton et al. 2013 and Warburton & Brown 2015. 
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Figure 4.1: Illustration to show the varying object recognition memory tests used to assess object 
recognition memory in rodents. A. Object novelty memory. B. Object location memory. C. Object-
in-Place memory. (Warburton & Brown 2015) 
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Task Task 
Description
Successful Memory 
Performance
Anatomical Structures 
Involved
Object Novelty Animals are exposed to two identical objects in a sample phase 
for a given period of time before a retention period. In the test 
phase one familiar object from the sample phase and one novel 
object is presented to the animal. These objects are presented 
in the same spatial locations as the objects presented in the 
sample phase.
Animals will explore the novel 
object in preference to the 
familiar object
Perirhinal Cortex 
(Object-based information)
Object Location Two identical objects are presented to animals for a given period 
of time in the sample phase. Following a retention interval, 
animals are re-exposed to the same two objects, however, one is 
now in a novel spatial location. 
Animals show preference to the 
object in the novel spatial 
location.
Hippocampus 
(Spatial-based information)
Object-in-Place Animals are exposed to four different objects in the sample 
phase. Following a retention interval, animals are re-exposed to 
the same four objects. However, two objects remain in the same 
place as in the sample phase and two are switched in place. 
The animal will explore the two 
objects that have switched from 
their original place.
Perirhinal Cortex
(Object-based information)
Hippocampus 
(Spatial/contextual-based information)
Medial Prefrontal Cortex
(Spatial/contextual-based information)
Table 4.1: Table describing the variations of object recognition memory tasks. These tasks are used in order to test object recognition memory and the functioning of specific 
neuroanatomical structures and/or pathways. Anatomical structures and neuronal circuits reviewed in Warburton et al. 2013 and Warburton & Brown 2015.
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In animals, novel object recognition memory has been proposed to be dissociated from 
HPC function (Borwn & Aggleton 2001). Brown and Aggleton proposed that the PRC 
supported object recognition memory and the HPC processed more complex information and 
stimuli, including spatial and environmental aspects (Brown & Aggleton 2001). Evidence 
from lesion studies showed that HPC ablation did not prevent rodents from discriminating 
novel and familiar objects. In contrast, lesions of the PRC resulted in an inability of animals 
to dissociate novel and familiar objects with delays of up to 24 hours (Bussey et al. 2000; 
Winters et al. 2004; Winters & Bussey 2005; Barker et al. 2007). However, other reports have 
identified a role for the HPC in object novelty memory (Gaskin et al. 2003; Hammond et al. 
2004).  
Gaskin (2003) reported that in rats with HPC lesions object novelty deficits were 
observed when familiar objects were presented prior to surgery, but not after. To determine 
this effect, rats were presented with sample objects for 5 minutes/day for 5 consecutive days, 
1 or 5 weeks prior to surgery. 15-20 days after surgery object novelty memory was tested. 
Rats with HPC lesions showed impaired object novelty memory, however, sham controls 
showed a preference to explore novel objects over familiar. Object novelty memory was 
further tested in HPC lesioned rats after surgery with a new pair of familiar objects. Object 
memory was tested in all rats using a 15-minute and 24-hour delay period. In these trials, both 
HPC lesioned and sham control rats performed at similar levels. The authors concluded that 
extrahippocampal circuitry is involved in object recognition memory when the HPC is not 
involved in object encoding (Gaskin et al. 2003). However, an alternative or further 
observation could propose that the HPC plays a role in recognition memory over much longer 
delay periods than 24-hours. Unfortunately, Gaskin and colleagues did not repeat the primary 
experiment whereby rats were exposed to sample objects prior to a delay period of up to 7 
weeks to observe if HPC lesioned rats were able to display novelty preference independent of 
the HPC over such a long-term delay period. Hammond and colleagues (2004) also reported 
that C57Bl/6 mice with HPC lesions showed object novelty deficits when recognition 
memory was tested 24-hours following sample phase, but not after a 5-minute delay. 
However, alothough less than sham controls, HPC lesioned mice still showed a significant 
preference to novel objects following a 24-hour delay and were therefore able to show 
memory towards the familiar object (Hammond et al. 2004).  
These conflicting reports to the independent role of the PRC in object-novelty memory 
appear most likely an effect of delays ≥24-hours. However, many studies report in-tact 
recognition memory using delays of ≤24-hours (Clark et al. 2000; Broadbent et al. 2010; 
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Barker & Warburton 2011; Warburton & Brown 2015a). Thus, evidence has suggested that 
successful completion of the object novelty memory task is sensitive to PRC function, and is 
independent of the HPC and mPFC across short term delay periods, however delays ≥24-
hours require further investigation to better conclude the function of the HPC in long-term 
object recognition memory. More recently, studies have identified receptors involved in the 
processing of object recognition memory within the brain structures involved within object 
recognition memory tasks (Warburton et al. 2013). These precise receptor based mechanisms 
will be discussed in Chapter 5 and in more detail in the thesis General Discussion. 
OiP memory refers to an animals’ ability to associate object information with a place 
or location (see Figure 4.1 and Table 4.1). Lesion data has revealed that the mPFC, HPC and 
PRC are essential for successful memory performance in this task, in both rodents and 
monkeys (Bussey et al. 2000; Barker et al. 2007; Bachevalier & Nemanic 2008; Wilson et al. 
2008; Barker & Warburton 2011). The interaction between these three brain regions plays a 
major role in the formation of object and place associations (Barker et al. 2007; Barker & 
Warburton 2011). Barker and colleagues (2007) reported that rats with bilateral lesions of the 
mPFC, PRC or unilateral lesions of the PRC and mPFC in contralateral hemispheres, showed 
a significant impairment in the OiP memory task compared to rats with unilateral PRC and 
mPFC lesions within the same hemisphere and SHAM controls (Barker et al. 2007). Barker et 
al., (ibid) also showed that all lesion groups were unimpaired in the object-location task and 
object novelty memory tasks following a 5 minute and 2 hour delay period, except rats with 
bilateral lesions of the PRC (Barker et al. 2007). These data provided evidence that an 
interaction between the mPFC and the PRC is essential for successful object and place 
associations required for the OiP task. In contrast, no lesions group was sensitive to the 
object-location task. These studies also confirmed the crucial role of the PRC in object-
novelty memory.  
A later study by Barker & Warburton (2011) examined the role of the HPC in 
recognition memory. In this study, rats initially received bilateral lesions of either the PRC, 
mPFC or HPC and were tested on object-novelty memory and spatial recognition (OiP and 
object-location) tasks (Barker & Warburton 2011). This study reported that HPC lesioned 
animals showed impairments in the OiP and object-location task, but no impairment in object-
novelty detection with delays of up to 24 hours. PRC lesioned animals, however, showed 
impairments in the OiP task and object-novelty memory at all delays tested (5 minutes, 3 and 
24 hours), whereas no impairment was observed in the object-location task. Therefore, the 
HPC appeared crucial in processing spatial information, while the PRC was essential for 
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encoding information regarding familiar objects. Collectively, both the PRC and HPC were 
essential for object recognition memory and spatial-associations (Barker & Warburton 2011). 
Similar to Barker and colleagues (2007), the interactions between the HPC, mPFC and PRC 
were assessed. Rats received unilateral lesions to the HPC combined with a further ipsilateral 
or contralateral lesion to either the PRC or the mPFC (Barker & Warburton 2011). These 
results showed that contralateral HPC-PRC and HPC-mPFC lesioned rats, but not ipisilateral 
lesioned groups were significantly impaired in the OiP task following a 5 minute delay, but 
not in the object-location or object-novelty task (Barker & Warburton 2011). This 
observation, confirmed a dual role of the PRC and HPC in the encoding of object and place 
associations and collectively with the dissociation study reported by Barker (2007), further 
suggested an intact PRC-HPC-mPFC circuit was essential for successful memory 
performance in the OiP task. Thus, disruption to this circuit by lesion or disease pathology is 
likely to impair the processing of object and place associative information.  
Tg mice overexpressing mutated hAPP have elevated levels of A that develop with 
age (Johnson-Wood et al. 1997; Hartman et al. 2005). In PDAPP mice, dense Aβ deposits 
appear in the molecular layer of the DG and the lateral entorhinal cortex (EHC) suggesting 
that the lateral perforant pathway may be particularly sensitive to amyloid pathology and may 
underpin some of the cognitive deficits in this mouse line (Games et al. 1995; Chen et al. 
2000; Reilly et al. 2003). Consistent with this pattern of pathology, PDAPP mice have also 
shown age-dependent deficits in spatial learning and memory that correlated with levels of 
amyloid (Chen et al. 2000; Hartman et al. 2005). Other Tg models of amyloid pathology, such 
as Tg2576 mice display age-related increased levels of Aβ in regions that include the HPC 
and the mPFC (Hsiao et al. 1996; Kawarabayashi et al. 2001; Zhuo et al. 2008). Tg2576 mice 
also showed age-related deficits in spatial-based memory tasks, including the OiP task, while 
object-novelty memory remained in tact (Hsiao et al. 1996; Hale & Good 2005; Good & Hale 
2007). One interpretation of this pattern of results is that the PRC remained unaffected by 
amyloid pathology in aged Tg2576 mice. In contrast, object-place associative memories are 
clearly impaired. Collectively these data would suggest that impaired OiP memory in Tg2576 
mice is likely due to amyloid-related pathology within the PRC-HPC-mPFC circuit
previously described by Barker and Warburton (Barker & Warburton 2011; Warburton & 
Brown 2015). Given that similar age-related pathology is observed in the cortex and HPC of 
PDAPP mice, it is likely that the PDAPP model will be sensitive to spatial recognition 
memory in the OiP task.
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 To date, no studies have assessed object recognition memory in male PDAPP mice 
bred on a C57Bl/6 background. The dissociation between the HPC and PRC in processing 
object and spatial information permits assessment of these systems across age in relation to 
the hAPPV717F mutation. Previous studies with PDAPP mice bred on a mixed background 
strain have reported an age-related deficit in object recognition memory (Dodart et al. 1999). 
However, this result has been inconsistent across laboratories (Chen, Chen, Knox, Inglis, 
Bernard, Martin, Justice, Mcconlogue, et al. 2000). There are a number of discrepancies 
between studies that must be considered. Differences in acquisition/familiarisation to the 
objects in the sample phase differed between both studies. Dodart (1999) allowed mice a 10 
minute sample phase, whilst Chen (2000) allowed mice to accumulate a 30 second total 
inspection time of objects (or a maximum of 20 minutes sample phase). Previous reports have 
observed that an increased time for acquisition in the sample phase can significantly improve 
object recognition memory (Ennaceur & Delacour 1988; Antunes & Biala 2012). However, 
neither study reported contact times with objects for WT and PDAPP mice. The delay period 
used in both studies prior to testing also differed. Chen (2000) reported 10 seconds, 1 and 10 
minutes, 1 and 4 hour delays, whereas Dodart (1999) used only a single 3-hour delay prior to 
testing. Dodart (1999) reported a significant difference at 9-10 months of age following a 3-
hour delay. Chen (2000) reported no significant differences between PDAPP and WT mice up 
to latest age point tested (18-21 months) with a 4-hour delay. It therefore appears unlikely that 
this difference was an effect of delay, or age, and is tempting to speculate that contact times 
with objects may have contributed to the differences between studies.  
One further experimental procedure differed across sample and test phase in these two 
studies that likely contributed to the differences in behavioural results reported. During the 
sample phase, Chen et al., (2000) exposed mice to two identical objects in fixed locations 
before replacing one of the sample objects with a novel object in the test phase. In contrast, 
Dodart and colleagues (1999) exposed mice to a single object in the sample phase and 
presented the familiar and a novel object in the test phase. The task used by Dodart et al., 
confounds object novelty with novel location information (of the novel object) and thus, the 
contribution of the spatial component to the recognition deficit in PDAPP mice remains 
unclear. Importantly, no study has yet directly assessed OiP memory in PDAPP mice. This 
analysis further highlights the need for careful and considered assessment of behavioural 
changes in Tg mice. Furthermore, mice from these studies were generated from different 
colonies and it is unclear if each study had an equal representation of each background strains 
phenotype. 
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The aim of the present experiment was to characterise object and object-in-place 
recognition memory in male PDAPP mice across an age range. Based on evidence for an age-
related deficit in spatial memory in PDAPP mice and intact object novelty memory as 
reported by Chen (2000), the hypothesis for this experiment was that transgenic mice would 
show a task specific and age-related deficit in visuo-spatial memory.  
4.2 - Experiment 4: Object Novelty Memory in PDAPP Mice   
4.2.1 Experiment Introduction 
 This chapter is composed of 3 experiments; 4, 5 and 6. Experiment 4 assessed object 
novelty memory in PDAPP mice across a range of ages, 6-8, 10-12 and 14-16 months of age 
in order to determine any age-dependent changes. The protocol used to assess object 
recognition memory in this experiment was similar to the original protocol reported by 
Ennaceur and Delacour (1988) and that used by Chen and colleagues (2000). Experiment 5 
assessed spatial and object associations using procedures similar to those adopted by Barker 
& Warburton (2011).  Experiment 6 assayed brain Aβ level across an age range, similar to 
previous studies (Games et al. 1995; Johnson-Wood et al. 1997; Dodart et al. 2000; Hartman 
et al. 2005). This experiment used ELISA assays to quantify levels of soluble and insoluble 
Aβ40 and Aβ42 changed at 3, 7, 11 and 15 months of age in the HPC of PDAPP mice. 
4.2.2 Design  
Subjects, Apparatus, Method: 
All mice used in the behavioural protocols to assess object novelty and OiP memory 
were identical to those described in Chapter 2 (section 2.3) 
Mice used to quantify Aβ were obtained from separate cohorts. A total of 26 male 
PDAPP mice were used to determine the levels of Aβ across ages. 5 PDAPP mice were culled 
by cervical dislocation at 3 months of age and a further 7 at 7, 11 and 15 months of age. The 
HPC was dissected and snap frozen and stored at -80oC. All extraction and ELISA protocols 
are described in Chapter 2, (section 2.4). 
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Statistics
Data were analysed as described in Chapter 2 (section 2.3 and 2.4). Due to high 
levels of variability in data sets, violations of Shapiro Wilk’s test and/or Levene’s test were 
observed (p<0.05). Therefore, data that violated these tests were subjected to transformation 
(ie. Square root, log-10) based on the level of positive/negative skew and reassessed. Data 
that no longer violated these assumptions were analysed by mixed measures ANOVA to 
determine age and genotype-related changes. Any further violations of Mauchly’s Test of 
Sphericity were reported according to Greenhouse-Geisser analysis. One sample t-tests were 
used to determine if the performance of each group of mice was above chance (0.5) level. 
Where data remained in violation of these tests, despite transformations, non-parametric tests 
were used. This was only apparent in data assessing levels of Aβ42. As these measures were 
compared as a between-subject analysis a Kruskal-Wallis test was performed with Dunn’s 
test with a Bonferroni correction for multiple comparisons. The adjusted p-values are 
reported. 
4.2.3 Experiment 4 - Results: 
PDAPP mice showed intact object-novelty memory at 6-8, 10-12 and 14-16 months of age:
Sample Phase Contact Times 
Table 4.2 shows the mean contact time with objects across sample phase of PDAPP 
mice and WT littermate controls at 6-8, 10-12 and 14-16 months of age. Inspection of these 
data suggests that PDAPP mice explored the two identical objects less in the initial sample 
phase, however both PDAPP and WT mice showed a reduced exploration of object contact 
times as the sample phase progressed. Exploration of the data and tests for normality revealed 
that distribution was not normal in specific data sets as assessed by Sahpiro-Wilk’s test, 
p<0.05. For this reason, the data were transformed by square rooting which avoided further 
violations, p>0.05. Results of repeat measures ANOVA revealed a significant main effect of 
genotype, F(1, 27) = 8.6, p<0.01, a main effect of age, F(2, 54) = 3.2, p<0.05, a main effect of 
sample phase, F(1.6, 43.6) = 271.8, p<0.001, a significant genotype x sample phase 
interaction, F(1.6, 43.6) = 16.8, p<0.001. No other main effects or interactions were 
significant (maximum F(4, 108) = 2.1, p>0.05: sample phase x age x genotype).  
Tests for simple main effects (between-subject comparison) revealed a main effect of 
genotype in terms of contact time at sample phase 1, F(1, 27) = 21.3, p<0.001, and sample 
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phase 2, F(1, 27) = 5.8, p<0.05, but not at sample phase 3, F(1, 27) = 1.9, p>0.05. A further 
within-subjects main effect of sample phase in both PDAPP, F(2, 26) = 56.2, p<0.001, and 
WT mice, F(2, 26) = 161.8, p<0.001 was also reported. Thus, WT mice explored the objects 
more during sample phase 1 and 2 than PDAPP mice, however both groups performed at 
similar levels by sample phase 3. Indeed, both PDAPP and WT mice show habituation of 
object exploration across sample phase, indicating successful processing of objects 
information prior to test phase.  
WT PDAPP
6-8 
Months
10-12 
Months
14-16 
Months
6-8 
Months
10-12 
Months
14-16 
Months
Sample 
Phase 1
Mean 25.69 17.15 11.86 18.48 12.21 8.87
SD 6.39 3.91 3.10 7.01 3.63 3.71
Sample 
Phase 2
Mean 21.40 14.10 9.38 13.51 9.90 8.01
SD 8.16 7.74 5.73 6.58 5.96 3.92
Sample 
Phase 3
Mean 25.97 13.64 9.81 14.60 11.01 7.81
SD 9.76 7.69 6.78 9.62 10.10 6.55
Table 4.2: Mean contact times (in seconds) of WT mice (n=15) and PDAPP mice (n=14) across all 3 
sample phases and ages tested. Standard deviations of the mean are also reported. 
Test Phase Contact Times 
Table 4.3 shows the mean contact time with objects during test phase for PDAPP mice 
and WT littermate controls across both delay periods (5 minutes and 24 hours) at 6-8, 10-12 
and 14-16 months of age. Inspection of this table suggests that across both delay periods and 
all ages, WT and PDAPP mice explored novel objects more than familiar. It further suggests 
that WT mice explored objects more than PDAPP mice. Tests for normality revealed that 
distribution of data were not normal in specific data sets as assessed by Sahpiro-Wilk’s test, 
p<0.05. Data were therefore transformed by square root to prevent further violations in 
distribution p>0.05.  
Transformed data were assessed by repeat measures ANOVA with genotype, object, 
delay and age as factors. Results revealed a significant main effect of genotype, F(1, 27) = 
22.1, p<0.001, a main effect of object, F(1, 27) = 351.1, p<0.001, a significant object x 
genotype interaction, F(1, 27) = 18.0, p<0.001, age x delay interaction, F(2, 54) = 7.0, 
p<0.001, age x object interaction, F(2, 54) = 13.8, p<0.001 and delay x object interaction, 
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F(1, 27) = 121.8, p<0.001. No further main effects or interactions were reported; maximum 
effect, F(2, 54) = 2.7, p>0.05; age x delay x genotype interaction. 
Tests for simple main revealed that following a significant object x genotype 
interaction WT mice explored both the novel object, F(1, 27) = 22.5, p<0.001 and familiar 
object, F(1, 27) = 19.7, p<0.001, more than PDAPP mice. However, both WT mice, F(1, 27) 
= 273.6, p<0.001 and PDAPP mice, F(1, 27) = 101.5, p<0.001 explored the novel object in 
preference to the familiar object in the test phase when data were collapsed across age and 
delay. 
An age x delay interaction revealed that mice explored objects more at 14-16 month of 
age following a 5-minute delay than mice at 6-8 months of age, F(2, 26) = 4.1, p<0.05. No 
further main effects of age were reported. The main effect of delay reported that mice 
explored objects more following a 24-hour delay at 6-8 months of age, F(1, 27) = 12.6, 
p<0.001. However, at 14-16 months of age, mice explored objects more following a 5-minute 
delay, F(1, 27) = 4.5, p<0.05. No effect of delay was observed at 10-12 months of age, p>0.1. 
The age x object interaction revealed that mice explored the novel object more at 14-
16 months of age when compared to mice at 10-12 months of age only, F(2, 26) = 3.5, 
p<0.05. No further effect of age was observed in this interaction. A main effect of object was 
observed across all ages, whereby all mice explored the novel object more than the familiar; 
minimal effect, F(1, 27) = 290.5, p<0.001. 
A delay x object interaction revealed a main effect of delay on object exploration. 
Mice explored the novel object less following a 24-hour delay compared to novel object 
exploration following a 5-minute contact time, F(1, 27) = 11.6, p<0.01. An opposite effect is 
observed for the familiar object whereby mice explored the familiar object more following a 
24-hour delay than familiar object exploration following a 5-minute delay, F(1, 27) = 60.8, 
p<0.001. Despite these differences a main effect of object was observed across both delay 
periods, whereby mice explored the novel object more than the familiar following a 5-minute 
delay, F(1, 27) = 302.6, p<0.001 and a 24-hour delay. F(1, 27) = 234.5, p<0.001. 
Collectively these data suggest that PDAPP mice explored objects less in the test 
phase than WT mice. However, both WT and PDAPP mice still showed a preference to 
explore the novel object over the familiar object. An effect of delay appeared to increase 
forgetting of the familiar object as determined by increased exploration of this object 
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following a 24-hour delay period when compared to the 5-minute delay exploration time. 
However, this effect was the same across genotype and age. 
5 minutes 24 hours
Wild Type PDAPP Wild Type PDAPP
Age Object Mean SD Mean SD Mean SD Mean SD
6-8
months
Novel 18.97 5.96 10.79 5.84 20.26 8.23 10.62 5.42
Familiar 5.37 2.02 3.55 2.06 10.57 4.01 7.33 3.54
10-12 
months
Novel 19.52 9.70 11.39 9.57 19.27 10.77 7.03 5.20
Familiar 6.55 3.07 4.10 3.51 12.80 8.09 5.09 4.38
14-16 
months
Novel 33.81 18.98 18.01 18.68 21.29 9.58 11.41 2.60
Familiar 8.13 6.00 5.52 5.98 10.55 3.27 6.45 1.73
Table 4.3: Mean contact times (s) with novel and familiar objects of WT mice (n=15) and PDAPP 
mice (n=14) during the test phase following a 5-minute and 24-hour delay. Standard deviations (SD) 
of the mean are also reported. 
Test Phase Discrimination Ratios 
To ensure sensitivity towards the differences between groups, the data were converted 
into a discrimination ratio (DR) (time spent exploring the novel object/ time spent exploring 
the novel and familiar objects). Figure 5C shows the DR scores of both PDAPP and WT mice 
across all ages and delays. A repeat measures ANOVA was carried out on the ratio scores 
with factors of genotype, age and delay to confirm the absence of impairment between 
PDAPP mice and WT littermate controls. Results revealed no main effect of genotype, F(1, 
27) = 2.5, p>0.1, a significant main effect of age, F(2, 54) = 7.7, p<0.001, and a main effect of 
delay, F(1, 27) = 248.7, p<0.001. No further main effects or interactions were reported 
(maximum effect observed, genotype x delay interaction, F(1, 27) = 2.8, p>0.1).  
 One sample t-tests showed that both WT and PDAPP mice differed from 0.5 (no 
discrimination) at each age and delay: WT mice at 6-8 months, 5 minutes and 24 hours delay, 
t(14) = 22.2 and 12.4, p<0.001, and PDAPP mice, t(14) = 13.1 and 5.5, p<0.001, WT mice at 
10-12 months, 5 minutes and 24 hours delay, t(14) = 18.7 and 7.1, p<0.001 and PDAPP mice, 
t(13) = 12.9 and 8.6, p<0.001 and WT mice at 14-16 months, 5 minutes and 24 hours delay, 
t(13) = 10.4 and 11.6, p<0.001 and PDAPP mice, t(13) = 16.1 and 14.5, p<0.001.  
These results confirm that both PDAPP and WT mice show an ability to discriminate 
novelty at a comparable level across all ages and delays tested in this study. Moreover, all DR 
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scores are significantly above chance level (0.5) indicating successful memory performance at 
each delay and age tested. 
Figure 4.2 PDAPP mice show comparable novel object recognition memory to WT littermate 
controls across all ages and delays tested. Mean discrimination ratio (DR) calculated from test phase 
data for PDAPP (n=14) and WT (n=15) control mice. Chance level (0.5) is represented as a solid black 
line on the graph. Error bars show the S.E.M.  
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4.3 Experiment 5: Object-in-Place Memory in PDAPP mice 
PDAPP mice show intact object location memory at 6-8 and 10-12 months of age, but 
impaired object-location memory at 14-16 months of age:
Sample Phase Contact Times 
Table 4.4 shows the mean contact time with objects across sample phase of PDAPP 
mice and WT littermate controls at 6-8, 10-12 and 14-16 months of age. Inspection of these 
data suggests that PDAPP mice explored four different objects less in the initial sample phase, 
however both PDAPP and WT mice showed a reduced exploration of objects as the sample 
phase progressed. Exploration of data and tests for normality revealed that distribution of data 
were not normal as assessed by Sahpiro-Wilk’s test, p<0.05. For this reason, the data were 
transformed by square root. Further exploration of transformed data revealed normal 
distribution across all WT and PDAPP exploration times, as assessed by Shapiro-Wilk’s test, 
p>0.05.  
Transformed data were assessed by repeat measures ANOVA with genotype, sample 
phase and age as factors. Results revealed a significant main effect of genotype, F(1, 27) = 
22.9, p<0.001, a main effect of age, F(2, 54) = 4.3, p<0.05, a main effect of sample phase, 
F(2, 54) = 277.8, p<0.001, a significant genotype x age interaction, F(2, 54) = 3.8, p< 0.05, 
and a significant genotype x sample phase interaction, F(2, 54) = 19.9, p<0.001. No other 
main effects or interactions were significant (maximum effect (Greenhouse-Geisser 
corrections), F(2.4, 63.4) = 1.7, p>0.05: sample phase x age x genotype).  
Tests for simple main effects carried out on the significant genotype x age interaction 
revealed WT mice explored objects more at 10-12 months of age, F(1, 27) = 16.0, p<0.001 
and 14-16 months of age, F(1, 27) = 14.5, p<0.001, but not at 6-8 months of age, F(1, 27) = 
3.3, p>0.05. A further simple main effect of age showed that WT mice displayed greater 
contact time with objects at 14-16 months of age, F(1, 27) = 6.0, p<0.01 when compared to 
contact times of WT animals at 6-8 and 10-12 months of age. This effect was not observed in 
PDAPP mice, which appeared to exhibit similar contact times across all ages examined, F(2, 
26) = 0.2, p>0.05.  
Tests for simple main effects on the genotype x sample phase interaction revealed that WT 
mice explored objects more at sample phase 1, F(1, 27) = 56.3,  p<0.001, and sample phase 2, 
F(1, 27) = 14.6, p<0.01, and sample phase 3, F(1, 27) = 8.0, p<0.05 than PDAPP mice when 
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analysis was collapsed across age. Analysis revealed a main effect of sample phase in both 
PDAPP F(2, 26) = 57.6,  p<0.001, and WT mice F(2, 26) = 189.5, p<0.001. These data 
indicate that WT mice showed greater contact with objects across sample phases than PDAPP 
mice. However, both PDAPP and WT mice showed reduced object exploration across sample 
phase, indicating both WT and PDAPP mice habituated to the four objects prior to test phase. 
WT PDAPP
6-8 
Months
10-12 
Months
14-16 
Months
6-8 
Months
10-12 
Months
14-16 
Months
Sample Phase 1 Mean 27.16 36.77 46.53 20.70 19.40 21.42
SD 9.48 8.06 17.03 7.64 6.31 12.21
Sample Phase 2 Mean 18.26 21.57 29.80 14.59 11.99 16.01
SD 5.95 10.19 14.55 5.70 4.67 11.52
Sample Phase 3 Mean 13.64 14.53 22.08 11.60 10.62 11.67
SD 3.88 7.52 10.59 4.57 3.35 6.45
Table 4.4: Mean contact times (s) of WT mice (n=15) and PDAPP mice (n=14) across all 3 sample 
phases and ages tested. Contact time measures are taken from animals exploring four different objects. 
Standard deviations of the mean are also reported. 
Test phase Contact Times 
Table 4.5 shows the mean contact time with objects during test phase of PDAPP mice 
and WT littermate controls across both delay periods (5 minutes and 24 hours) at 6-8, 10-12 
and 14-16 months of age. Data suggested that across both delay periods and all ages, WT and 
PDAPP mice explored objects in a novel spatial arrangement more than those in a familiar 
spatial location. However, WT mice explored novel arrangements more than PDAPP mice 
overall. It further suggests that WT mice explored objects more than PDAPP mice, as 
previously observed in object-novelty task. Similar to exploration times assessed in sample 
phase, exploration of data and tests for normality revealed that distribution of data were not 
normal as assessed by Sahpiro-Wilk’s test, p<0.05. Data were transformed by square root. 
Further exploration of transformed data revealed normal distribution across all WT and 
PDAPP exploration times, p>0.05.  
Repeated measures ANOVA with genotype, place, delay and age as factors. revealed a 
significant main effect of genotype, F(1, 27) = 25.8, p<0.001, a main effect of place, F(1, 27) 
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= 276.6, p<0.001, a main effect of delay, F(1, 27) = 12.1, p<0.001, a significant place x 
genotype interaction, F(1, 27) = 45.2, p<0.001, a significant place x delay interaction, F(1, 
27) = 14.1, p<0.001, a significant age x place x genotype interaction, F(2, 54) = 4.6, p<0.05. 
No further main effects or interactions were reported (maximum effect; age x delay x 
genotype interaction, F(2, 54) = 2.4, p>0.05). 
Tests for simple main effects following a place x genotype interaction reported WT 
showed greater contact times with objects in novel locations, F(1, 27) = 36.2, p<0.001, and 
familiar locations, F(1, 27) = 22.4, p<0.001 than PDAPP mice. However, both WT, F(1, 27) = 
287.9, p<0.001, and PDAPP mice, F(1, 27) = 44.6, p<0.001 explored objects in novel 
locations in preference to objects in familiar locations. 
A place x delay interaction revealed that animals explored objects in familiar locations 
more following a 24 hour delay, F(1,27) = 33.0, p<0.001, compared to contact times with 
objects in familiar locations following a 5-minute delay. No difference was observed when 
comparing contact times with objects in novel locations, F(1, 27) = 3.6, p>0.05. Despite this 
increased exploration of objects in familiar locations following a 24 hour delay, animals 
continued to explore objects in novel spatial locations more than objects in familiar locations 
following a 5 minute delay period, F(1, 27) = 204.4, p<0.001 and a 24 hour delay, F(1, 27) = 
118.3, p<0.001.  
A three-way interaction of age x location x genotype revealed that WT mice explored 
both novel and familiar object arrangements more than PDAPP mice across all ages (minimal 
effect = F(1, 27) = 8.3, p<0.01, familiar exploration at 14-16 months of age). A main effect of 
place revealed that both WT and PDAPP mice explored objects in novel locations more than 
familiar locations at 6-8 and 10-12 months of age, however, only WT mice showed this 
preference at 4 -16 months of age (minimal effect; PDAPP mice at 10-12 months of age, F(1, 
27) = 23.6, p<0.001). PDAPP mice at 14-16 months of age showed no preference to objects in 
novel locations, F(1, 27) = 3.2, p>0.05. No overall main effect of age was reported when 
comparing overall changes in total contact times with objects in familiar or novel locations 
(maximal effect; novel place exploration of WT mice, F(2, 26) = 2.3, p>0.1). 
 Collectively this analysis showed that WT mice explore objects more than PDAPP 
mice. However, despite increased contact time of WT mice, both WT and PDAPP mice were 
able to discriminate objects in novel spatial locations at 6-8 and 10-12 months of age. 
However at 14-16 months of age WT mice maintained this ability, whereas PDAPP mice no 
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longer showed a preference to explore objects in novel spatial locations over familiar spatial 
locations. 
5 minutes 24 hours
Wild Type PDAPP Wild Type PDAPP
Age Object Mean SD Mean SD Mean SD Mean SD
6-8
months
Novel 18.93 12.80 9.69 5.24 16.64 6.18 11.81 5.37
Familiar 8.59 3.83 5.02 2.49 11.92 4.29 9.56 4.95
10-12 
months
Novel 20.44 14.62 10.25 8.14 26.82 10.99 10.71 8.95
Familiar 10.08 6.26 6.20 5.32 16.36 6.32 7.37 5.97
14-16 
months
Novel 24.57 17.04 8.81 7.88 27.52 16.41 9.82 6.89
Familiar 11.08 7.33 6.69 5.68 15.92 6.01 8.42 5.60
Table 4.5: Mean contact times (s) with objects in novel and familiar spatial locations of WT mice 
(n=15) and PDAPP mice (n=14) during the test phase following a 5-minute and 24-hour delay. 
Standard deviations (SD) of the mean are also reported. 
Test Phase Discrimination Ratios 
Figure 4.3 shows the DR scores of both PDAPP and WT mice across all ages and 
delays. A repeat measures ANOVA was carried out on the DR scores with factors of 
genotype, age and delay to confirm differences between groups observed in Table 4.5.Results 
revealed a significant main effect of genotype, F(1, 27) = 54.9, p<0.001, a main effect of 
delay, F(1, 27) = 25.9, p<0.001, a significant age x genotype interaction, F(2, 54) = 9.2, 
p<0.05. No further main effects or interactions were reported (maximum effect; delay x age 
interaction, F(2, 54) = 2.4, p>0.1). 
 Tests for simple main effects following a significant age x genotype interaction 
revealed that WT mice showed no change in OiP memory performance across all ages tested 
(maximal effect, 6-8 months vs 14-16 months, F(2, 26) = 2.3, p>0.1). However, PDAPP mice 
showed a significant reduction in OiP memory performance when comparing PDAPP DR 
scores at 14-16 months of age with 6-8 and 10-12 months of age, F(2, 26) = 9.8, p<0.001. 
Analysis further revealed a main effect of age in genotype. WT mice showed no difference in 
OiP memory performance compared to PDAPP mice at 6-8 months of age, F(1, 27) = 1.9, 
p>0.1, or 10-12 months of age, F(1, 27) = 2.4, p>0.05. However, PDAPP mice showed 
reduced memory performance compared to WT mice at 14-16 months of age, F(1, 27) = 49.9, 
p<0.001.  
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Figure 4.3 PDAPP mice show an age-dependent deficit in object-in-place memory. Mean 
discrimination ratio (DR) scores of WT (n=15) and PDAPP (n=14) mice with objects of novel object-
place associations. Chance level (0.5) is marked with a solid black line. Error bars show the S.E.M.  
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One sample t-tests showed that both WT and PDAPP mice differed from 0.5 (no 
discrimination) at each age and delay: WT mice at 6-8 months, 5 minutes and 24 hours delay, 
t(14) = 9.5 and 8.7, p<0.001, and PDAPP mice, t(13) = 8.8 and 6.1, p<0.001, WT mice at 10-
12 months, 5 minutes and 24 hours delay, t(14) = 9.4 and 12.8, p<0.001 and PDAPP mice, 
t(13) = 6.4 and 6.5, p<0.01 and WT mice at 14-16 months, 5 minutes and 24 hours delay, 
t(14) = 6.0 and 6.8, p<0.001 and PDAPP mice, t(13) = 3.4 and 3.9, p<0.05.  
Collectively, these analyses of the DR scores revealed that both PDAPP and WT mice 
remained significantly above chance at all ages and delays tested. Therefore mice remained 
able to successfully complete the OiP memory task. However, PDAPP mice showed an age-
dependent deficit in performance.  
4.4 Experiment 6: Amyloid Pathology in PDAPP Mice 
PDAPP mice showed an age-related increase in Aβ
Figure 4.4 shows an age-related profile of amyloid pathology in the HPC of ageing PDAPP 
mice. Inspection of Figure 4A shows an age-related increase in levels of soluble Aβ40. 
However, despite levels of soluble Aβ40 showing a general trend to increase with age, this 
observation was not confirmed statistically following analysis by Kruskal-Wallis test, X2(3) = 
2.7, p>0.1. Nevertheless, a significant change in the levels of insoluble Aβ40 was observed 
following analysis with Kruskal-Wallis test, X2(3) = 14.5, p<0.01. Dunn’s test revealed that 
mice at 7 months of age (p<0.01) and 11 months of age (p<0.01) had a greater level of 
insoluble Aβ40 when compared to mice at 3 months of age. No differences were observed 
with any age when compared to 15 months of age, p>0.1. 
However levels of both soluble and insoluble Aβ42 (Figure 4.4 C, D) increased with 
age in the HPC of PDAPP mice. These age-related changes were confirmed by Kruskal-
Wallis test in soluble Aβ42, X2(3) = 10.5, p<0.05. Dunn’s test for multiple comparisons 
showed a significant increase in the levels of soluble Aβ42 when comparing mice at 3 months 
and 15 months of age, p<0.05. A similar statistical report was observed for levels of insoluble 
Aβ42, X2(3) = 9.9, p<0.05. Dunn’s test confirmed a significant increase in levels of insoluble 
Aβ42 from 3 months of 15 months of age in the HPC of PDAPP mice.
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Figure 4.4: Levels of Aβ increase with age in the HPC of PDAPP mice. Soluble and insoluble 
levels of Aβ40 (A and B) and Aβ42 (C and D) were measured by ELISA. Amyloid levels were 
determined at 3 (n=5), 7 (n=7), 11 (n=7) and 15 (n=7) months of age. Error bars represent s.e.m. 
*p<0.05, **, p<0.01. 
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4.5 Chapter Discussion 
The main aim of the present study was to examine the effect of the hAPPV717F
mutation on object recognition memory processes in PDAPP mice. The primary rationale for 
this was to identify any age-related change(s) in recognition memory that could be targeted 
for treatment with 2B3 (see Chapter 5). An additional rationale for this study was the 
conflicting evidence concerning an age-related deficit in object novelty detection reported in 
the literature (Dodart et al., 1999; Chen et al., 2000). Furthermore, despite some evidence for 
spatial memory impairment in PDAPP mice no study has established the effects of the 
mutation on detecting mismatches in object-in-place (OiP) associations. WT and PDAPP 
mice displayed OiP memory and showed a preference to explore objects in novel locations 
between 6-12 months of age. However, in contrast to their performance in object novelty 
detection, PDAPP mice showed a decline in OiP performance at 14-16 months of age. 
Concurrent with this decline in memory performance, soluble and insoluble forms of Aβ 
showed an age-related increase in the level of Aβ42 in the HPC of PDAPP mice at 15 months 
of age. The absence of a deficit in object novelty discrimination in PDAPP mice in this study 
indicates that the representational processes and neural systems involved in novelty detection 
and object identity remained intact. Furthermore, it would argue for a specific age-dependent 
deficit in processing object-place information, which may be associated with an age-related 
increase in Aβ42.  
It is important to note that the sample phase data from both tasks revealed that PDAPP 
mice explored the objects less than WT mice at all ages. This suggests that hAPP
overexpression may influence either locomotor activity, or engagement with objects. 
Spontaneous locomotor activity has been reported to be altered in PDAPP mice when 
compared to WT controls, however there is conflicting evidence. For example, Dodart and 
colleagues (1999) reported that PDAPP mice showed increased locomotor activity compared 
to WT control mice in ages up to 10 months (Dodart et al. 1999). However, Hartman and 
colleagues reported no significant difference in locomotor activity between PDAPP and WT 
mice in young and aged mice (exact ages not reported; Hartman et al. 2005). A notable 
difference between these studies is that Dodart and colleagues used male PDAPP mice bred 
on a mixed background, whereas Hartman and colleagues used male and female PDAPP mice 
bred on just a C57Bl/6 background (Dodart et al. 1999; Hartman et al. 2005). It has previously 
been observed that different background strains and gender show altered behavioural 
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phenotypes likely to be responsible for such differences between these two studies (Võikar et 
al. 2001; Şık et al. 2003). Due to the differences influenced by gender and background strain, 
it may be plausible that reduced contact times with objects reported in this chapter may be an 
effect of using male PDAPP mice bred on a C57Bl/6 background. Nevertheless, it is 
important to note both WT and PDAPP showed a significant reduction in object contact time 
across the sample phases. This suggests that short-term habituation remained intact in PDAPP 
mice and object information was encoded during the sample phase. This would further 
indicate that the deficit observed in OiP memory is unlikely to be explained by gross visual or 
motor impairments. 
As discussed in the chapter introduction, the PRC is crucial in the processing of object 
information, while the HPC is essential for processing associative context/spatial information 
related to the object (Winters et al. 2004; Good et al. 2007; Barker & Warburton 2011). Given 
the involvement of the PRC in object novelty memory, and the HPC in processing spatial 
associative information, it is unclear whether this deficit in PDAPP mice reported by Dodart 
and colleagues reflected an impairment in object novelty detection per se or impaired 
processing of object position information. The data reported by Chen (2000) and that in this 
chapter showed in tact object novelty memory in PDAPP mice (Chen, Chen, Knox, Inglis, 
Bernard, Martin, Justice, Mcconlogue, et al. 2000). It is therefore likely that PRC function in 
PDAPP mice is relatively unaffected by age and the hAPPV717F mutation.  However, the 
impaired OiP memory observed in PDAPP mice at 14-16 months of age and increased levels 
of Aβ in the HPC of 15 month PDAPP mice suggests impaired functioning of the HPC and 
processing of spatial information required for successful OiP memory performance. 
Moreover, the significant age-dependent impairment in OiP memory and increased levels of 
Aβ in the HPC at 14-16 months of age in PDAPP mice compliments previous findings of 
amyloid and age-related deficits in OiP memory in Tg2576 mice (Hale & Good 2005; Good 
& Hale 2007).  
Interestingly, other Tg models of AD have also showed mixed recognition memory 
profiles. The TgCRND8, J20, APP/PS1 and 3xTg models have been reported to display object 
recognition deficits following amyloid deposition (Mucke et al. 2000; Chishti et al. 2001; 
Oddo et al. 2003; Clinton et al. 2007; Escribano et al. 2009; Francis et al. 2012; Heneka et al. 
2013; McClean & Hölscher 2014). In contrast, PDAPP, Tg2576 and APP23 mice showed no 
deficits in object recognition memory (Chen et al. 2000; Hale & Good 2005; Heneka et al. 
2006; Good & Hale 2007). Interestingly, the Tg models reported to display object recognition 
memory deficits all express multiple transgenes related to AD pathology, including more than 
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one APP mutation. PDAPP, Tg2576 and APP23 mice however only express single mutant 
hAPP transgenes. These deficits may therefore be sensitive to the overall level of mutant APP 
and other transgene expression. Moreover, there is evidence for PRC plaque pathology in 
TgCRND8 and APP/PS1 mice and hypoperfusion in the PRC of J20 mice from a young age 
(Minkeviciene et al. 2009; Romberg et al. 2012; Hébert et al. 2013). To date, no study has 
determined pathology in the PRC of APP23 mice, whilst almost no amyloid burden has been 
reported in the PRC of PDAPP mice by 9-10 months of age (Dodart et al. 2000). Plaque 
pathology in the PRC of Tg2576 mice has been reported at 22.5 months of age. However this 
age is much greater than the age (16 months) at which object recognition memory has been 
assessed in Tg2576 mice (Lim et al. 2005; Good & Hale 2007; Yassine et al. 2013). 
Collectively these data indicate that whereas some Tg models may show intact object 
recognition memory at ages where increased levels of amyloid are present in the HPC and 
cortical regions, others show impaired recognition memory, which may be related to altered 
PRC function. These differences appear to be based on the level of transgene expression and 
differences in regional amyloid pathology. Therefore, caution is required when comparing 
object recognition memory profiles in different Tg models of AD, as well as when 
considering object memory assessment of spatial/contextual associative information such as 
in this experimental chapter. 
In conclusion, this study is the first to characterise object recognition memory in male 
PDAPP mice on a C57Bl/6 background. Following repeated exposure to objects, PDAPP 
showed comparable discrimination of familiar and novel objects over 5 minute and 24 hour 
delays at 6-8, 10-12 and 14-16 months of age. In contrast, PDAPP mice showed a deficit in 
OiP memory only at 14-16 months of age. Collectively these data reveal an age-dependent 
deficit in OiP memory that is unlikely to be a reflection of impairments in novelty detection 
per se. Furthermore, the deficit coincides with an elevation in Aβ levels in the HPC. These 
observations provide a sufficient rationale to evaluate the hypothesis that an antibody directed 
to the β-secretase cleavage site may have impact on Aβ production and cognition in aged 
PDAPP mice.  
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Chapter 5: 2B3 reverses an age-dependent cognitive deficit in PDAPP mice  
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Chapter Overview 
This experimental chapter examines the hypothesis that inhibition of APP metabolism 
and Aβ production by administration of 2B3, an anti-APP antibody, is able to improve 
memory in PDAPP mice. To investigate this, chapter 6 has been divided into two main 
experiments. Experiment 7 assessed the in vivo effects of 2B3 in PDAPP mice following a 14-
day intracerebroventricular (ICV) administration. Experiment 8 assessed ex vivo tissue of 
PDAPP mice treated with 2B3 or PBS for metabolites of BACE1 cleavage of APP and 
NMDAR-related synaptic plasticity mechanisms thought to underpin object-in-place (OiP) 
memory . 
5.1 Chapter Introduction 
β-Secretase as a therapeutic target for Alzheimer’s disease 
Despite promising early findings of anti-Aβ immunotherapy in preclinical AD models, 
little translational benefits has been observed in clinical trials, as discussed in Chapter 1 
(section 1.5.3). Nevertheless, many current therapeutic strategies still focus on the role of 
amyloid and its proteogeneis in AD pathology. One specific target is BACE1, or the BACE1 
cleavage site of APP. Many studies have reported BACE1 to play a significant role in the 
generation of Aβ. Inhibition of BACE1 activity should, therefore, prevent the production of 
Aβ. Consistent with the view, BACE1 knock-out (KO) mice crossed with Tg2576 or PDAPP 
mice have almost undetectable levels of A and βCTF (Luo et al. 2001; McConlogue et al. 
2007). Furthermore, BACE1 deficiency in Tg2576 and 5xFAD models is reported to rescue 
spatial working and reference memory deficits to comparable levels of WT controls (Ohno et 
al. 2004; Ohno et al. 2007). More recently, a human BACE1 knock-in model has been 
reported (Plucińska et al. 2014).  This model showed progressive AD-like pathology, 
including increased levels of βCTF and soluble Aβ*56 as well as cognitive abnormalities at 6 
months of age. Evidence has also revealed Aβ-independent contributions to pathology 
specifically focusing on βCTF (Pimplikar et al. 2010; Tamayev et al. 2012; Kim et al. 2015). 
It has been reported in vitro that increased βCTF stimulated the overactivation of rab5, a 
regulator of early endosomes. This overactivation lead to endosomal swelling, accelerated 
endocytosis and impaired axonal transport of rab5 positive endosomes (Kim et al. 2015). 
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Moreover, in vivo inhibition of BACE1, but not γ-secretase cleavage of APP lead to improved 
LTP and novel object memory in a model of familial Danish dementia (Tamayev et al. 2012). 
This study suggested that βCTF and/or sAPPβ may act as neurotoxic metabolites, independent 
of Aβ. Collectively, these studies provide evidence implicating BACE1 cleavage of APP in 
AD pathogenesis and identify BACE1 as a prominent target for AD therapy. 
Since the discovery of BACE1 and its role in amyloidogenic processing, there has 
been considerable research into developing small molecule BACE1 inhibitors. First 
generation BACE1 inhibitors consisted of non-cleavable peptidomimetic analogues of the 
APP β-secretase cleavage site, which successfully reduced soluble Aβ both in vitro and in 
vivo (Kimura et al. 2005; Asai et al. 2006). However, these first generation peptide-based 
drugs faced early complications and could not deliver appropriate pharmacokinetic properties, 
including poor oral bioavailability, BBB penetrability and long serum half-life (De Strooper et 
al. 2010; Yan & Vassar 2014). Continued development of BACE1 inhibitors has led to small 
molecule inhibitors that exhibit significantly improved pharmacokinetics, display robust Aβ 
reduction and improved cognition in Tg models (Hussain et al. 2007; Fukumoto et al. 2010). 
As a result, several BACE1 inhibitors are currently in clinical trials (www.clinicaltrials.gov). 
One of the most promising of these, MK-8931 (Merck & Co.), is currently in a phase III 
clinical trial with a total of 1500 prodromal and mild-moderate AD patients. This compound 
showed much promise in earlier clinical phase 1b trials in mild-moderate AD patients, which 
reported a robust dose-dependent reduction of CSF Aβ concentrations without any serious 
adverse reactions (Forman et al. 2013).  
However, one major concern about BACE1 inhibition is the potential side effects 
caused by chronic BACE1 inhibition in non-APP processing pathways. Early reports in 
BACE1 null mice suggested a lack of negative phenotypes, however subsequent studies have 
reported more than a dozen abnormalities (as reviewed in Yan & Vassar 2014). BACE1 is 
now reported to have multiple substrates and is a regulator of physiological pathways 
including neuron myelination, axon guidance and neurogenesis (von Arnim et al. 2005; Hu et 
al. 2008; De Strooper et al. 2010; Hitt et al. 2012; Hu et al. 2013; Yan & Vassar 2014). 
However, the effects of BACE1 knockout are present from conception and it is therefore 
unclear to what extent the phenotypes described previously may reflect BACE1 inhibitor side 
effects in later stages of life. For this reason, the risk of BACE1 inhibition-related toxicity will 
depend on the extent of therapeutic efficacy. The results of on going clinical trials will, no 
doubt, provide answers to these questions. 
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To overcome these challenges an alternative strategy has been developed using 
antibodies targeting the β-secretase cleavage site of APP (Arbel et al. 2005; Thomas et al. 
2006). Arbel and colleagues (ibid) designed a monoclonal antibody  (mAb) called “blocking 
β-site 1” (BBS1), which was raised against multiple antigenic peptides for the β-secretase 
cleavage site of APP (Arbel et al. 2005). These multiple antigenic peptides consisted of eight 
copies of the amino acid sequence representing the β-secretase cleavage site of healthy human 
APP (ISEVKMDA), as well as half of the Swedish APP mutation (ISEVKLDA). This 
approach was taken to overcome poor immunogenicity to short peptides as well as tolerance 
to self-antigens (Arbel et al. 2005). In vitro analysis of BBS1 treatment of CHO cells, 
transfected with the human APP 751 isoform, revealed that BBS1 reduced intracellular and 
secreted Aβ when compared to non-treated CHO-APP cells. Furthermore, Arbel and 
colleagues were able to visualize BBS1 internalisation and co-localisation with EEA1, a 
marker of early endosomes, where BACE1 cleavage of APP is believed to occur (Kinoshita et 
al. 2003; Arbel et al. 2005).  
To determine if BBS1 had a similar effect in vivo, Tg2576 mice and mice harbouring 
the hAPP London mutation were subjected to chronic systemic BBS1 treatment (Moechars et 
al. 1999; Rakover et al. 2007; Arbel-Ornath et al. 2009). Results showed improved object 
recognition memory in Tg2576 mice receiving a dose of 16mg/kg. However, no changes in 
levels of soluble or insoluble Aβ or βCTF were reported, although a reduction in 
neuroinflammation was observed (Rakover et al. 2007). Mice expressing the hAPP London 
mutation, however, did show reduced Aβ plaque burden and reduced intracellular Aβ 
accumulation following BBS1 administration at 16mg/kg (Arbel-Ornath et al. 2009). These 
mice were further assessed on the Morris water maze (MWM), however no significant 
improvement was observed following BBS1 administration. Further studies by this group 
used 3xTg mice administered with BBS1 by ICV administration at 7.5 mg/kg/week for a 
period of 1 month at 17 months of age (Rabinovich-Nikitin et al. 2012; Rabinovich-Nikitin & 
Solomon 2014). Rabinovich-Nikitin and colleagues revealed BBS1 was able to improve 
object recognition memory performance in 3xTg mice to a level comparable to WT controls. 
Ex vivo tissue analysis also revealed that BBS1 treatment lead to reduced plaque size, total Aβ 
load and a reduction in phospho-tau and total GSK3β levels (Rabinovich-Nikitin et al. 2012). 
It was later reported in these mice that BBS1 treatment reduced phospho-GSK3β, the active 
form of GSK3β, as well as p53, a signalling molecule associated with neuronal apoptosis 
(Jordán et al. 1997; Rabinovich-Nikitin & Solomon 2014). Collectively, these data suggest 
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that targeting the β-secretase cleavage site of APP may have therapeutic value for the 
treatment of AD-related pathology. 
Thomas and colleagues (2006) reported that 2B12, a similar mAb directed against the 
β-secretase cleavage site of APP, inhibited BACE1 cleavage of APP and reduced levels of 
Aβ40 in MOG-G-UVW and SH-SY5Y, an astrocytoma and neuroblastoma cell line (Thomas 
et al. 2006). It was later observed that 2B3 was also effective at blocking BACE cleavage of 
APP and showed similar effects to 2B12 (Thomas et al. 2011) Both 2B3 and 2B12 were 
raised against a 15 amino acid sequence spanning the human β-secretase cleavage site of APP 
(EEISEVKMDAEFRHD) (Thomas et al. 2011). However, both were observed to have 
different epitopes, but 2B3 showed a greater recognition of the β-secretase cleavage site of 
APP, as well as full length APP. Thomas et al., (2011) also showed that 2B3 was able to 
maintain a strong interaction with a secondary APP epitope containing the β-secretase 
cleavage site at pH4. This indicated that 2B3 should maintain an ability to inhibit BACE1 
cleavage of APP in an equivalent acidic environment found in early endosomes, which 
provides optimal conditions for BACE1 activity (Vassar & Citron 2000). When determining 
BACE1 activity in a cell free assay containing only culture media, BACE1 and sAPPα, 2B3 
and 2B12 showed little reduction in levels of sAPPα compared to media treated with a control 
N-terminal APP antibody. In fact, 2B3 virtually abolished BACE1 metabolism of sAPPα and 
it was determined that 2B3 inhibited BACE1 cleavage of the APP β-secretase cleavage site by 
“steric hindrance” (Thomas et al. 2011).  
To further determine if both 2B3 and 2B12 were able to reduce levels of Aβ40 or 
Aβ42, Thomas et al. (2011) treated MOG cells with either 2B3 or 2B12 for 48 hours. Results 
indicated that 2B3 was more effective at reducing Aβ40 and Aβ42 as well as levels of βCTF 
when compared to 2B12 treated MOG cells. A more recent study by Thomas et al., (2013) 
showed that 2B3 was able to significantly reduce soluble Aβ40 in mouse C57Bl/6 primary 
cortical neurons. 
 Given the evidence from Rabinovich-Nikitin et al., (2012) for a positive impact of 
mAb-mediated blockade of BACE1 processing on cognition in transgenic APP mice, the 
present study evaluated the hypothesis that inhibition of BACE1 cleavage of APP by 2B3 
administration in vivo would ameliorate the cognitive deficit in visuo-spatial memory in 
PDAPP mice.  
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5.2 Experiment 7: In vivo assessment of 2B3 
5.2.1 Introduction 
 As reported in Chapter 4, PDAPP mice displayed an age-dependent deficit in object-
in-place memory at 14-16 months of age. Given the extensive work carried out to determine 
HPC involvement in the object-in-place task (as discussed in Chapter 4 and reviewed in 
Barker & Warburton 2013), this task was chosen over the foraging task to test the hypothesis 
that 2B3 would attenuate the cognitive deficits in PDAPP mice. 
 In this experiment, the same mice reported in Chapters 3 and 4 mice were 
administered 2B3 by ICV administration at 17-18 months of age. This age point provides an 
appropriate time at which to test 2B3 in vivo. Numerous studies have previously reported 
increased amyloid levels with age and further age-dependent cognitive deficits, sensitive to 
increased levels of Aβ pathology in the HPC (Chapter 3 and 4; Johnson-Wood et al. 1997; 
Chen et al. 2000; Hartman et al. 2005). This age point therefore allows an assessment of the 
abilities of 2B3 to reduce amyloid production and potentially alleviate cognitive dysfunction. 
A concern regarding immunotherapy targeting the CNS is access to the brain via the 
BBB. The BBB is a highly regulated protective membrane separating the CNS from the 
periphery. Despite previous immunotherapy studies delivering mAbs via peripheral 
administration in animals, very few have reported positive antibody presence in the brain 
(Wilcock, Rojiani, Rosenthal, Levkowitz, et al. 2004; Yamada et al. 2009). Moreover, it has 
been estimated that approximately 0.1% of an antibody dose delivered peripherally will cross 
the BBB and spread into the brain (Banks et al. 2002). Therefore, to optimally assess the 
ability of 2B3 to inhibit β-secretase cleavage of APP and improve memory in PDAPP mice, 
2B3 was delivered directly into the left lateral ventricle of the brain using osmotic minipumps 
(Alzet, Cupertino, USA). A pilot study had previously been carried out to show 2B3 was 
successfully delivered into the brain using this method and was able to spread into HPC and 
cortical structures (PhD Thesis: Hvoslef-Eide, 2013). 
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5.2.2 Method: 
Design 
 To assess the effect of 2B3 on OiP memory, PDAPP and WT control mice used in 
Chapters 3 and 4 were assessed on the OiP task with a five-minute delay between the sample 
and test phase. The experimental protocol was identical to that described in Chapter 2. All 
mice used in this experiment were tested at 14-16 months of age prior to surgical implantation 
of osmotic minipumps in order to allow a pre-treatment as well as post-treatment measure to 
be taken. This allowed for both within-subjects and between subjects comparisons to be 
carried out. 
 Transgenic mice were administered with 2B3 or PBS vehicle control. A group of WT 
mice were also administered PBS vehicle control and a further WT group received no 
treatment. The latter group was included to assess whether osmotic minipump implants 
altered the performance of mice in the OiP task. Treatment was continuous for a 14-day 
period. On days 13 and 14, OiP memory was assessed and mice were culled following the 
final test on day 14 for ex vivo tissue analysis, discussed in Experiment 8 of this chapter. It 
was hypothesised that PDAPP mice receiving 2B3 treatment would show improved memory 
performance relative to PDAPP vehicle treated mice. 
Subjects 
A total of 21 PDAPP mice and 21 WT controls were used in this experiment. The 
same 14 PDAPP and 15 WT mice used in Chapters 3 and 4 were used in this study. A second 
cohort of animals were also used to replicate the age-related changes in PDAPP mice, as 
discussed in Chapter 3 and 4, and were also administered 2B3 in an identical fashion. These 
mice were used in order to increase the sample size of treatment groups in this study and 
improve the statistical power of the analysis used in this study (Baguley 2004; Cohen 1992). 
Therefore, a further 7 PDAPP and 6 WT mice were also used. These additional mice had 
undergone the same behavioural tasks in an identical fashion as described in Chapters 3 and 4, 
however only at 6-8 and 14-16 months of age. These mice therefore received similar levels of 
exposure to behavioural assays as the initial group of mice. At 17-18 months of age 21 
PDAPP mice underwent surgical osmotic minipump fitting. Of these, 10 PDAPP mice 
received 2B3 (2.1mg/ml) treatment and 11 received PBS vehicle control. A further 10 age-
matched WT mice underwent identical surgical procedures and received PBS vehicle only 
and 11 WT mice received no treatment. 
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Production of 2B3 
2B3 producing hybridoma cells, stored in liquid nitrogen, were thawed on ice. Cells 
were resuspended in 1.5ml of cell culture medium [RPMI1640 (Sigma-Aldrich, Dorset, UK), 
2mM Glutamine, 10% Foetal Bovine Serum, 1% Penicillin, 1% Streptomycin] before being 
added to a further 30ml of media. The solution was centrifuged at 1000rpm for 5 minutes at 
room temperature (RTP) and the supernatant removed. Pelleted hybridomas were resuspended 
in 1ml of media, pre-heated in an incubator (Pierce, Rockford, USA) at 37oC. Cells were 
transferred to a single well of a 24 well cell culture plate (Corning Incorporated, NY, USA) 
and grown at 37oC in 5% CO2. Cells were split appropriately when confluent by resuspension 
into fresh, pre-heated media, and further grown in 25 and 75cm2 flasks (Corning 
Incorporated). When cells were grown to confluence, the media containing 2B3 was collected 
at approximately 50% cell viability. The media was centrifuged at 1000rpm for 5 minutes at 
RTP and the supernatant was collected and stored at 20oC. 
Concentration 
2B3 cell media was concentrated using Amicon Ultra centrifugal filter units (Millipore, 
Billerica, USA) with a 100kDa molecular weight cut off. 10ml of media was centrifuged in a 
JS7.5 swing bucket rotor (Beckman Coulter, High Wycombe, UK) at 3000g at 4oC for 1 hour. 
Following centrifugation, media filtrate was discarded, and 10ml of fresh media was added. 
This pattern continued until approximately 70ml had passed through one centrifugal filter 
unit. When multiple centrifugal units were used, the concentrated antibody was pooled before 
the concentration of 2B3 was determined.  
Quantification of 2B3 using ELISA 
The methods utilised to determine the concentration of concentrated 2B3 were based 
on the procedure used by Thomas et al., (2006, 2011). A 96-well plate was coated in a sheep 
anti mouse IgG (Greiner Bio One, Frickenhausen, Germany) at a concentration of 1:4000, 
diluted in a carbonate/bicarbonate buffer (15mM Na2CO3, 35mM NaHCO3, pH 9.6) and left 
overnight at 4oC. The plate was then washed 3 times with PBST (137mM NaCl, 2.5mM KCl, 
8mM Na2HPO4, 1.5mM KH2PO4, 0.05% Tween20) between each stage, and all incubations 
were carried out at RTP. Following washing, the plate was then aspirated and blocked with 
0.1% (w/v) milk powder in PBST for 1 hour. Standards, samples and negative controls were 
then added in duplicate at 100uL/well and were incubated for 2 hours at RT. Standards ranged 
from 200  0.3ng/ml in doubling dilutions. Doubling dilutions of the 2B3 sample were 
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applied, from 1/1000 to 1/2,048,000. 2B3 was detected following a 1-hour incubation with 
100uL/well secondary goat anti-mouse antibody conjugated to HRP, 1:6000 (Pierce). The 
enzyme substrate, o-phenylenediamine (OPD) (Sigma-Aldrich), in 0.1M citrate phosphate 
buffer (24mM citric acid, 51mM Na2HPO4, pH5) was applied at 100uL/well and incubated for 
approximately 20 minutes in the dark. The reaction was stopped using 50μl 2.5M H2SO4 and 
read at 492nm using a spectrophotometer. The concentration of 2B3 was then determined 
using GraphPad Prism 4.0 and Microsoft Excel. 
Purification 
Concentrated media containing 2B3 was purified using an affinity chromatography 
MAb TrapTM Kit (GE Healthcare, Buckinghamshire, UK) with the aim of both purifying and 
further concentrating the IgG solution. Binding and elution buffers, as well as the antibody 
sample were passed through a HiTrap Protein G column containing recombinant protein G, 
genetically altered to lack the ability to bind albumin, while maintaining a high affinity for 
IgG. Binding and elution buffers within the kit were diluted 1:10 with dH2O prior to use, and 
all flow through was collected in 1.5ml Eppendorf tubes containing 60uL neutralising buffer 
to maintain IgG activity. The column was washed with dH2O at approximately 1 drop per 
second, to clear ethanol residues following storage. The column was equilibrated with 3ml of 
binding buffer before 2B3 was applied. 10mls of binding buffer was passed through the 
column to remove molecules other than the 2B3, before 5ml of elution buffer was passed to 
release 2B3.  
Dialysis 
The purified antibody was dialysed to remove MAb Trap buffers using PBS (137mM 
NaCl, 2.5mM KCL, 8mM Na2HPO4, 1.5mM KH2PO4, pH7.2) to ensure compatibility with 
the Tris and Glycine based buffers of the MAb TrapTM Kit. Slide-A Lyzer Dialysis 
Cassettes (Pierce) of 0.5  3ml sample volume with a 10kDa molecular weight cut off were 
utilised. Cassettes were rotated in 2 litres of PBS at 4oC overnight before 2B3 was collected. 
The PBS used for 2B3 dialysis was used as the vehicle control in the minipump study. 
Following dialysis, one last quantification measure was carried out in order to determine the 
final concentration of purified 2B3. This was performed using the NanoVue 
spectrophotometer (GE Healthcare Ltd, Buckinghamshire, UK), which is able to quantify 
IgG concentrations. A final concentration of 2.1mg/ml was determined. 
145
Sterilisation
Once the final concentration was determined, both 2B3 and PBS vehicle were 
sterilised. This was carried out by passing 2B3 and vehicle PBS through a 5μm sterile filter 
into sterile collection tubes. Following this, treatment samples were frozen at -20oC until 
required. 
Surgical Insertion of Osmotic Minipumps 
 The purified and sterilised 2B3 was administered to PDAPP mice by 
intracerebroventricular (ICV) infusion via osmotic minipumps. Sterile PBS was administered 
in an identical manner as a vehicle control. 
 Osmotic minipumps (Alzet, 1002) administered both solutions at a constant flow rate 
of 0.25μl/hour for a period of 14 days. Minipumps were filled with 200μl of either 2B3 or 
vehicle and back-filled through a 2.5cm catheter attached to a 28G cannula (Alzet, 0004760). 
Minipumps were then inserted into the mice as follows: Mice were anaesthetised by 
isoflurane carried by O2 for the duration of stereotaxic surgery. One the mouse was under 
anaesthesia, one small hole was drilled through the skull of the animal 0.5mm posterior and 
1.2mm lateral to bregma where the 28G cannula was then inserted upto 3.0mm ventral into 
the left lateral ventricle of the brain. The cannula was fixed to the skull initially with four 
screws and secured in place using dental cement. A small subcutaneous cut was made at the 
lower neck of the mouse and the minipump was carefully inserted below the skin between the 
scapulae, spanning the lower back of the animal. Mice were sutured and allowed to recover in 
an incubator. All mice were then housed individually to prevent any chance of interference 
with the sutures, minipumps or mounts. 
Behavioural Procedure 
 The OiP behavioural procedure was carried out using an identical method to that 
described in Chapter 2. However, only a 5-minute delay interval was interpolated between the 
sample and test phase. 
Scoring and Data Analysis 
 Scoring and data analysis were carried out in an identical manner to that described in 
Chapter 2. 
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5.2.3 Experiment 7: Results 
Pre-treatment analysis
 Prior to minipump implantation, WT and PDAPP mice were divided into 4 groups; 
WT untreated (WT UT), WT vehicle (WT V), PDAPP vehicle (PDAPP V) and PDAPP 2B3. 
To ensure that the groups were matched in terms of their surgical assignments two separate 
2x2 repeat measures ANOVAs were carried out on sample phase and test phase contact time 
data and a one-way ANOVA was performed with post-hoc Tukey analysis on DR data 
previously reported in Chapter 4, Experiment 6.  
 Data displaying contact times in sample phases 1-3 can be observed in Table 5.1. 
Contact times, violated Levene’s test of equality of error variances, p<0.05. Therefore, the 
data were transformed by square root transformation. Despite transformation no longer 
violating this test, Mauchly’s test of Sphericity remained violated, p<0.05. Therefore, 
Greenhouse-Geiser comparisons were reported where appropriate. Repeated measures 
ANOVA revealed a significant main effect of sample phase, F(1.7, 63.5) = 50.2, p<0.001, no 
significant sample phase x treatment group interaction, F(5.0, 63.5) = 0.6, p>0.5 and a 
significant main effect of treatment group, F(3, 38) = 5.6, p<0.01. Post-hoc Tukey analysis of 
the significant main effect of treatment group revealed that only WT UT mice explored 
objects (when collapsed across sample phase) more than PDAPP V mice, p<0.01. No further 
significant differences in total contact times were reported (WT V vs PDAPP V, p=0.052). 
A repeat measures ANOVA analysed the pre-treatment contact times. Times displayed 
in Table 5.2 were transformed by square root due to violations in Levene’s Test of Equality of 
Error Variance. The analysis reported a significant main effect of object location, F(1, 38) = 
70.4, p<0.001, a significant object location x treatment group interaction, F(3, 38) = 10.3, 
p<0.001 and a significant main effect of treatment group, F(3, 38) = 9.1, p<0.001. Post-hoc 
Tukey analysis of the between-subject main effect collapsed across object location revealed 
no significant difference between WT UT and WT V mice, p>0.1. WT UT mice showed a 
greater contact time with objects than PDAPP V, p<0.001 and PDAPP 2B3, p<0.01. No 
further significant differences between treatment groups were reported. Because there was a 
significant object location x treatment group interaction, tests for simple main effects were 
performed. Between-subjects comparisons revealed that WT UT mice explored objects in 
novel locations more than both PDAPP groups, p<0.001. WT V mice explored objects in 
novel locations more than PDAPP V mice only. No further significant effects were reported 
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when the novel location data. WT UT mice showed a greater contact time with objects in 
familiar locations than PDAPP V mice only, p<0.05. No further differences in contact times 
with objects in familiar locations were reported. Within-subjects analysis to determine if 
objects in novel locations were explored significantly more than familiar locations revealed 
that both WT UT and WT V mice explored objects in novel locations significantly more than 
objects in familiar locations, p<0.001. Neither PDAPP V or PDAPP 2B3 mice explored 
objects in novel locations more than objects in familiar locations, both p’s >0.05. 
One-way ANOVA analysis of DR scores revealed a significant main effect of group, 
F(3, 41) = 5.8, p<0.01. Post-hoc analysis revealed no significant differences between either 
WT group, p>0.5, or PDAPP group, p>0.5. The only significant differences were reported 
when comparing WT groups to PDAPP groups respectively, p’s <0.05, which was previously 
reported in Chapter 5, Experiment 6. Taken together, this pre-treatment analysis showed that 
mice habituated to objects across sample phases without differential effects across treatment 
group as determined by a lack of sample phase x treatment group interaction. Test phase 
contact times revealed that both WT groups showed a discrimination toward objects in novel 
locations over objects in familiar locations, whereas both treatment groups of PDAPP mice 
did not. This was further observed when contact times were converted to DRs, both WT 
groups showed significantly greater DR scores than either PDAPP group. Collectively, 
dividing WT and PDAPP mice into 4 separate treatment groups showed no significant 
differences within genotypes or novel differences between groups previously unreported in 
Chapter 4. Therefore, any changes in behaviour reported post surgical treatment cannot be 
attributed to pre-treatment differences in performance.    
Control groups analysis
The initial analysis following pre- and post-treatment determined if any changes were 
observed by the implantation of osmotic minipumps in WT mice. This analysis was 
performed with the intention to collapse across both WT control groups and prevent 
unnecessary multiple comparisons in the mixed measures ANOVA used to determine the 
effects of 2B3 in vivo. Both contact times with objects and DR scores were analysed using 
repeated measures ANOVA. Two main factors, treatment group (between-subject) and time 
(pre- and post-treatment intervention; within-subject), were analysed. One further within-
subject analysis of object location was analysed for the contact time data as well as the effect 
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of sample phase was assessed prior to test phase. Due to violation of Levene’s test of equality 
of error variances, all contact time data were transformed by square root. 
Sample phase contact times were analysed in a 2x3x2 repeat measures ANOVA. 
Analysis revealed a significant main effect of sample phase, F(2, 38) = 53.7, p<0.001, no 
significant sample phase x treatment group interaction, F(2, 38) = 2.0, p>0.1, no significant 
main effect of time (pre-treatment and post-treatment), F(1, 19) = 0.9, p>0.1, no significant 
time x treatment group interaction, F(1, 19) = 0.04, p>0.5, no significant sample phase x time 
interaction, F(2, 38) = 0.9, p>0.1 and no significant sample phase x time x treatment group 
interaction, F(2, 38) = 1.7, p>0.1. No significant main effect of treatment group was reported, 
F(1, 19) = 2.9, p>0.1. Therefore the effect of sample phase remained equal across both WT 
groups. No effect of surgical implantation of osmotic minipumps and vehicle administration 
in WT mice was apparent compared to mice that received no treatment. 
Contact times with objects in novel and familiar locations were analysed with a 2x2x2 
repeat measures ANOVA. This analysis reported a significant main effect of object location, 
F(1, 19) = 89.4, p<0.001, no significant object location x treatment group interaction, F(1, 19) 
= 1.8, p>0.1, no significant main effect of time, F(1, 19) = 0.7, p>0.1, no significant time x 
treatment group interaction, F(1, 19) = 1.7, p>0.1, no significant object location x time 
interaction, F(1, 19) = 0.6, p>0.1, no significant object location x time x treatment group 
interaction, F(1, 19) = 1.7, p>0.1. No significant main effect of treatment group was reported, 
F(1, 19) = 2.5, p>0.1. These results showed no effect of minipumps implantation in WT mice. 
 DR scores were analysed using a 2x2 repeat measures ANOVA. No significant main 
effect of time, F(1, 19) = 0, p>0.5 and no significant group x treatment time interaction, F(1, 
19) = 0.1, p>0.5 was reported. There was no significant main effect of group, F(1, 19) = 0.13, 
p>0.5. As no changes were observed following within- and between-subject comparisons the 
data from both WT groups were collapsed for all subsequent analyses. 
2B3 treatment and habituation to objects
 Sample phase data (Table 5.1) obtained following 2B3 treatment was analysed using a 
3x2x3 repeat measures ANOVA. These violated Levene’s test of equality of error variances
and was therefore transformed using square root. Despite this transformation, sample phase 
data violated the Mauchly’s Test of Sphericity and analysis of this factor was performed with 
Greenhouse-Geisser corrections. This analysis revealed a significant main effect of sample 
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phase, F(1.6, 63.2) = 88.4, p<0.001, no significant sample phase x treatment group 
interaction, F(3.2, 63.2) = 0.5, p>0.1, no significant main effect of time, F(1, 39) = 1.3, p>0.1, 
no significant time x treatment group interaction, F(2, 39) = 0.1, p>0.5, no significant sample 
phase x time interaction, F(2, 78) = 1.2, p>0.1 and no significant sample phase x time x 
treatment group interaction, F(4, 78) = 0.9, p>0.1. A significant main effect of treatment 
group was reported, F(1, 39) = 16.9, p<0.001. A post-hoc Tukey analysis revealed that WT 
mice explored objects significantly more than PDAPP V mice, p<0.001 and PDAPP 2B3 
mice, p<0.01. No significant difference in contact times was reported between either PDAPP 
treatment group, p>0.1. These results indicate that 2B3 treatment did not effect habituation of 
object contact times in PDAPP mice. 
Sample Phase
Treatment Group
WT Untreated WT Vehicle PDAPP Vehicle PDAPP 2B3
Pre Post Pre Post Pre Post Pre Post
Sample 
Phase 1
Mean 43.60 43.52 34.53 27.16 17.10 17.60 24.23 23.10
SD 20.90 13.45 20.56 10.87 6.28 10.62 15.86 10.24
Sample 
Phase 2
Mean 28.84 24.32 25.17 19.47 9.95 9.06 15.95 15.71
SD 14.82 11.71 12.61 13.49 4.14 7.28 10.49 8.81
Sample 
Phase 3
Mean 23.40 17.56 15.67 16.35 8.22 4.80 12.46 10.30
SD 15.71 7.75 8.68 8.90 3.66 3.01 8.28 7.95
Table 5.1: Mean contact time scores with objects of WT untreated (n=11), WT V (n=10), PDAPP V 
(n=11) and PDAPP 2B3 (n=10) mice across sample phase 1-3 and standard deviations (SD). Both pre- 
and post-treatment scores are reported in seconds. 
2B3 treatment and object-in-place memory in PDAPP mice
 Table 5.2 shows the mean contact times with objects in novel and familiar locations 
across treatment groups and pre- and post-treatment intervention. A 2x2x3 repeat measures 
ANOVA analysed the main effects of object location, time and treatment group. This analysis 
revealed a significant main effect of object location, F(1, 39) = 84.1, p<0.001, a significant 
object location x treatment group interaction, F(2, 39) = 15.5, p<0.001, no significant main 
effect of time, F(1, 39) = 0.002, p>0.5, no significant time x treatment group interaction, F(2, 
39) = 0.8, p>0.1, no significant object location x time interaction, F(1, 39) = 1.2, p>0.1, no 
significant object location x time x treatment group interaction, F(2, 39) = 2.8, p>0.05. A 
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significant main effect of treatment group, F(2, 39) = 10.1, p<0.001 was also reported. Post-
hoc Tukey analysis of the significant main effect of treatment group revealed that WT mice 
had higher contact times with objects than either PDAPP V mice, p<0.01 and PDAPP 2B3 
treated mice, p<0.05. No significant difference in contact times were observed between either 
PDAPP treatment group, p>0.1. The significant object location x treatment group interaction 
was further analysed with tests for simple main effects. Within-subjects comparisons reported 
that all groups showed an ability to discriminate objects in novel locations as determined by a 
significant difference in exploration times between objects in novel vs familiar locations, 
p’s<0.05. Between-subjects analysis revealed that WT mice explored objects in novel 
locations more than PDAPP V mice, p<0.001, and PDAPP 2B3 mice, p<0.01. WT mice also 
showed greater contact times with objects in familiar locations than PDAPP V mice, p<0.01, 
but not PDAPP 2B3 mice, p>0.1. No significant difference was reported between PDAPP 
mice for objects in novel or familiar locations, both p’s>0.1 This analysis suggests that 2B3 
treatment in PDAPP mice did not increase overall contact time with objects. 2 
Figure 5.1 displays the DR scores of mice before and following treatment with 2B3. 
These data were analysed using a 3 x 2 repeat measures ANOVA to determine if 2B3 
treatment had any effect on OiP memory in PDAPP mice. The two main factors analysed 
were treatment (PDAPP Vehicle, PDAPP 2B3 etc.) and Time (pre- vs post-treatment). The 
analysis revealed a significant main effect of time, F(1, 39) =  4.12, p<0.05 and a significant 
treatment x time interaction F(2, 39) = 3.27, p<0.05 and a significant main effect of treatment, 
F(1, 39) = 16.59, p<0.001. A post-hoc Tukey analysis of the main effect of treatment revealed 
that overall WT mice showed higher DR scores than PDAPP vehicle treated mice, p<0.001 
and PDAPP 2B3 treated mice, p<0.05. It was also revealed that PDAPP 2B3 treated mice 
showed an overall improvement in DR scores compared to PDAPP vehicle treated mice, 
p<0.05. Tests for simple main effects were performed following the significant treatment x 
time interaction. Within-subjects analysis revealed no change in pre- vs. post-treatment DR 
scores for WT mice or PDAPP vehicle mice, p>0.5. However, 2B3 treated mice showed a 
significant improvement in post-treatment OiP memory performance, p<0.01. The between-
subjects analysis revealed that PDAPP 2B3 treated mice showed significantly lower DR 
scores in the pre-treatment stage when compared to WT mice, p<0.01, but were not 
significantly different compared to PDAPP vehicle mice, p=1.0. However, following 2B3 
treatment PDAPP mice showed no difference in DR scores compared to WT mice, p=1.0, but 
did show significantly better DR scores than PDAPP vehicle control mice, p<0.001. WT mice 
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showed a significantly greater DR score than PDAPP vehicle mice across both pre- and post- 
time periods, p<0.001.  
Treatment 
Group
Pre-Treatment Post-Treatment
Novel Familiar Novel Familiar
Mean SD Mean SD Mean SD Mean SD
WT Untreated 30.51 16.90 13.51 6.77 23.82 19.22 11.40 6.87
WT Vehicle 16.01 5.48 8.77 5.33 18.32 11.32 9.98 8.81
PDAPP Vehicle 6.51 3.54 4.85 1.69 6.53 3.56 4.87 2.91
PDAPP 2B3 12.78 9.17 9.02 6.72 13.19 7.16 7.14 4.65
Table 5.2: Mean contact time scores with objects in novel and familiar locations of WT untreated 
(n=11), WT V (n=10), PDAPP V (n=11) and PDAPP 2B3 (n=10) and standard deviations (SD). Both 
pre- and post-treatment scores are reported in seconds. 
One sample t-tests were also run to determine if WT and PDAPP mice DR scores were 
significantly above chance (0.5). The analysis showed that all treatment groups at both pre- 
and post-treatment time points were significantly above chance level: WT UT mice pre-
treatment, t(10) = 7.9, p<0.001 and post-treatment, t(10) = 10.8, p<0.001, WT V mice pre-
treatment, t(9) = 7.4, p<0.001 and post-treatment, t(9) = 5.8, p<0.001. PDAPP vehicle treated 
mice, t(10) = 3.1, p<0.05 and post-treatment, t(10) = 4.8, p<0.01. PDAPP 2B3 treated mice, 
t(9) = 2.9, p<0.05 and post-treatment, t(9) = 11.2, p<0.001. 
Despite a non significant difference in total contact times between PDAPP treatment 
groups, there was an observed bias of increased overall contact time with objects in 2B3 
administered PDAPP mice (both in pre- and post-treatment conditions). For this reason, the 3 
mice with the highest contact times in the 2B3 administered group and the 3 mice with the 
lowest contact times in the vehicle administered PDAPP group were removed to observe if 
this effect in any way biased the overall DR scores. Following removal of these mice the 
mean contact time with objects can be observed in table 5.3. An identical analysis of DR 
scores was then carried out as described above, revealing the same overall results. Thus, this 
difference in contact times initially observed did not show any bias in the ability of 2B3 
administered PDAPP mice to discriminate objects in novel locations when compared to 
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vehicle treated PDAPP mice. Collectively these results show that 2B3 treatment improved 
OiP memory performance in PDAPP mice. 
Treatment 
Group
Pre-Treatment Post-Treatment
Novel Familiar Novel Familiar
Mean SD Mean SD Mean SD Mean SD
WT Untreated 30.51 16.90 13.51 6.77 23.82 19.22 11.40 6.87
WT Vehicle 16.01 5.48 8.77 5.33 18.32 11.32 9.98 8.81
PDAPP Vehicle 7.77 3.32 5.78 0.57 5.85 3.44 4.36 3.08
PDAPP 2B3 5.14 3.48 3.95 2.63 9.39 5.66 4.66 3.12
Table 5.3: Adjusted mean contact time scores with objects in novel and familiar locations of WT 
untreated (n=11), WT V (n=10), PDAPP V (n=8) and PDAPP 2B3 (n=7) and standard deviations 
(SD). Both pre- and post-treatment scores are reported in seconds. 
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Figure 5.1: 2B3 treatment improved OiP memory in PDAPP mice. Graph shows mean DR 
scores of WT untreated (n=11), WT V (n=10), PDAPP V (n=11) and PDAPP 2B3 (n=10) mice. 2B3 
treatment showed a significant improvement in memory performance in PDAPP mice when compared 
to pre-treatment performance and when compared to PDAPP vehicle treated mice. Graph shows the 
mean DR scores of pre- and post-treatment times for all groups tested. Error bars indicate S.E.M. A 
solid black line indicates chance level at 0.5. ***p<0.001 between-subjects difference between post-
treated PDAPP vehicle mice and post-treated PDAPP 2B3 mice. ++p<0.01 within-subject difference 
between pre-treated and post-treated PDAPP 2B3 mice. 
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5.2.4 Discussion 
 Results from this experiment have shown that ICV 2B3 administration to PDAPP 
mice significantly improved OiP recognition memory performance. To date, two previous 
reports have assessed the cognitive benefits of passive immunotherapy in PDAPP mice 
following the onset of an age-related cognitive deficit (Dodart et al. 2002; Hartman et al. 
2005). For example, Dodart and colleagues reported significant improvements in object 
recognition memory performance following peripheral administration of m266, an anti-Aβ 
antibody, in a dose-dependent manner (Dodart et al. 2002). The results reported in 
Experiment 7 compliment these findings and, in addition, show that interfering with 
Aproduction by steric hindrance of APP β-secretase cleavage site activity can improve 
visuo-spatial object recognition memory in PDAPP mice. 
No overall changes in contact time with objects were observed in any treatment group 
following vehicle or 2B3 treatment in this experiment, suggesting that 2B3 did not interact 
with motor performance or a tendency to engage with novel of familiar objects. Moreover, 
this suggests that overall reduced contact times with objects, also reported in Chapter 4, was 
an effect of APP overexpression and unlikely to be related to age-related Aβ production.  
Observation of test phase contact times in 2B3 administered PDAPP mice suggested a shift in 
the distribution of contact times. PDAPP mice spent more time exploring objects in novel 
locations and less time exploring objects in familiar locations. However, this effect was subtle 
and no significant location x time x treatment group interaction was observed. However, when 
contact times were converted to DR scores a difference in the discriminability of the novel 
and familiar locations within and between groups was clearly observed. Therefore, the results 
reported in this experiment provide evidence that in vivo administration of 2B3 significantly 
improved OiP memory in aged PDAPP mice. 
 These results also compliment other studies using a similar antibody approach. BBS1 
improved non-spatial object recognition memory in both Tg2576 and 3xTg mice following 
chronic intraperitoneal or 4-week ICV administration respectively (Rakover et al. 2007; 
Rabinovich-Nikitin et al. 2012). In contrast to the present study, neither of these earlier 
reports assessed pre-drug performance scores. The partially within-subject design used in the 
present study allowed the severity of memory impairment to be established prior to and after 
2B3 administration. Following 2B3 administration, no significant difference in DR scores was 
observed when comparing 2B3 administered PDAPP mice and WT vehicle mice. Rabinovich-
Nikitin et al. (2012) reported a similar result in 3xTg mice testing the BBS1 antibody. 
However, the comparison to WT controls was not reported in the Rakover et al., (2007) study 
155
using Tg2576 mice. A more thorough comparison of the designs used in these studies will be 
reserved until the chapter discussion. 
Collectively, the behavioural analysis reported in Experiment 7 showed significant 
improvements in OiP memory.  This task is exquisitely sensitive to manipulations involving 
the hippocampus. These results support the hypothesis that antibodies targeting the β-
secretase cleavage site of APP can improve memory performance in aged Tg models of 
amyloid pathology and may provide an exciting therapeutic strategy for the treatment of early 
stage AD.   
5.3 Experiment 8: Ex vivo tissue analysis of 2B3 treated mice 
5.3.1 Introduction 
 The aim of this experiment was determine if 2B3 administration changed APP 
metabolism in ex vivo tissue of PDAPP mice. As discussed in Chapter 1 and Chapter 6 
introduction, 2B3 binds at the β-secretase cleavage site of APP, preventing the processing of 
Aβ by steric hindrance in vitro (Thomas et al. 2011; Thomas et al. 2013). It was therefore 
hypothesised that 2B3 administration in PDAPP mice would reduce the levels of APP 
metabolites, including βCTF, Aβ40 and Aβ42.   
The second aim of this experiment was to investigate if 2B3 inhibition of APP 
processing by beta-secretase would have down stream consequences on NMDARs activity. 
The mechanism under investigation has previously been described in Chapter 1. Briefly, 
NMDARs in the hippocampus contribute to OiP memory performance (Barker & Warburton 
2008; Barker & Warburton 2013). Previous reports using hAPP Tg mice have reported 
increased phosphorylation of the NMDAR subunit NR2B (Ittner et al. 2010). This increase in 
NR2B phosphorylation led to impaired spatial working memory, as determined by T-maze 
alternation task (Ittner et al. 2010). It was therefore hypothesised that inhibition of Aβ 
production by steric hindrance of β-secretase cleavage of APP reduced NR2B 
phosphorylation. The administration of 2B3 to PDAPP mice may thereby have improved 
NMDAR-dependent activity required for the OiP memory task.  
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5.3.2 Methods 
 All methods used in this experiment have previously been detailed in Chapter 2. 
Samples 
All samples used in this experiment were prepared as described in Chapter 2.  WT 
vehicle (n=10), PDAPP vehicle (n=11) and PDAPP 2B3 administered (n=10) mice were used 
for analysis in this experiment. All Western blot analysis used all 3 groups. ELISA analysis 
used PDAPP mice only. Due to violations in data normality and distribution (described 
below), one PDAPP 2B3-treated mouse was removed from all ELISA analysis. 
Statistics 
 All data in this experiment were analysed using one-way ANOVA with post-hoc 
Tukey analysis or independent samples t-tests. Prior to these analyses, data were explored for 
normality of distribution using the Shapiro-Wilk test. Extreme outliers were also observed 
using Tukey’s box plots in SPSS. If violations of normality occurred and outliers were 
reported, data were transformed appropriately. If transformations showed no effect it was 
determined if the violations were caused by individual outliers. As it has been reported that 
Tukey’s box plots (used in SPSS) may not be appropriate for detecting outliers in smaller 
sample sizes, more robust models for labelling outliers were used (Iglewicz & Hoaglin 1993). 
Methods for labelling outliers were adopted as according to Hoaglin & Iglewicz for normally 
distributed data and Carling for non-normally distributed data (Hoaglin & Iglewicz 1987; 
Carling 1998). These methods were chosen due to similar mathematical protocols for 
identifying outliers; the method reported by Carling is an adaptation using the “Median Rule” 
as opposed to the adapted “Tukey Rule” proposed by Hoaglin & Iglewicz. If any data points 
labelled as outliers were reported from non-normally distributed data these data points were 
removed and normality was re-analyzed. If the removal of this datum or data generated a 
normal distribution as determined by Shapiro-Wilk test the excluded values were referred to 
as “extreme outliers” and were removed from the study. In this analysis, one mouse from the 
PDAPP 2B3 administered group met the criteria for an extreme outlier in APP, Aβ40 and 
βCTF ELISA analyses and was hence removed from all ELISA analyses.  
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5.3.3 Experiment 8 – Results: 
2B3 treatment alters APP processing ex vivo without affecting levels of APP expression
APP  
To establish that 2B3 administration did not alter levels of total APP, left HPC 
homogenates of 2B3 treated PDAPP mice were compared to vehicle treated PDAPP mice. 
Western blot analysis (Fig 6.2A) showed a small reduction in total levels of APP in 2B3 
treated mice. However, this trend was not observed following ELISA quantification of APP 
(Fig 6.2B). Independent samples t-test reported no difference in APP levels in either Western 
blot, t(19) = 1.02, p>0.1, or ELISA, t(18) = 1.33, p>0.1, measurements. 
APP Metabolites 
To determine if 2B3 altered APP processing in PDAPP mice levels of soluble Aβ40 
and Aβ42 and βCTF were analysed by ELISA (Fig 6.2 A-C). A significant reduction in Aβ40 
was observed in 2B3 treated PDAPP mice (Fig 6.2A), t(18) = 2.28, p<0.05, however this was 
not observed with Aβ42, t(18) = 1.01, p>0.1. Consistent with the finding that levels of soluble 
Aβ40 were reduced following 2B3 treatment, there was a significant reduction in βCTF was 
in 2B3 treated PDAPP mice, t(18) = 2.22, p<0.05. Collectively, these results show that 2B3 
treatment of PDAPP mice altered APP processing in the HPC most likely by steric hindrance 
of β-secretase cleavage of APP. 
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Figure 5.2: Levels of total APP in vehicle and 2B3-treated PDAPP mice. No significant differences 
in total levels of APP were observed in Western blot analysis. (A) shows a representative example of 
three PDAPP mice/treatment group. (B) shows quantified levels of APP in PDAPP vehicle (n=11) and 
PDAPP 2B3 (n=10) determined by Western blot. (C) displays ELISA quantification of APP for 
PDAPP vehicle (n=11) and PDAPP 2B3 mice (n=9). Error bars represent S.E.M.  
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Figure 5.3: Quantification of Aβ40, Aβ42 and βCTF by ELISA in hippocampal homogenates 
of 2B3 treated PDAPP mice. 2B3 treatment showed a significant reduction in the total levels of 
soluble Aβ40 (A), but not Aβ42 (B). A significant reduction in βCTF levels was also observed 
following 2B3 treatment (C). Error bars represent S.E.M. All measures were determined by ELISA. 
*p<0.05 represents a significant reduction in protein levels in PDAPP 2B3 mice (n=9) compared to 
PDAPP vehicle mice (n=11). 
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Treatment with 2B3 alters NMDA receptor phosphorylation
 Western blot analysis was used to determine if 2B3 caused any changes in total 
PSD95, a synaptic marker, total NMDAR (NR1) expression and the level of NR2B and the 
phosphorylated state of the regulatory tyrosine residue 1472 (pY1472). 
 No significant changes in total levels of NR1 (a measure of total NMDAR) was observed, 
F(2, 28) = 0.05, p>0.5, nor were any differences in total levels of PSD95 reported, F(2, 28) = 
0.3, p>0.5 as determined by one way ANOVA (Fig 6.4A). Following this result, any changes 
observed in NR2B and pY1472 cannot be attributed to changes in total levels of NMDARs or 
total synaptic density.  
Figure 6.4B shows levels of NR2B and pY1472. Analysis by one-way ANOVA 
revealed no significant difference of total NR2B, F(2, 30) = 1.3, p>0.1. Despite a small 
numerical increase in pY1472 being observed in PDAPP vehicle mice, this was not 
significant, F(2, 30) = 1.7, p>0.1. A ratio of total NR2B to pY1472 was calculated to 
determine if levels of NR2B pY1472 were altered relative to the total levels of NR2B. A 
significant difference was reported when analysing the NR2B:pY1472 ratio, F(2, 30) = 8.9, 
p<0.001. Post-hoc Tukey analysis revealed that PDAPP vehicle mice showed a significantly 
greater level pY1472 as a ratio of NR2B than WT vehicle mice, p<0.01 as well as PDAPP 
2B3 administered mice, p<0.001. PDAPP 2B3 mice showed no significant difference when 
compared to WT vehicle administered mice, p>0.5. These results provide evidence that NR2B 
phosphorylation as a ratio of total NR2B is reduced in PDAPP mouse HPC following 2B3 
treatment. 
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Figure 5.4: 2B3 reduced NR2B phosphorylation in PDAPP mice. Quantification by Western blot 
of synaptic proteins in PDAPP mice following 2B3 treatment. (A) Mice showed no overall changes in 
total levels of PSD95, NR1. (B) Numerical reductions in NR2B were observed and small increase in 
total pY1472 can also be observed in PDAPP V mice, however significant changes are observed when 
total levels of pY1472 are expressed as a ratio of total NR2B. Error bars represent S.E.M. **p<0.01 
significant difference between WT vehicle (n=10) and PDAPP vehicle (n=11) groups. +++p<0.001 
significant difference between PDAPP vehicle and PDAPP 2B3 (n=10). 
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5.3.4 Experimental Discussion 
In this experiment, 2B3 administration showed significant reductions of soluble Aβ40 
and βCTF without affecting total levels of APP. No change in the level of Aβ42 was reported. 
A significant reduction in total levels of βCTF was observed in the HPC of PDAPP mice 
following 2B3 administration. No change in Aβ42 was reported following BBS1 treatment in 
3xTg and Tg2576 mice (Rakover et al. 2007; Rabinovich-Nikitin et al. 2012). In contrast to 
the present study, there was no evidence that BBS1 treatment reduced the levels of CTFs 
(Rakover et al. 2007; Rabinovich-Nikitin et al. 2012). This novel finding in the present study 
is consistent with the hypothesis that the 2B3 monoclonal antibody targeted the APP β-
secretase cleavage site.  
 To date, no study assessing the effects of amyloid-based immunotherapies have 
identified changes in a receptor-based mechanism linked to amyloid pathology. This study has 
shown for the first time that the 2B3-induced inhibition of APP processing in vivo reduced the 
phosphorylation of the NR2B subunit. The increased phosphorylation of NR2B has 
previously been linked with working memory impairments in APP23 mice (Ittner et al. 2010). 
There is also compelling evidence for the involvement of NMDAR-dependent synaptic 
processes in the object-in-place memory task used in Experiment 7 (Barker & Warburton 
2008; Barker & Warburton 2013). Taken together the present study suggests that 2B3 
improved memory function in PDAPP mice by reducing the amyloid-related increase in 
NMDAR phosphorylation. A more in-depth analysis of these results will be provided in the 
Chapter Discussion.  
5.4 Chapter Discussion 
Early studies using monoclonal anti-Aβ antibodies as a passive immunotherapy in 
PDAPP mice showed a reduction in amyloid load in the brains of 16 month old mice (Bard et 
al. 2000). Subsequent work showed that passive immunisation of PDAPP and Tg2576 mice 
was able to improve age-related cognitive deficits (Dodart et al. 1999; Dodart et al. 2002; 
Kotilinek et al. 2002a; Westerman et al. 2002). These early studies suggested that the 
reduction and clearance of Aβ from the brain by immunotherapy was a promising therapeutic 
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strategy for the treatment of AD. However, clinical trials using passive immunotherapies have 
yet to deliver successful reductions in levels of amyloid and improved cognition. 
Other strategies to reduce Aβ levels in the brain have also been investigated, 
including the use of β-secretase inhibitors to prevent amyloidogenic metabolism of APP. This 
studies have revealed positive effects of with BACE1 inhibitors as well as BACE1 KO mice 
crossed with Tg models of amyloid pathology (Luo et al. 2001; Asai et al. 2006; Hussain et al. 
2007; Vassar et al. 2009). However, targeting BACE1 directly has lead to concerns about the 
potential negative impact of inhibiting various other roles of BACE1 (Vassar et al. 2009; De 
Strooper et al. 2010a). In order to overcome these challenges, anti-APP antibodies targeting 
the β-secretase cleavage site, such as 2B3 and BBS1, have been generated to selectively 
inhibit amyloidogenic processing of APP (Arbel et al., 2005; Thomas et al. 2011; Thomas et 
al. 2013). 
Previous results assessing the effects of 2B3 in vitro have reported significant 
reductions of Aβ levels in MOG-G-UVW astrocytoma cells, as well as mouse primary 
cortical neurons (Thomas et al. 2011; Thomas et al. 2013). Based on these results, 2B3 was 
hypothesised to reduce amyloid processing and improve behavioural deficits in PDAPP mice 
(reported in Chapters 3 and 4). Experiment 7 showed that following 2B3 administration 
PDAPP mice exhibited a significant improvement in object-in-place memory. Rakover et al. 
(2007); Rabinovich-Nikitin et al. (2012) used a similar antibody to 2B3 (BBS1) which also 
targeted the β-secretase cleavage site of APP, and reported improved recognition memory 
following its administration in Tg2576 and 3xTg mice. A number of differences exist between 
these studies and that reported in Experiment 7, including age of mice, the transgene(s) 
expressed and route of antibody administration and the behavioural design  
The behavioural protocols assessing in vivo effects of BBS1 differ significantly. As 
discussed in detail in Chapter 4, alterations in behavioural methodology can lead to different 
results and performance in recognition memory (Dodart et al. 1999; Chen et al. 2000). The 
protocol used by Rakover and colleagues tests object novelty detection (A+B  A+C) and 
has been reported to rely on perirhinal cortex (PRC) function (Warburton & Brown 2010; 
Barker & Warburton 2011;  Warburton & Brown 2015). Rabinovich-Nikitin and colleagues 
exposed animals to one object during the sample phase followed by a test phase in which the 
familiar object and a novel object were presented (A  A+B), therefore the novel object was 
also presented in a novel spatial location This type of procedure is likely to involve the PRC 
to dissociate novel and familir object information, but also the HPC in relation to processing 
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changes in the spatial organisation of the object array (Winters et al. 2004; Barker & 
Warburton 2011; Barker & Warburton 2013). The behavioural phenotype exhibited between 
models is also reported to be different. 3xTg mice have previously been reported to show 
object-novelty memory deficits at 9 and 15 months of age, which was also observed by 
Rabinovich-Nikitin and colleagues at the 18 month age in the control 3xTg mice tested 
(Clinton et al. 2007; Rabinovich-Nikitin et al. 2012). However, Tg2576 mice have shown 
intact object novelty memory at 14 and 16 months of age, which was not observed by 
Rakover and colleagues (Hale & Good 2005; Good & Hale 2007; Rakover et al. 2007).  
Although both studies using recognition memory to assess in vivo effects of BBS1 
report improved performance, it is unclear given the differences in behavioural methodology 
and Tg model phenotype whether the antibody improved overall HPC function and processing 
of information in the HPC in either Tg2576 or 3xTg mice. No study to date using BBS1 has 
observed a significant improvement in a cognitive task sensitive to HPC function. Therefore 
the improvement in memory function reported in 3xTg mice following BBS1 administration 
may be due to improved PRC function and/or HPC function, but can not be concluded given 
the behavioural protocol used (Rabinovich-Nikitin et al. 2012). The improved memory 
performance in Tg2576 mice following chronic BBS1 treatment is likely to be a consequence 
of improved PRC function (Rakover et al. 2007). However, the PBS administered Tg2576 
control mice showed a preference for the familiar object over the novel object (Rakover et al. 
2007). This suggests a neophobic response (anxiety of novel objects) in the Tg2576 mice used 
in this study and thus any improvement in performance may not have been an overall measure 
of improved memory function, but reduced anxiety. Finally, Arbel-Ornath and colleagues 
assessed the London mutation model following chronic BBS1 administration of the MWM 
(Arbel-Ornath et al. 2009). No significant improvement in spatial reference memory was 
observed in the probe trial of the MWM following BBS1 administration, however a numerical 
improvement was observed (Arbel-Ornath et al. 2009). Collectively, although in vivo
assessment of BBS1 has reported improvements in behaviour following BBS1 administration, 
it is unclear whether these effects are specific to HPC function or altered emotionality and 
require further investigation. 
 In Experiment 7, PDAPP mice showed a significant improvement in OiP memory 
following 2B3 administration. As reported in Chapter 4, PDAPP mice showed no deficit in 
object recognition across all ages tested. A large body of work suggests that the OiP task 
involves an interaction between the PRC and HPC for successful memory performance 
(Warburton & Brown 2015b).  Given the evidence of intact novelty recognition in aged 
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PDAPP mice it is likely that changes the OiP deficit reflected impaired spatial processing and 
not a failure to discriminate between objects. Therefore, the 2B3-induced improvement in OiP 
memory is likely caused by improvements in HPC function or improved connectivity in the 
neural circuit connecting the PRC and HPC in PDAPP mice. This observation is further 
supported by 2B3-induced the changes in hippocampal Aβ and βCTF levels in PDAPP mice. 
Therefore, this study has presented evidence that inhibition of APP cleavage at the β-secretase 
cleavage site improved memory performance in an object-in-place recognition task sensitive 
to HPC dysfunction. 
To compliment the findings that 2B3 improved object-in-place performance in 
PDAPP mice, there were significant changes in markers of APP processing, specifically 
hippocampal Aβ and βCTF levels, without changes in total levels of APP. These neurotoxic 
peptides have been implicated in the cognitive deficits observed in Tg and experimental 
models of AD (Nalbantoglu et al. 1997; Choi et al. 2001; Chishti et al. 2001; Cleary et al. 
2005). In Exeriment 8, levels of Aβ40 were reduced by 51.7% in PDAPP mice by 2B3 
administration. However levels of Aβ42 remained unaffected. Published evidence indicates 
that the Aβ42 peptide is significantly more neurotoxic than the Aβ40 peptide (Klein et al. 
1999; Walsh & Selkoe 2004). Indeed, it has also been shown in PDAPP mice that there is a 
much greater ratio of Aβ42 to Aβ40 (Johnson-Wood et al. 1997; Fryer et al. 2005; Hartman et 
al. 2005). These data are consistent with the view that increasing Aβ42 levels is more likely to 
be the cause of cognitive deficits in PDAPP mice than Aβ40. However, rat models of AD in 
which Aβ40 is infused into the ventricles display cognitive deficits, including impaired spatial 
memory (Nitta et al. 1994; Özdemir et al. 2013; Xu et al. 2015). These models showed that 
Aβ40 pathology is sufficient to drive cognitive deficits and potentially impair HPC function, 
independent of Aβ42. The result that 2B3 reduced levels of Aβ40 in the HPC of PDAPP mice 
and improved memory is consistent with the view Aβ40 peptide contributes to neuronal 
changes that underpin cognitive deficits in APP transgenic mice. This result may imply that 
soluble Aβ40 also contributes to memory deficits in PDAPP mice as well as Aβ42.
2B3 also caused a 23.9% reduction in total levels of βCTF in the HPC of PDAPP 
mice. Despite the fact that most research has focussed on the role of Aβ and tau pathology in 
AD, increased levels of βCTF have been observed in AD patients. Furthermore, βCTF have 
been implicated in the disruption of neuronal physiology and cognitive deficits in rodents 
(Nalbantoglu et al. 1997; Choi et al. 2001; Holsinger et al. 2002; Liu et al. 2009; Tamayev et 
al. 2012; Kim et al. 2015). Indeed, recent research into the role of βCTF has revealed an Aβ-
independent mechanism causing dysregulated endocytosis (Pimplikar et al. 2010; Kim et al. 
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2015). Thus, increased levels of βCTF can cause pathologically accelerated endocytosis and 
up-regulation of rab5, a marker of early endosomes (Grbovic et al. 2003; Kim et al. 2015). 
Enlarged endosomes and endosome related genes, including rab5, are up-regulated in early 
AD (Cataldo et al. 2000; Ginsberg et al. 2010). βCTF-induced acceleration of endocytosis 
caused endosome swelling and impaired axonal transport of endosomes in mouse primary 
cortical neurons (Kim et al. 2015). Endocytosis is involved in multiple signalling pathways 
and trafficking of neuronal receptors, including NMDARs (Washbourne et al. 2004; Nixon 
2005; Lau & Zukin 2007). A disruption of endosomal processing is therefore likely to 
contribute to impaired neurotransmission and thus cognitive deficits. It remains possible that 
this mechanism is improved by the 2B3-induced reduction in βCTF in PDAPP mice and this 
may also contribute to enhanced memory function. However, further work is required to test 
this. 
Similar changes in APP metabolites following in vivo administration of the anti-APP 
antibody BBS1 have also been reported (Arbel-Ornath et al. 2009; Rabinovich-Nikitin et al. 
2012). However, inconsistencies exist between studies. Tg2576 mice administered BBS1 
showed no change in levels of soluble or insoluble Aβ40 and Aβ42 (Rakover et al. 2007). 
3xTg mice administered BBS1 also showed no significant reduction in soluble Aβ42, but 
significant reductions in total Aβ load, plaque size and reduced tau pathology (Rabinovich-
Nikitin et al. 2012). These results were similar to the BBS1-mediated reduction in plaque size, 
intracellular Aβ and Aβ oligomers reported in London mutation APP mice (Arbel-Ornath et 
al. 2009). However, to date, no study assessing BBS1 or any anti-Aβ antibodies ex vivo has 
reported any changes in levels of βCTF.
Despite in vivo assessment of a number of anti-Aβ antibodies and BBS1 showing 
improved cognition and reduced Aβ pathology, no study has yet reported the impact of the 
antibody on a receptor-based mechanism linked Aβ toxicity. Hippocampal NMDARs 
contribute to successful performance on the OiP memory task (Barker & Warburton 2008). 
Experiment 8 showed that there was no overall change in total levels of NMDARs in 2B3 
treated PDAPP mice. However, Aβ has been observed to reduce NMDAR surface expression 
in primary cortical neurons and in primary neurons of APPSwe mice, without affecting total 
levels of NMDARs (Snyder et al. 2005). A reduced surface expression of total NMDARs has 
also been reported in 12 month old Tg2576 mice (Kurup et al. 2010). In this study, the precise 
localisation of NMDARs was not assessed due to differences in protein extraction protocols 
used here and by Kurup and colleagues. However, it is possible that surface NMDARs may 
not have been reduced to the same extent in the present study as that reported by Kurup et al., 
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(2010). In Experiment 8, PBS control PDAPP mice showed increased phosphorylation of the 
tyrosine 1472 (Y1472) residue of the NR2B subunit. This phosphorylation has been reported 
to increase the interaction of PSD95 with NMDA-NR2B containing complexes and prevent 
receptor internalisation (Lin et al. 2004; Prybylowski et al. 2005). Tg2576 mice show a 
reduction in phosphorylated Y1472 (pY1472) when compared to age-matched WT controls 
(Zhang et al. 2010). This may explain why Tg2576 mice showed reduced NMDAR surface 
expression. However, to date, no study has reported NMDAR surface expression of PDAPP 
mice. It is tempting to speculate that it may be increased relative to Tg2576 mice or WT 
control mice because of the increased NR2B pY1472. However, further analysis is required to 
test this hypothesis.  
Figure 5.5: Schematic illustration demonstrating the interactions between Aβ, tau and Fyn 
leading to NMDAR-mediated neuronal excitotoxicity. Src kinase Fyn interacts with phosphorylated 
tau protein leading to the translocation of both proteins to the post synapse (1-2). Fyn at the synapse 
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phosphorylates the NR2B subunit of the NMDAR complex, stabilizing its interaction with PSD95 and 
expression at the synapse (3-4). Increased Aβ and enhanced expression of NR2B containing NMDARs 
at the synapse causes disproportionate influx of Ca2+ leading to downstream neurotoxicity.  
No change in levels of PSD95 was observed in either WT or PDAPP treatment group 
in this study. This may indicate that there was no overall neuronal or synaptic loss. However, 
previous research has shown in PDAPP mice that significant reductions in numbers of 
dendritic spines occurs with age and overall synaptic loss has also been reported (Games et al. 
1995; Lanz et al. 2003). These data were obtained using more optimal protocols (confocal 
microscopy and photomicrographs of Golgi-stained neurons) to determine synaptic 
quantification. It may therefore be likely that the Western blot quantification of HPC 
homogenate used in this study was not sensitive enough to quantify synaptic changes caused 
by Aβ-induced neurotoxicity in aged PDAPP mice. 
Phosphorylation of the NMDAR NR2B subunit has been found to be altered in mouse 
models of AD (Ittner et al. 2010; Zhang et al. 2010) It must be noted however, that while 
Tg2576 and 3xTg mice have been reported to show reduced NR2B phosphorylation, APP23 
mice have shown increased NR2B phosphorylation (further discussion of these conflicting 
studies is provided in Chapter 6, section 6.3). This increased NR2B phosphorylation was 
observed in 18-month control PDAPP mice reported in Experiment 5B. The reasons for these 
differences between Tg models remain undetermined. The increased ratio of total NR2B to 
NR2B pY1472 observed in PBS administered PDAPP mice was reduced by 2B3 without 
affecting total levels of NR2B or total NMDARs. The phosphorylation of NR2B is reported to 
increase NMDAR-PSD95 interaction (Figure 5.5), NMDAR surface expression and has been 
shown to be regulated by SRC kinase Fyn (Prybylowski et al. 2005; Ittner et al. 2010). This 
enhanced NMDAR surface expression is thought to lead to increased NMDAR activation and 
Ca2+ influx leading to excitotoxicity in neurons (Figure 5.5; Ittner et al. 2010) In AD brains 
increased levels of Fyn have been observed (Ho et al. 2005). Indeed, overexpression of Fyn in 
the J9 and J20 mouse model of AD caused more severe cognitive deficits than control Fyn 
overexpression and hAPP overexpression alone, as well as an increased loss of synapses 
(Chin et al. 2004; Chin et al. 2005). The increased loss of synapses and increased cognitive 
impairment is a likely an effect of Aβ-induced and fyn-mediated increased phosphorylation of 
Y1472 of the NR2B subunit as proposed by Ittner and colleagues (Figure 5.5; Ittner et al. 
2010; Ittner & Götz 2011). This mechanism may further be implicated in the synaptic loss 
reported in PDAPP and APP23 mice, both of which have shown increased pY1472 (Games et 
al. 1995; Calhoun et al. 1998). Given the reduced level of Aβ40 in 2B3-administered mice, it 
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may be possible that fyn activity is also reduced leading to the reduction of the 
phosphorylated NR2B Y1472 residue. However, further research is required to confirm this 
mechanism.  
Finally, the phosphorylation state of the NR2B Y1472 subunit has been observed to 
play a significant role in memory performance. APP23 mice exhibited significant 
impairments of a T-maze working memory task and increased pY1472 (Ittner et al. 2010). 
However, following administration with a peptide compound, Tat-NR2B9c, which has been 
shown to prevent NMDA-induced excitotoxicity and perturb the NR2B containing NMDAR-
PSD95 interaction, APP23 mice showed significant improvement in T-maze performance 
(Aarts et al. 2002; Ittner et al. 2010). More recently a mouse model expressing the Arctic APP 
mutation and WT human tau (ArcTau) crossed onto a heterozygous BACE KO line to produce 
ArcTau/BACE+/- and ArcTau/BACE+/+ mice has been reported (Chabrier et al. 2012).
ArcTau/BACE+/- mice showed improved spatial learning and reference memory when 
compared to the ArcTau/BACE+/+ mice. Moreover a significant reduction in soluble Aβ40 and 
phospho-tau S396/404 were also observed in ArcTau/BACE+/-. Interestingly, a reduction of 
PSD95-associated NR2B was also reported as a result of partial BACE KO (Chabrier et al. 
2012).  These data are supportive of those reported in Chapter 5 suggesting altered APP 
processing by BACE can improve learning and memory in mice, which is associated with 
NMDAR function. 
Given the above evidence it is tempting to conclude that improved performance in the 
OiP task may be related to 2B3-induced changes in NR2B phosphorylation. Further research 
is required to confirm the involvement of NR2B-containing NMDAR complexes in the OiP 
recognition memory task. Collectively, results reported Experiment 7 and 8 show that 2B3 
administration reversed an age-dependent OiP recognition memory deficit in PDAPP mice. 
2B3 also reduced total levels of soluble Aβ40 and βCTF without affecting total levels of APP. 
Furthermore, the results have highlighted a receptor-based mechanism linked to amyloid-
induced excitotoxicity. More specifically, the normalisation of NR2B phosphorylation may 
play a role in the improved cognition observed in PDAPP mice administered 2B3. This is a 
novel finding and provides important new evidence that the inhibition of APP processing at 
the β-secretase cleavage site by steric hindrance can improve both memory and synaptic 
pathology in the PDAPP mice.  
171
Chapter 6: Thesis Discussion 
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6.1 Thesis Overview 
 The main aims of this thesis were three-fold. Firstly, to characterise the behavioural 
phenotype of the PDAPP model on a C57Bl/6 background and identify any age-dependent 
cognitive deficits and age-associated changes in Aβ pathology. The second was to administer 
2B3, an anti-APP antibody that binds at the β-secretase cleavage site of APP and evaluate its 
impact on cognition in PDAPP mice. The third was to evaluate a possible mechanism by 
which 2B3 improved synaptic and thereby cognitive function. In this chapter, a summary of 
the findings are reported, followed by a more detailed discussion of how these data contribute 
to our current understanding of amyloid pathology, potential therapies associated with this 
target and cognitive decline in AD. 
6.2 Summaries and Discussion of Findings 
 Currently, clinically available treatments for AD target the symptomatology of AD 
and not the underlying mechanisms of the disease (i.e. progressive amyloid and tau 
pathology). Transgenic mouse models of AD have provided insight and theories regarding the 
mechanisms underpinning neurodegeneration and provided tools to investigate therapies 
targeting amyloid and/or tau-based mechanisms of AD (Götz & Ittner 2008; Solomon & 
Frenkel 2010; C. a Lemere 2013; Herrmann & Spires-Jones 2015). Although positive effects 
are often reported in current mouse models there has been little success in translating this to 
the clinical condition. While several factors may contribute to this lack of translation one 
common concern is that there is a marked mismatch between mouse models and patients in 
terms of the severity and stage of the disease (Qian et al. 2015; Reardon 2015). The use of 
therapies derived from mouse models may be beneficial if used at the earliest possible stage 
of disease pathogenesis in humans. In this regard there is still on-going research into the safe 
and effective modulation of APP processing, a mechanism that remains a corner stone of the 
amyloid cascade hypothesis of AD.  
 The main aim of this thesis was to evaluate the hypothesis that an antibody-mediated 
inhibition of -secretase activity would reduce amyloid production and improve memory 
performance in a transgenic mouse overexpressing mutant human APP. Before addressing 
this issue it was first necessary to establish the profile of amyloid pathology and cognitive 
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function in PDAPP mice. Although PDAPP mice have been available for some time, they 
have recently been switched to a pure C57Bl/6 background strain (for reasons as discussed in 
Chapter 1, section 1.4.2). Previous studies have reported age-related memory impairment and 
amyloid pathology in PDAPP mice bred on a mixed genetic background (Swiss-Webster, 
DB2 and C57Bl/6) (Games et al. 1995; Johnson-Wood et al. 1997; Dodart et al. 1999; Chen et 
al. 2000). To-date, only one study has characterised behaviour in PDAPP mice bred on a 
C57Bl/6 background (Hartman et al. 2005). Hartman and colleagues reported age-
independent deficits in spatial learning and spatial reference memory as determined by the 
Morris water maze (MWM), which nevertheless worsened with age. Moreover the age-related 
deterioration in spatial reference memory was correlated with a significant increase in levels 
of Aβ in the HPC (Hartman et al. 2005). This supported the initial aim and hypothesis of this 
thesis that PDAPP mice would show an age-dependent (and task-specific) memory 
impairment, together with increased levels of Aβ production (see Chapters 3 and 4).   
The extensive evidence that human APP mutations cause deficits in spatial navigation 
and spatial working memory (SWM) in several mouse lines led to the decision to evaluate 
SWM in PDAPP using a novel foraging task (based on the Olton radial arm maze procedure 
and prior studies of navigation in pigeons; Pearce et al. 2005). Mice with excitotoxic HPC 
lesions performed poorly on this task relative sham control mice. Moreover when the reliance 
upon spatial cues was removed and each pot was given a unique design, the performance of 
sham and lesioned mice was similar. These data indicated a role for the hippocampus in 
processing spatial information and complimented findings published by Pearce and colleagues 
(2005).  
Given extensive evidence that HPC neuronal function is compromised by excess 
amyloid production, the foraging task was used to examine SWM performance in PDAPP 
mice across a range of ages. In addition, object recognition memory and object-place 
associations were also analysed in Chapter 4 in order to assess the distinct components of 
recognition memory and the integrity of circuits thought to underpin them. Previous studies 
have reported task specific impairments in the PDAPP model and other APP mouse lines, 
including the Tg2576 mouse model (Dodart et al. 1999; Hale & Good 2005; Good & Hale 
2007). Chapters 3 and 4 reported age-dependent deficits in SWM and OiP memory at 14-16 
months of age, but intact object recognition memory across all ages tested. These deficits 
were paralleled by a significant increase in levels of soluble and insoluble Aβ42 in the HPC of 
15-month old PDAPP male mice (Chapter 4, Experiment 6). Data obtained from Chapters 3 
and 4 provide evidence that different tasks that require processing of spatial information are 
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sensitive to amyloid pathology. Collectively, these data further validated the use of the 
PDAPP model of amyloid pathology to assess the in vivo effects of 2B3. 
The main aim of this thesis was to assess a monoclonal antibody, 2B3, in a mouse 
model of amyloid pathology. 2B3 had been shown to bind to APP at the β-secretase cleavage 
site and prevented the production of Aβ in multiple cell lines, including mouse primary 
cortical cultures (Thomas et al. 2011; Thomas et al. 2013). It was hypothesised that in vivo
administration in APP transgenic mice would inhibit β-secretase mediated APP metabolism 
and thus Aβ production. Given a putative reduction in amyloid it was also hypothesised that 
2B3 would improve memory function in transgenic APP mice. Following a 14-day ICV 
administration of 2B3 by osmotic minipumps, PDAPP mice were tested on the OiP task. 2B3 
administration showed a significant improvement in OiP memory, as well as reduced levels of 
soluble Aβ40, βCTF and reduced phosphorylation of the NMDAR NR2B subunit. These data 
support the hypothesis that administration of 2B3 in vivo will improve memory function by 
inhibiting APP cleavage at the β-secretase cleavage site. However, the overall levels of 
soluble Aβ42 were not significantly reduced by 2B3 administration. The absence of a 
significant reduction in Aβ42 may simple reflect the high levels variability in this measure 
and the need for greater statistical power. A similar observation was made with 3xTg mice 
following four-week ICV BBS1 administration. Despite significant reductions in total Aβ 
load and plaque size (Rabinovich-Nikitin et al. 2012), there was no significant change in 
soluble Aβ42. A longer duration of treatment may arguably have a greater impact on Aβ 
production. Nevertheless, the changes in levels of βCTF and soluble Aβ40 provide 
compelling evidence that 2B3 administration in PDAPP mice inhibited APP metabolism via 
the β-secretase cleavage site.  
More recent studies with the antibody BBS1 have assessed its therapeutic values in a 
number of mouse models including Tg2576, the London APP mutation, as well as the 3xTg 
model (Rakover et al. 2007; Arbel-Ornath et al. 2009; Rabinovich-Nikitin et al. 2012). Data 
obtained between these studies however are often variable. For example, chronic 
intraperitoneal administration of BBS1 to Tg2576 mice showed reduced neuroinflammation 
(a reduction in active microglia). However, this effect was not observed in mice expressing 
the APP London mutation or 3xTg mice, which observed no change in either microglia or 
astrocyte activation and a reduction in astroglial activity only, respectively (Rakover et al. 
2007; Arbel-Ornath et al. 2009; Rabinovich-Nikitin et al. 2012). Moreover, improved 
recognition memory performance was reported by Rakover (2007) and Rabinovich-Nikitin 
(2012) in Tg2576 and 3xTg mice, but no improvement in spatial learning and memory was 
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reported in the APP London mutation mice (Rakover et al. 2007; Arbel-Ornath et al. 2009; 
Rabinovich-Nikitin et al. 2012). Changes in amyloid pathology are also inconsistent following 
BBS1 treatment. BBS1 in the London APP mouse model showed significant reduction in 
insoluble Aβ40 and Aβ42, but not total levels of soluble Aβ. However, intraneuronal Aβ was 
significantly reduced (Arbel-Ornath et al. 2009). In the 3xTg mice BBS1 caused a significant 
reduction in plaque size and overall amyloid load (Rabinovich-Nikitin et al. 2012). However, 
no change in soluble or insoluble levels of Aβ40 or Aβ42 was observed in Tg2576 mice 
following chronic IP administration of BBS1 (Rakover et al. 2007). Variability in the impact 
of BBS1 on amyloid pathology may be due to (1) transgene or background differences in the 
Tg model, (2) route of administration, (3) duration of treatment and methodology used to 
assess protein levels ex vivo. Collectively, however, the BBS1 studies suggests that inhibition 
of APP metabolism via the β-secretase site provides a beneficial effect at both the cognitive 
and pathological level in transgenic mice. 
 Similar to 2B3 and BBS1, a non-antibody peptide treatment, S1, has been reported by 
Yang et al. (2012). S1 reportedly interacts and binds to the APP β-secretase cleavage site to 
inhibit BACE1 cleavage of APP. APP/PS1 mice received 5 weekly bilateral ICV infusions of 
S1 by Hamilton micro syringe prior to behavioural testing and ex vivo tissue analysis. S1 
administration showed significant reductions in levels of soluble and insoluble Aβ40, Aβ42 
and total levels of βCTF in ex vivo tissue of APP/PS1 mice (Yang et al. 2012). These mice 
also showed improved spatial learning and memory as determined by the MWM. 
Collectively, these data show that multiple compounds targeting the β-secretase cleavage site 
of APP can significantly improve memory performance and reduce amyloid pathology in 
multiple models of AD. It is therefore likely that the beneficial effects reported in Chapter 5 
are therefore not specific to the PDAPP mouse model. Moreover, the data reported in Chapter 
5 contributes to the growing evidence that inhibition of APP metabolism by β-secretase is a 
potential therapeutic target site for the treatment of early stage AD. 
6.3 Does 2B3 Improve Synaptic Function underpinning memory in PDAPP Mice? 
NMDA Receptors and Recognition Memory 
As discussed in Chapter 4 (Section 4.1 and 4.4), successful memory performance in 
the OiP memory task is sensitive to HPC, mPFC and PRC dysfunction (Barker & Warburton 
2011; Warburton & Brown 2015b). The receptors involved in processing object-based and 
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spatial information in these structures have also been investigated. Bilateral infusion of AP5, 
an NMDA receptor antagonist, into the PRC impaired novel object memory only in delays 
greater than 1 hour, but not less than (Barker et al., 2006; Winters & Bussey, 2005b). 
However, following infusion of kainite and muscarinic antagonists into the PRC, novel object 
memory impairments were observed following delays of less than 1 hour (Barker et al., 2006; 
Tinsley et al., 2011). Collectively these data indicate that object novelty memory is sensitive 
to different receptor mechanisms in a delay-dependent manner. Data reported in Chapter 4 
showed no change in object recognition memory performance in PDAPP mice compared to 
WT controls across all delays and ages tested. As “short-term” delay periods have been 
defined as ≤ 5-minutes and “long-term” as ≥ 1-hour in the studies discussed above, this would 
suggest that all receptor mechanisms involved in processing object-based information remain 
intact in the PRC with age in PDAPP mice.  
 The roles of the HPC and mPFC in the OiP task have been reported to involve 
NMDAR-dependent processes, as the infusion of AP5 into each region independently 
impaired performance (Barker & Warburton, 2008, 2009). The neural circuit involved in 
processing object and place information was further determined following contralateral 
unilateral infusions of AP5 into the mPFC and PRC or HPC and PRC. AP5 infusion caused 
impairment following long delay periods, while short term object-in-place memory remained 
unaffected in rats (Barker & Warburton, 2009; Barker & Warburton, 2013). It has further 
been reported that OiP memory is impaired in both short- and long-term delays after 
subsequent crossed unilateral AP5 and CNQX infusion in mPFC and HPC (Barker & 
Warburton 2009; Barker et al., 2013). Thus, the processing of spatial-based information in the 
OiP memory task is sensitive to NMDA and glutamate receptor manipulations across both 
short and long-term delays. In contrast, object-based information is only NMDA-sensitive 
with long delays. Based on this analysis one can conclude that as PDAPP mice showed intact 
object recognition memory (Chapter 4, Experiment 4), but impaired OiP memory at 14-16 
months of age (at both delays tested; Chapter 4, Experiment 5), it is likely that the behavioural 
impairment is a result of glutamate receptor, and more specifically, NMDAR function. 
Chapter 4 (Experiment 6) reported an age-related increase in levels of soluble and 
insoluble Aβ42 in the HPC of PDAPP mice at 15 months of age, it is likely that Aβ42 played 
a significant role in the impaired processing of spatial information required for successful 
memory performance in the OiP task in PDAPP mice. Elevated levels of A reduced synaptic 
NMDAR expression in cortical neuronal cultures (Kelly et al., 1996; Snyder et al., 2005; 
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Shankar et al., 2007). This reduced NMDAR expression has also been reported in 
synaptosomal membranes of 3xTg and Tg2576 mice (Zhang et al. 2010). Therefore it is likely 
that increased levels of Aβ in the HPC of PDAPP mice impacted upon the NMDAR-sensitive
mechanisms involved in processing spatial information.
Although conflicting to findings in vitro and in Tg2576 and 3xTg mice, a further 
synaptic mechanism suggesting enhanced synaptic NMDAR expression has also been 
reported (Ittner et al. 2010). A more detailed discussion of these conflicting mechanisms can 
be found in the following section “Aβ and NR2B – An enzymatic imbalance”. The synaptic 
mechanism described by Ittner and colleagues reported an NR2B-associated mechanism 
stimulating NMDA activity and Aβ-mediated hyper-excitotoxicity, which has already been 
discussed in this thesis (Chapter 1, section 1.3.5). More specifically, the phosphorylation of 
the NR2B subunit at the tyrosine 1472 (Y1472) residue by the Src kinase, Fyn. Increased 
phosphorylation of the NR2B Y1472 subunit increases NR2B interaction with PSD95, 
inhibits AP2 clathrin-mediated endocytosis and stabilizes post-synaptic NMDARs 
(Prybylowski et al. 2005). Aβ activates NMDARs causing increased Ca2+ influx and neuronal 
excitotoxicity (Ittner et al. 2010). APP23 Tg mice have been reported to show increased levels 
of phosphorylated NR2B Y1472, leading to increased neuronal hyper excitability and SWM 
deficits in the T-maze. This deficit was reversed following ICV administration of Tat-
NR2B9c, a peptide reported to protect from NMDAR-induced excitotoxicity (Ittner et al. 
2010). APP23 mice have also been reported to show improved spatial learning and reference 
memory in the MWM following administration of memantine, a non-competitive NMDAR 
antagonist (Van Dam & De Deyn 2006)  Results in Chapter 5 (Experiment 5B) revealed that 
vehicle-treated PDAPP mice showed an increase in NR2B phosphorylation at the Y1472 
residue as a ratio to total NR2B levels. It is possible that this effect prevented NMDAR 
internalisation at the synapse in PDAPP mice and further caused neuronal excitotoxicity. 
However, to date, no study has determined NMDAR expression at the synapse in comparison 
to internalised NMDARs in order to confirm this in PDAPP mice.  
The NR2B subunit in the HPC and forebrain of mice has been implicated in spatial 
learning and memory (von Engelhardt et al. 2008). Mice lacking the NR2B receptor 
specifically in the HPC showed in-tact spatial reference memory in the MWM. However, the 
same mice showed an impairment in reversal learning in the MWM and SWM in a 
spontaneous alternation protocol of the T-maze (von Engelhardt et al. 2008). Similarly, 
PDAPP mice show impaired reversal learning on the MWM and SWM deficits reported in 
Chapter 3 (Chen, Chen, Knox, Inglis, Bernard, Martin, Justice, Mcconlogue, et al. 2000; 
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Daumas et al. 2008). Following Aβ active immunotherapy in PDAPP mice, Chen et al., 
(2007) reported reductions in total levels of Aβ that negatively correlated with improved 
learning capacity on a serial reversal learning protocol in the MWM (Chen et al. 2007). In 
Chapter 5 (Experiment 5B) 17-18 month old PDAPP mice showed increased phosphorylation 
of the NR2B Y1472 subunit, which was reversed along following 2B3 administration. This 
reversal of NR2B phosphorylation is likely to have contributed to 2B3 mediated improvement 
in OiP memory in PDAPP mice. This finding parallels that reported by Chen et al., 2007 who 
demonstrated lower overall Ab load and improved learning capacity in PDAPP mice 
following an immunotherapy. Interestingly NR2B has been observed to facilitate both LTD 
and LTP in the CA1 region of the HPC (von Engelhardt et al. 2008; Dong et al. 2013). 
Interestingly, novel object and place associations stimulate the induction of LTD in the rat 
HPC CA1 sub region (Kemp & Manahan-Vaughan 2012). It is therefore tempting to suggest 
that the effects observed following 2B3 administration may be linked to improved LTD 
facilitation in PDAPP mice. However, further investigation is required in order to confirm this 
theory. 
Aβ and NR2B – An enzymatic imbalance 
Although increased NR2B phosphorylation at tyrosine 1472 in PDAPP mice was 
reported in Chapter 5, and in APP23 mice by Ittner and colleagues (2010), contradictory 
findings have been reported in other Tg models of AD (Zhang et al. 2010). Zhang and 
colleagues reported that Tg2576 and 3xTg mice showed an age-related decrease in levels of 
NR2B phosphorylated at the Y1472 residue. Ittner and colleagues reported the 
phosphorylation of the NR2B subunit was regulated by Fyn in a tau-dependent manner (Ittner 
et al 2010). However, Ittner and colleagues (2010) gave no consideration to the regulatory 
STriatal Enriched protein tyrosine Phosphatase (STEP).  
STEP has been reported to act as a regulatory tyrosine phosphatase, which 
dephosphorylates the NR2B Y1472 residue as well as Fyn in order to inhibit Fyn kinase 
activity (Figure 6.1) (Nguyen et al. 2002; Snyder et al. 2005; Zhang et al. 2008). Increased 
levels of STEP have been reported in the brains of AD patients and in Tg models of AD (Chin 
et al. 2005; Kurup et al. 2010; Zhang et al. 2010). As well as being associated with increasing 
Fyn activity, Aβ has been reported to indirectly increase STEP activation and increase its 
translation via interaction with the α7-nicotinic acetylcholine receptor (α7nAChR) and 
metabotropic glutamate receptor 5 (mGluR5) respectively through downstream signalling 
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mechanisms (Snyder et al. 2005; Zhang et al. 2008). Interestingly, oligomeric Aβ coupled to 
the cellular prion protein activates Fyn via a physical interaction with mGluR5 leading to an 
increase in intracellular Ca2+ (Um et al. 2013). Thus, it is plausible that Aβ-mediated 
increased Fyn activation could be counteracted by increased STEP activity. Indeed, in vitro
data have demonstrated this effect in a time-dependent manner (Um et al. 2012). WT cortical 
neurons treated with oligomeric Aβ for 15-minutes showed a significant increase in NR2B 
pY1472 and active Fyn. However, following 3 hours oligomeric Aβ treatment a significant 
increase in levels of STEP was observed compared to baseline conditions. This result was 
paralleled by a reduction in NR2B pY1472 and active Fyn relative to the 15-minute treatment 
group (Um et al. 2012). This result was further complimented by a time-dependent reduction 
in surface NR2B expression and suppressed NMDA-induced calcium signals (Figure 6.1). 
Given that STEP normalises NR2B pY1472 and active Fyn in vitro, it is paradoxical that data 
reported in the literature have observed reduced NR2B pY1472 in Tg2576 and 3xTg mice, but 
increased in APP23 and PDAPP mice (Ittner et al. 2010; Zhang et al. 2010; Chapter 5, 
Experiment 8).
Behavioural studies focusing on this mechanism have shown evidence for Fyn and 
STEP in the deregulation of neuronal activity and cognitive performance. A study using J9 
and J20 mice crossed with mice overexpressing Fyn (double transgenic) reported more severe 
spatial reference memory deficits following MWM assessment than J9 or J20 mice with 
physiological levels of Fyn (Chin et al. 2005). Moreover, when these double transgenic mice 
were further crossed onto a tau knockout background they showed similar spatial learning and 
reference memory to non-Tg controls, whilst double transgenic mice expressing endogenous 
tau remained impaired (Roberson et al. 2011). These data are consistent with the mechanism 
proposed by Ittner and colleagues (2010) that fyn-tau interactions at the synapse in the APP23 
mouse model of AD are responsible for neuronal excitotoxicity (Ittner et al. 2010) . 
Despite this evidence focussing on Aβ, tau and Fyn, STEP knock out (KO) models 
have also been reported (Zhang et al. 2010; Venkitaramani et al. 2011). Zhang and colleagues 
(2010) investigated the role of STEP by crossing STEP KO mice with either 3xTg mice or 
Tg2576 (Zhang et al. 2010). In this study, double mutant 3xTg mice/STEP-/- showed 
improved spatial learning and reference memory in the MWM and SWM in the spontaneous 
alternation Y maze. No behavioural analysis was performed on Tg2576 mice. However, 
biochemical analysis of synaptosomal preparations showed increased membrane NR1, NR2B 
and NR2B pY1472 levels in both Tg2576/STEP-/- and 3xTg/STEP-/-. (see also Zhang et al. 
2010; Venkitaramani et al. 2011 for STEP KO mouse). STEP KO effects were further 
180
paralleled to increased Fyn activity as well as active ERK, also involved in synaptic 
strengthening and memory performance (Satoh et al. 2007; Zhang et al. 2010). 
Figure 6.1: Increased activation of STEP reduces NR2B phosphorylation and increases NMDAR 
endocytosis. Aβ interaction with the α7nAChR results to an increase in Ca2+ influx and downstream 
signalling leading to an increase in STEP activity. Active STEP dephosphorylates Fyn kinase causing 
its deactivation and prevents further Fyn-mediated phosphorylation of the NR2B Y1472 residue. 
STEP also dephosphorylates the NR2B Y1472, which leads to an increase in NMDAR endocytosis 
and reduced NMDAR Ca2+ influx and excitotoxicity. Figure from (Venkitaramani et al. 2007) 
The data considered above suggests that enzymatic activity of Fyn and STEP play 
significant roles in cognitive function and neuronal signalling pathways, particularly those 
involving NMDARs and the NR2B subunit. These pathways appear to be modulated by both 
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extracellular Aβ and intracellular tau protein. The physiological balance of the activity of Fyn 
and STEP is clearly of importance in memory performance in Tg AD models. However, it 
appears that discrepancies exist between specific mouse models such as the PDAPP and 
APP23 mouse model and the Tg2576 and 3xTg. Precise reasons why these differences exist 
remain elusive.  
6.4 Are Transgenic Mouse Models of AD a useful tool for preclinical 
investigations? 
Tg APP models of amyloid pathology often only exhibit increased amyloid production 
and deposition without developing NFTs. It has been argued that these models of AD only 
model pre-clinical AD at best (Zahs &Ashe, 2010). Therefore, how useful a tool are they to 
examine immunotherapy or indeed any therapy for AD? Despite a lack of NFT pathology in 
Tg models (except the 3xTg), APP mice show the majority of early stage AD pathologies; 
elevated Aβ, plaque pathology and neuroinflammation (Games et al. 1995; Hsiao et al. 1996; 
Mucke et al. 2000; Oddo et al. 2003; Oakley et al. 2006). Abnormal tau phosphorylation has 
been observed in a number of Tg mouse models, including the Tg2576, TgCRND8, APP/PS1 
and APP23 (Kawarabayashi et al. 2004; Chauhan et al. 2005; Kurt et al. 2003; Bellucci et al. 
2007; Maia et al. 2013). More recently, evidence has suggested that, similar to Aβ, 
hyperphosphorylated tau is likely to be neurotoxic, particularly at the synapse (Tai et al. 2012; 
Perez-Nievas et al. 2013; Pooler et al. 2013; Pooler et al. 2014). Indeed, fibrillar amyloid and 
associated oligomeric amyloid and increased phosphorylated tau protein at the synapse were 
correlated with dementia, whilst NFTs were not when compared to high-pathology controls 
(Perez-Nievas et al. 2013).  
Currently, no anti-Aβ immunotherapy study using Tg APP mice has reported reduced 
tau phosphorylation as an effect of therapy, except when using the 3xTg mouse model (Oddo 
et al. 2004; Oddo, Vasilevko, et al. 2006; Rasool et al. 2013). However, although promising, it 
is unclear whether changes in tau phosphorylation in 3xTg mice are a true reflection of tau 
hyperphosphorylation induced by Aβ, independent of the P301L mutation, which, of course, 
is not a mutation associated with AD. Tg models such as Tg2576 and APP/PS1 mice have 
been observed to show hyperphosphorylated tau at 11 and 12 months of age respectively (Shi 
et al. 2011; G.-P. Liu et al. 2013). To date, very few studies have investigated the benefits of 
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pharmacological intervention in these models and changes in tau phosphorylation. However, 
it has been reported that reduced tau phosphorylation is observed in Tg2576 and APP/PS1 
mice coupled with reduced total Aβ load following silencing of inhibitor-2 of protein 
phosphatase-2A and anti-TNF-α ICV infusion respectively (Shi et al. 2011; Liu et al. 2013). 
These results show that tau hyperphosphorylation in Tg APP models is sensitive to 
pharmacological intervention. However, these effects are yet to be investigated by anti-Aβ or 
anti-APP immunotherapy. Moreover, it would be interesting to investigate if this 
hyperphosphorylation in Tg APP models contributed to overall pathology or impaired 
cognitive function in these mouse models through the use of tau-directed therapies, including 
tau immunotherapy.  
A missing parallel when comparing preclinical immunotherapy assessment with 
clinical trials is a matching stage of pathology between AD patients and AD mouse models. 
Clinical evidence has shown that immunotherapy treatment in late stages of the disease is 
unable to show clinical benefits, whilst preclinical trials in AD mouse models showed 
significant reversals in cognitive deficits and reduced pathology (Karran & Hardy 2014). 
These preclinical data strongly suggest that early intervention prior to NFT pathology may 
have significant benefit. However, no study has yet been able to investigate this in APP 
mouse models or human AD. Therefore, current models of AD are certainly not without 
limitation. Despite showing increased soluble Aβ and plaque pathology and increased tau 
phosphorylation, Tg APP models do not recapitulate the full extent of human AD 
pathophysiology, including NFT development and brain atrophy. Despite the generation of 
the 3xTg, a more representational model of AD that is able to develop the full AD pathology 
is required. At the same time, improved diagnostic protocols, which are not limited to 
research purpose only are required in order to detect the onset of AD at much earlier ages in 
order to optimise chances for significant clinical benefit from immunotherapy and other 
pharmacological trials to prevent/delay the onset of AD.  
6.5 Is there still hope for immunotherapy and Alzheimer’s disease?  
 Numerous pre-clinical studies assessing AD immunotherapies have shown both 
improved cognition as well as reduced pathology in Tg models (Solomon & Frenkel 2010; 
Karran & Hardy 2014). However, as discussed in Chapter 1 (Section 1.5), limited success has 
been observed at the clinical level using anti-Aβ immunotherapy. Despite this, the most recent 
data from clinical immunotherapy trials is beginning to show more promising results 
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(Reardon 2015; Qian et al. 2015). Despite these marginal improvements emerging from on-
going clinical trials, certain risk factors associated with immunotherapy have emerged which 
must be considered for chronic treatment periods that are likely required for AD treatment. 
One major risk factor is an increased incidence of amyloid-related imaging abnormalities 
(ARIA) and micro-haemorrhage. Increased micro-haemorrhage associated with cerebral 
amyloid angiopathy (CAA) has been reported in a number of preclinical investigations 
(Wilcock et al. 2004; Racke et al. 2005; Wilcock et al. 2006; Karlnoski et al. 2008). These 
effects were associated with duration of treatment (Wilcock et al. 2006). This preclinical 
change was also observed following clinical Phase II trials with Bapinezumab (humanized 
3D6), whereby ARIA-related complications, including abnormalities associated with 
parenchymal vasogenic oedema and micro-haemorrhages were reported (Sperling et al. 2012). 
A likely mechanism for these observations was the removal of Aβ from cerebral vasculature 
associated with increased BBB penetrability and the onset of micro-haemorrhage (Sperling et 
al. 2012; Farlow & Brosch 2013).
One interesting observation was reported following comparative immunotherapy of 
3D6 (Bapinezumab, an N-terminal directed anti-Aβ antibody) and m266 (Solanezumab, 
targeting residues 16-24 of Aβ), in PDAPP mice over a period of six weeks. Following 3D6 
treatment, PDAPP mice exhibited an increase in CAA-related micro-hemorrhage, also 
reported to be dose-dependent (Racke et al. 2005; Schroeter et al. 2008). However, this effect 
was not observed following treatment with m266, which showed no effect on CAA-associated 
micro-hemorrhages (Racke et al. 2005; Schroeter et al. 2008). Moreover, no ARIA-related 
complications were reported following clinical evaluation of Solanezumab trials. The 
mechanisms reported for Aβ clearance mediated by either 3D6 or m266 also differ 
significantly. 3D6 has been observed to bind Aβ plaques and induce Fc-mediated microglial 
phagocytosis, whilst m266 is believed to sequestrate peripheral Aβ, shifting the equilibrium of 
Aβ movement and increasing its removal from the brain as proposed by the “peripheral sink” 
hypothesis (DeMattos et al. 2002; Bard et al. 2003). These data indicate that targeting Aβ 
differentially can have significantly different clinical side effects, despite both antibodies 
providing preclinical benefit at the cognitive level. Understanding individual antibody 
mechanisms for Aβ clearance is therefore important in order to best monitor, limit or prevent 
side-effects discussed above.  
The data obtained in this thesis on 2B3, alongside data obtained from BBS1 suggests 
that targeting APP at the β-secretase cleavage site provides a promising alternative/additional 
approach to anti-Aβ immunotherapy. Indeed, the added reduction in βCTF observed in 
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PDAPP mice following 2B3 administration may provide further clinical benefit where anti-
Aβ immunotherapy is unable. However, further evaluation of 2B3 is still required as 
discussed below (section 6.6). It is tempting to suggest that effects such as micro-
hemmorhage are unlikely using 2B3 immunotherapy as Aβ production is inhibited by binding 
to APP, not Aβ for subsequent removal from the brain as with 3D6 and m266. Moreover, a 
significant reduction in brain micro-hemorrhage was observed following BBS1 treatment in 
Tg2576 mice (Rakover et al. 2007). However, inconsistencies between studies assessing 
BBS1 (as discussed in Chapter 5, Section 5.4) exist and therefore these tests should be 
performed following 2B3.  
Despite the lack of translational success from preclinical to clinical evaluation, 
multiple factors complicate such a transition between levels of research. These include the 
obvious differences that mice themselves do not develop (or do not naturally live long enough 
to develop) all AD symptoms. Tg models exhibit symptoms more closely associated with pre-
clinical AD, not the mild-moderate AD that has been used to evaluate immunotherapies. 
Testing memory function in AD mice often relies on visual, non-verbal memory tasks, 
whereas those used in patients with AD often require both verbal communication and visual 
memory. Therefore, the precise memory systems being used in order to complete or show 
successful memory performance likely differ significantly. Despite this, Tg models of AD 
remain a focus for research into the pathological mechanisms of AD and associated cognitive 
deficits. It is arguable that for successful translational research from preclinical to clinical, 
lessons must be learnt from oversights of past research. Thus, future preclinical evaluation 
must be more thorough whilst reducing the clinical gap in terms of the model-based systems 
available to optimise the chance of successful translation of putative AD immunotherapies. 
6.6 Future directions 
 Despite the exciting data obtained in Chapter 5 (Experiments 4 and 5), these results 
merely indicate a proof-of-principle that direct application of 2B3 into the brain and inhibition 
of APP metabolism at the β-secretase cleavage site can improve memory function in PDAPP 
mice. A number of further studies are still required in order to better understand how 2B3 
improves memory, receptor activity and amyloid pathology in the PDAPP model. 
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 Following altered NR2B phosphorylation, it is likely that surface NMDAR expression 
may be altered following 2B3 administration. Thus, it would be worthwhile examining altered 
neuronal activity through use of techniques such as in vivo 2-photon imaging or slice 
electrophysiology. Previous anti-Aβ immunotherapies have recently reported increased 
neuronal hyper-excitability in PDAPP and Tg2576 mice (Busche et al. 2015). However, 
Busche and colleagues determined this effect using 3D6 and β1, both anti-Aβ N-terminal 
antibodies. Therefore, it remains unclear if this is an effect limited to antibodies directed at the 
N-terminus of Aβ. However, it has previously been reported that PDAPP mice administered 
10D5 (anti-Aβ antibody targeting Aβ epitopes 3-6) showed improved spatial learning and 
LTP in the hippocampal CA1 region compared to control PDAPP mice (Hartman et al. 2005). 
Busche and colleagues (2015) determined cortical neuronal activity in PDAPP mice, whereas 
Hartman and colleagues (2005) assessed HPC activity in the CA1 region. It would be of 
interest therefore to assess the effects of immunotherapy, such as 2B3, on neuronal activity in 
multiple regions of the brain, the HPC as well as specific cortical regions such as the 
entorhinal cortex and prefrontal cortex.  
 Further biochemical assays should also be carried out to provide a clearer 
understanding of how 2B3 affects amyloid pathology and NMDAR physiology ex vivo. 
Despite measures of PSD95 being reported in Experiment 5B, analysis was performed on 
whole HPC soluble extracts. A more reliable measure of synaptic density might be obtained in 
Western blot analysis using synaptosomal preparations. Moreover, it would be interesting to 
observe whether altered NR2B phosphorylation changes NMDAR surface expression and 
whether this change in phosphorylation state is an effect of altered Fyn or STEP 
levels/activity in synaptosomal preparations (Ittner et al. 2010; Zhang et al. 2010). Following 
a significant reduction in levels of βCTF, an interesting study would be to examine changes in 
endocytosis, such as those described by Kim and colleagues (2015). Here, persistent rab5 over 
activation caused by increased levels of βCTF led to pathologically accelerated endocytosis 
and impaired axonal transport in AD brain (Kim et al. 2015). It is tempting to postulate that 
investigating this mechanism with 2B3 treatment may reveal that inhibiting APP metabolism 
at the β-secretase cleavage site might improve AD-related pathologies through more than one 
physiological process. 
 Experiment 7 only measured OiP memory following 2B3 administration. However, 
other cognitive deficits associated with age related changes in Aβ pathology have been 
reported and indeed reported in Chapter 3 (Experiment 2) (Dodart et al. 1999; Chen, Chen, 
Knox, Inglis, Bernard, Martin, Justice, Mcconlogue, et al. 2000; Hartman et al. 2005; Daumas 
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et al. 2008). Further investigation into whether 2B3 administration is able to improve memory 
across a range of memory tasks, sensitive to AD pathology would be beneficial to examine 
the generality of cognitive changes across different performance parameters. Moreover, 
cognitive tasks more closely associated with memory deficits observed in AD may provide a 
closer parallel for AD-related cognitive deficits. For example, AD patients display episodic 
memory deficits, an inability to recall events in relation to their content and temporal-spatial 
information (Tulving 1972; Butters et al. 1987; Greene et al. 1996). Rodent cognitive tasks 
have been able to assess an analogue of episodic-like memory that interrogate an animals 
ability to exhibit an integrated memory for  “what” happened, “where” and “when”. These 
tasks include adaptations of object-based and fear conditioned memory paradigms (M. A. 
Good et al. 2007; Iordanova et al. 2008; Iordanova et al. 2011). These types of tasks offer a 
potentially more suitable cognitive platform in which to evaluate immunotherapies such as 
2B3 prior to clinical investigation. 
 A final further investigation for 2B3 focuses on a more clinical application. In Chapter 
5, 2B3 was administered directly into the brain of PDAPP mice. However, clinical application 
requires peripheral administration. The effects observed in Experiments 4 and 5 therefore 
need repeating following a peripheral route of administration, such as delivery into the 
intraperitoneal space, as with previous preclinical immunotherapy investigation of anti-Aβ 
and anti-APP antibodies (Bard et al. 2000; Dodart et al. 2002; Hartman et al. 2005; Rakover et 
al. 2007; Arbel-Ornath et al. 2009). Given that approximately 0.1% of antibody dose crosses 
the BBB, it may be possible that the effects of 2B3 observed following ICV administration 
occur due to the relatively high concentration that might have been present in the HPC. 
Moreover, a more chronic treatment period is also required for investigation, in order to 
assess the long-term affects of inhibiting APP metabolism at the β-secretase cleavage site. 
Indeed such an analysis could be extended to WT mice to explore the normal function of beta-
secretase cleavage of APP 
6.7 Thesis Summary and Conclusions 
187
 Over 15 years has passed since the initial report using antibody directed therapy to 
treat AD in Tg mouse models was presented (Bard et al. 2000). This strategy appears to still 
exist as one of the most promising forms of preventative treatment targeting the amyloid 
cascade hypothesis and AD pathogenesis. The success and advance of this potential treatment 
approach for AD owes a great deal to the use of Tg mouse models of AD and their 
contribution to our understanding today of AD mechanisms. It is with much excitement and 
anticipation that the results of on-going clinical trials using immunotherapy (and other forms 
of treatment) are awaited for. 
The data presented in this thesis extends the current understanding of the behavioural 
phenotype of the PDAPP mouse model in relation to age-related amyloid pathology. The 
preclinical evaluation of 2B3 showed a significant improvement in OiP memory and 
significant reductions in Aβ40 and βCTF. These analyses also revealed changes in NMDAR 
phosphorylation; a receptor class inextricably linked visuo-spatial memory. Collectively, 
these data offer novel in vivo and ex vivo findings following immunotherapy targeting the β-
secretase cleavage site of APP. More extensive work to assess, confirm and extend these 
findings is still required. However, the data presented in this thesis are novel and important 
and provide support for the hypothesis that inhibition of Aβ production by steric hindrance 
can improve memory and amyloid-related pathology. 
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